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Introduction: Diabetes mellitus (DM) causes life altering microvascular complications, 
such as diabetic nephropathy and retinopathy (DR and DN). The endothelial glycocalyx 
(eGlx), containing proteoglycans (core proteins with glycosaminoglycan (GAG) sidechains), 
lines all blood vessels and helps to maintain vascular permeability barriers. Heparan 
sulfate (HS) is the most abundant GAG in the eGlx. In DM, heparanase, an HS degrading 
enzyme, is upregulated. The aim of this PhD was to show that eGlx HS is important in 
glomerular and retinal microvascular barriers and that preventing its shedding, using a 
novel heparanase inhibitor, OVZ/HS-1638, is protective in DM. 
Methods: EGlx HS was removed in mice by i.v. of heparinase III, or by an Ext1 (an HS 
biosynthesis enzyme) endothelial-specific conditional knock-out mouse (Ext1CKO). Type 
2 diabetic mice (db/db) were treated with OVZ/HS-1638 or vehicle for two weeks, with a 
9-week and 11-week old endpoint. Fluorescein angiography analysis was used as a 
measure of retinal apparent solute flux, and albumin staining to measure vascular leak. 
Mice were Ringer or Alcian blue/glutaraldehyde perfused for apparent glomerular 
permeability (Ps’alb) studies and electron microscopy (EM), respectively. EGlx depth and 
coverage was measured by EM. Urine albumin creatinine ratios (uACRs) were measured 
at endpoint. 
Results: A reduction of eGlx, using heparinase III or in Ext1CKO mice, was associated with 
increased retinal solute flux and Ps’alb. Ext1CKO mice also had increased uACR when 
tubular absorption was blocked. In 9-week-old db/db, OVZ/HS-1638 increased retinal eGlx 
depth and reduced retinal albumin leak. In 11-week-old db/db mice, OVZ/HS-1638 
restored glomerular eGlx depth and restored Ps’alb. uACR was no longer significantly 
increased. 
Conclusions: Together, this work shows that eGlx HS is structurally and functionally 
important in two spatially and functionally distinct vessel beds and suggests that HS is 
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 Introduction  
 The Importance of Vascular Permeability 
1.1.1 Preamble  
This thesis focuses on the role of heparan sulphate within the endothelial glycocalyx in 
vascular permeability. I will investigate whether endothelial glycocalyx heparan sulphate 
can be targeted therapeutically to prevent microvascular complication in diabetes, using 
vessel beds in the kidney and eye as examples. As will be discussed, the endothelial 
glycocalyx has a role in the maintenance of permeability in microvessels and is damaged 
in diabetes. The principles of permeability will be introduced in order to understand the 
various factors that contribute to microvascular permeability and the importance it has in 
health and disease. With this understanding, the known microvascular and endothelial 
glycocalyx changes that occur in diabetes in the kidney and eye will then be discussed. 
Lastly, I will introduce evidence for a potential key role for heparan sulphate in the 
glycocalyx and development of microvascular complications and will be the focus of my 
investigation.  
1.1.2 The Role of Vascular Permeability in the Body 
The circulatory system is essential to life as it delivers oxygen and nutrients to tissues 
throughout the body while simultaneously removing waste products. This vital job is 
accomplished by two vascular groups, the macrovasculature and microvasculature. 
Macrovascular vessels are larger and come in the form of arteries and veins. Because of 
their size and vessel structure, they possess the ability to transport large volumes of blood 
rapidly to and from organs (1). Microvessels on the other hand are small, in the form of 
venules, capillaries, and arterioles. Arterioles are largely thought to regulate local blood 
perfusion by contractile and relaxation capabilities, made possible by the smooth muscle 
cells that cover them (1).  As capillaries and venules typically lack smooth muscle cells, 
and are composed largely of endothelial cells that lack vasomotor functions, they are 
responsible for the blood-tissue exchange that is crucial for a healthy functioning organ 
(1). The exchange vessels allow water and small solutes to pass relatively freely while 
restricting the free passage of larger molecules. As will be discussed in detail in this thesis, 
the manifestation of diseases in microvessels, and consequently the breakdown of their 
barrier function, can be detrimental to tissues and even fatal, showing the importance of 




 Initial Physiological Studies on Microvascular Permeability  
1.2.1 Fluid Filtration in Microvessels  
Because of the essential role microvessels play in maintaining tissue homeostasis, the 
movement of molecules across microvessel walls has long been an area of intensive 
research. In 1896 a British physiologist, named Ernest H. Starling, proposed that fluid 
movement across the capillary wall is driven by the difference of two forces (2). The first 
force is hydrostatic pressure, which is generated by circulating blood fluid. The second is 
colloid osmotic pressure (oncotic), which comes from the plasma proteins within the 
lumen of the vessel (inside vessel) relative to proteins in the extravascular (interstitial) 
space. Later work in 1932 by an American physiologist, Eugene Landis (3), helped to 




= 𝐿𝑝[(𝑃𝑐 − 𝑃𝑖) − 𝜎(∏𝑐 − ∏𝑖)] 
Equation 1-1 
                                    
Here, Lp is the coefficient that describes the permeation property of the capillary wall to 
water, known as hydraulic conductivity (cm/s/mm Hg),  Jv is the fluid volume filtration rate 
(mL/s), A is the surface of the endothelial cell (cm2), Pc is the blood fluid hydrostatic 
pressure inside the capillary (mm Hg) as well as Pi , but in the interstitial space.  Пc is the 
oncotic pressure in the plasma (mm Hg) as well as Пi but for the interstitial space.  Finally, 
σ is the reflection coefficient, which is the molecular sieving property of the capillary wall 
to a specific molecule, where if σ=0, the molecule is completely permeable and if σ=1, the 




= 𝐿𝑝[𝛥𝑃 − 𝜎𝛥∏] 
Equation 1-2 
                               
where ΔP is determined by capillary blood pressure (12-54 mmHg) and ΔП is the 







Under normal microvasculature conditions, hydrostatic pressure is higher at the arteriolar 
end than at the venular end, favouring fluid filtration out of the vessel into the tissue, 
while the opposite is true at the venular end (FIGURE 1-1) (4). This was understood to be 
key for the proper function of microvessels. In diseased states in which there is a 
breakdown in the barrier, as will be discussed in later sections, naturally Lp would be 
increased, allowing plasma proteins to accumulate in the interstitial space (4). This would 
result in an increased oncotic force that promotes fluid accumulation into the tissue that 
prevents fluid absorption by the microvessels (1). However, we now know that there is no 
steady state absorption  in to microvessels, as will be discussed below, and lymphatic 
vessels are responsible for clearing excess of fluid in the interstitial space (5), but this work 
has served as a solid foundation for describing the movement of molecules across a 
capillary wall. 
Figure 1-1 The Forces that Drive Fluid Filtration in Microvessels 
1. At the arteriole end, hydrostatic pressure is higher than the oncotic pressure and drives fluid 
filtration out of the vessel. 2. The change in hydrostatic pressure and oncotic pressure is the 
difference of respective pressures inside the capillary and outside the capillary. 3. At the venule end, 
oncotic pressure is greater than hydrostatic pressure, believed to cause fluid absorption into the 
vessel. It is now known that the lymphatic vessels are responsible for fluid reabsorption. Image 





1.2.1.1 The Glycocalyx and Vascular Permeability  
1.2.1.1.1 Modification of Starling-Landis Equation to Account for Glycocalyx  
The endothelial glycocalyx (eGlx), a mesh like layer lining the luminal side of endothelial 
cells, was first visualised by  transmission electron microscopy (EM) in 1966 (6) and, thanks 
to a  wealth of research, is now known to contribute to vascular permeability.  As a result 
Curry, Levick, and Michael (4,7) proposed a modification to the original fluid filtration 
model (EQUATION 1-1) to account for the contribution of the eGlx , stating: 
𝐽𝑣
𝐴
= 𝐿𝑝[(𝑃𝑐 − 𝑃𝑖) − 𝜎(∏𝑐 − ∏𝑔)] 
Equation 1-3 
                          
The equation is almost identical to the original described in EQUATION 1-1, but Пp is now  
Пg, where Пg is the oncotic pressure of the sub eGlx space. Therefore, if we go back to the 
simplified version in EQUATION 1-2, ΔП is now the oncotic pressure difference across the 
eGlx, rather than across the endothelium (FIGURE 1-2). Since the sub glycocalyx space is 
protein free, the glycocalyx oncotic pressure (Пg) is lower, resulting in no steady state 
absorption into the vessel (FIGURE 1-2), contrary to what was originally believed to occur 
under unrevised Starling Principles. This has been shown experimentally where albumin 
Figure 1-2 The Glycocalyx in Revised Starling Principles  
Left: In the original model, the difference in oncotic pressure (∏) is determined by the oncotic 
pressure of the plasma in the capillary and the intestinal fluid.  Right: In the revised model, the 
glycocalyx is a barrier that separates the lumen from the plasma protein restricted area below 
the glycocalyx (subglycocalyx space). As a result, the change in oncotic pressure is now 
contributed to by oncotic pressure in the lumen and oncotic pressure in the subglycocalyx space. 





concentrations are directly changed inside and outside the vessel, and show that an 
increase of fluid filtration into the vessel does not occur (8). 
1.2.1.1.2 The Glycocalyx: Structure and Function   
Since its first visualisation it is now accepted that the eGlx lines the luminal side of virtually 
all endothelial cells found in the vasculature throughout the body, and serves as a 
selective barrier based on size and charge (9–11). The eGlx is a carbohydrate rich layer 
made primarily of proteoglycans and glycoproteins, which includes different families of 
glycosaminoglycans (GAGs); heparan sulphate (HS), chondroitin/dermatan sulphate (CS), 
and hyaluronic acid (HA) (6). With the exception of HA, GAGs are covalently attached to 
soluble and membrane bound proteoglycans,  anchoring them to the cell surface (6).  
HS is the most abundant GAG, representing 50-90% of the eGlx proteoglycans (12). Each 
GAG family is characterized by specific combinations of distinct disaccharide unit repeats, 
made of D-glucuronic acid (GlcA), L-iduronic acid, or D-galactose bound to either D-N-
acetylglucosamine (GlcNAc) or D-N-acetylgalactosamine (GalNAc) (FIGURE 1-3) (6). CS is 
composed of GalNAc and GlcA linked by a glycosidic linkage GlcA (1→3) GalNAc (1→4) 
to form unbranched GAG chains (13). HS on the other hand is a linear polysaccharide that 
ranges from 50-150 disaccharide units, the most prominent being GlcA and GlcNAc with 
a -GlcA(1→4)GlcNAc- linkage and unique variations in number of acetyl groups and 
sulphation (14).  
Figure 1-3 Structure and Components of Glycosaminoglycans (GAGs) 
The three main GAGs are chondroitin sulphate, heparan sulphate, and hyaluronic acid. GAGs are 
made of different patterns of GluA, GlcNAc, and GalNac, with variations in sulphation and 




Additionally, each GAG chain can contain up to 50 disaccharide subunits, also with 
variable sulfation (13). Because changes in lengths and sulphation and/or (de)acetylation 
modifications heavily influences function, different tissues have predominating lengths, 
disaccharide variations, and modifications that meet the need of that tissue type (15). As 
will be discussed in more detail in CHAPTER 3, work on HS has been primarily focused on 
its role in the basement membrane and involvement in inflammatory responses, but how 
it contributes to eGlx structure and permeability function is not well known.  
In addition to its barrier functions, the eGlx also serves as a protective layer, shielding the 
endothelial cell. Studies show that changes in fluid shear stress, caused by blood flow in 
the vessels, results in redistribution of GAG components, which may lead to a decrease in 
shielding of the endothelial cell membranes (11,16).  It can also help regulate leukocyte 
adhesion, since the endothelium has leukocyte binding receptors, such as ICAM-1 and 
VCAM-1, which can be blocked or made accessible by the eGlx (14). It also has a role in 
controlling  the microenvironment, acting as a reservoir for molecules like vascular 
endothelial growth factor-A (VEGF), chemokines, and antithrombin III, which can be 
released upon eGlx shedding (14). Its direct and continual interaction with flowing blood 
render it sensitive to changes in its local environment, including cation concentration, pH, 
and blood pressure, allowing this dynamic and versatile structure to adjust as required  
(11,14). 
1.2.1.2 Solute Diffusion in Microvascular Permeability 
The glycocalyx model (EQUATION 1-2) and the Starling-Landis model (EQUATION 1-1) both 
describe the forces responsible for driving fluid filtration in a microvessel, but do not 
describe the  free diffusion of molecules across a semi permeable membrane. This is 






                                               
Diffuse solute flux (Js) is equal to the product of the diffusion coefficient (D), the surface 
area of the exchange membrane (A), and the solute concentration gradient (ΔC) divided 




As D is determined by the barrier permeability (Ps) to a specific solute, which is inversely 
proportional to the square route of the solute’s molecular mass (1), EQUATION 1-4 can be 
expressed as: 
𝐽𝑠 =   𝑃𝑆𝐴𝛥𝐶 
Equation 1-5 
 
This describes the relationship in which a molecule can diffuse freely. However, this 
equation does not consider other forces which may prevent free diffusion.                                          
1.2.1.3 The Pore Theory  
The pore theory was developed when similarities in permeability characteristics of 
capillaries from living organisms and artificial porous membranes were observed (17). The 
pore theory states that capillaries have many ultramicroscopic pores, which are too small 
to allow the passage of plasma proteins, but large enough to allow the observed passage 
of water and non-protein plasma molecules, when measuring permeability. Furthermore, 
Pappenheimer et al., acknowledged that there were many indications suggesting 
capillaries from different regions of the body and species differed in their permeability 
characteristics, and therefore may be contributed to by differences in pores. The Stokes-
Einstein Radius states that the size of the pores can be estimated by the amount of 
restriction the pores exert on a molecule as it moves through the poor (18), or: 
 𝐷 =  𝑅𝑇/6 𝜋ƞ𝑎𝑁 
Equation 1-6 
                                     
Where D remains the free diffusion coefficient as stated above, (R) is the gas constant, (T) 
the absolute temperature, (N) is Avogadro’s constant, and (a) is the molecular radius of 
the pore. Recall that Fick’s Law (EQUATION 1-4) gives the diffusive solute flux for free 
diffusion of a solute, but does not consider restrictions of diffusion. Similarly, the Stokes-
Einstein Radius does not take into account that solutes moving through a narrow pore will 
encounter restrictions on diffusions. For example: 
1. Pores may be oblique in respect to the capillary wall, and therefore the pore 




2. The area available for diffusion (A) is confined to the area covered by the pores 
(Ap)  which is equal to the pore area (πrp)np where rp is pore radius and  np is 
number of pores (5).  
3. As the radius of the solute increases, solute drag coefficient (D’) between the 
solute and pore wall will increase (5).  
4. The surface area available for diffusion is also dependant on the radius of the pore 
and the solute (5). For example, If the solute is spherical in nature and has an area 
of ‘’a’’ and is diffusing through a pore with the radius ‘’r’’ than the area available 
for diffusion is decreased to π(r-a)2. This relationship between the total pore area 
and the actual area available for diffusion is described by the partition coefficient 
(φ), which can be calculated from φ= (rp-a)2/rp2 (5). 
This gives rise to a modified version of Fick’s Law for solute flux (JS’) which now accounts 





Further modifications have been made to account for things like variation in pore size and 
distribution (19). Additionally, in modern interpretations of the pore theory, the 
glycocalyx is suggested to be responsible for the sieving properties which the pore theory 
describes (1). In this theory, the structure of the glycocalyx, which is a mesh like structure 
of carbohydrates, acts as a sieving system with a uniform pore size (19).    
1.2.1.4 Solute Permeability  
It is clear there are several factors that contribute to permeability of a given solute. But 
returning to Starling’s original theory, ultimately it is hydraulic conductivity, the reflection 
coefficient of a molecule, and diffusion that will determine the permeability of a given 
solute.  
The many years of investigation and refinement of Starling’s original equation has given 
rise to the following: 






As in EQUATION 1-5, A is surface area of the exchange membrane, ΔC is the solute 
concentration gradient, but Js, which originally did not account for restricted diffusion, is 
replaced by Js’, which can be calculated from EQUATION 1-7. These refinements are all 
based on what is now known as Starling’s Principles, and through evidence from multiple 
studies, this is now widely accepted as an accurate model of microvascular permeability 
(20).  
 Microvascular Permeability in the Kidney and Eye 
1.3.1 Microvascular Permeability in the Kidney  
1.3.1.1 The Glomerular Filtration Barrier  
The permeability principles described, and the theory behind how the eGlx contributes to 
them, lays down a good foundation for discussing the importance of microvascular 
permeability in the kidney. The kidney has a vital functional role in the body. Kidneys are 
responsible for filtering blood to eliminate waste products into the urine and returning 
nutrients to the body. This is accomplished by the nephron, the functional unit of the 
kidney (FIGURE 1-4A,B) (21). The nephron is divided into two main components, the 
Figure 1-4 Structure of the Nephron in the Kidney 
A. The renal artery feeds blood into the kidney, which is filtered, and waste products are eliminated 
via the ureter. The afferent and efferent arteriole feed into the glomerulus in B. B. Magnified image 
of the nephron shows the segments of the nephron, with a circular bundle of capillaries in the top left, 





tubular epithelium and the glomerulus. The tubular epithelium is further divided into 
functionally distinct segments, the proximal tubule, the loop of Henle, distal convoluted 
tubule, and the connecting tubule (FIGURE 1-4B). The tubular epithelium plays an 
important role in maintaining tissue homeostasis, including reabsorption of important 
molecules as is the case for the proximal tubules, but also water reabsorption, electrolyte 
balance, and urine concentration(21,22). However, the glomerulus serves as the sole 














The glomerulus is encapsulated by the bowman’s capsule, which contains the urinary 
space where waste products are filtrated into (FIGURE 1-5) (21,23). The glomerulus is a 
circular structure made up of a bundle of capillaries with highly specialised cells: 
mesangial cells, podocytes, and endothelial cells (FIGURE 1-5).  The mesangium, in 
addition to providing structural support to the glomerular capillaries, can also alter 
intraglomerular capillary flow, given the mesangial cell’s contractile property (24). As can 
be seen in FIGURE 1-5, glomerular capillaries are atypical, as they are compromised from 
multiple cell types and do not have an interstitium surrounding them, instead they have 
the urinary space. The podocytes, glomerular basement membrane and endothelial cells 
The glomerulus is the filtering unit of the kidney. Mesangial cells provide structural support to 
capillaries amongst other functions. Podocytes and endothelial cells in the glomerular 
capillaries form the glomerular filtration barrier. Image adapted from (Kitching and 
Hutton,2016)(23).  




form the glomerular filtration barrier (GFB). Podocytes line the exterior surface of the 
glomerular capillaries, resembling an octopus like structure, with a cell body and major 
cytoplasmic processes. These extend outward and form interdigitating foot processes, 
with functional slit diaphragms, serving as a filter to passing plasma molecules (FIGURE 
1-6). Podocyte foot processes are covered by the glycocalyx, believed to help maintain 
podocyte-podocyte cytoarchitecture by promoting physical separation, due to repelling 
charge forces (25). The unique structure of podocytes not only provide structural support 
to the capillaries, but also have important cell signalling functions that allow 
communication with neighbouring endothelial cells, crucial for GFB function (26). The 
podocytes on the exterior of the capillaries and the endothelial cells on the luminal side 
of the GFB form a sandwich with the glomerular basement membrane (GBM) in between 
the middle (Figure 1-6). The GBM is an extracellular matrix made of laminin, collagen IV, 
proteoglycans and HS laid down by the exterior podocytes and endothelial cells that acts 
an important physical barrier in the GFB (27).  
 
The most interior cell of the GFB is the endothelial cell, whose luminal side comes in direct 
contact with flowing blood and therefore plays a fundamental role in determining which 
molecules are filtered. The endothelial cell has unique pores all throughout its cell body, 
known as fenestrations (FIGURE 1-6). These fenestrations are essential in the GFB, as they 
Figure 1-6 The Glomerular Filtration Barrier. 
Schematic of a cross-section of a single glomerular capillary. The GFB is a trilayer. Podocytes 
are on the abluminal side of the capillaries and have podocyte foot processes that form part 
of the GFB. In between podocytes and endothelial cells sits the basement membrane. 
Endothelial cells sit on the luminal side of capillaries and are fenestrated. The endothelial 
glycocalyx is found on the surface of the luminal side of endothelial cells and prevents passive 




allow relatively free passage of solutes and small molecules from the blood through the 
GFB into the urinary space.  Fenestrations are 60-80nm in width (28,29)  and act as a 
selective size barrier, preventing free passage of larger plasma proteins such as albumin. 
There is also evidence showing that eGlx plugs the endothelial cell fenestrations, 
suggesting a role for eGlx in selective permeability in the fenestrations (30).  Similar to 
other cell types in the glomerulus which are high in metabolic activity, endothelial cell 
surfaces are covered with signalling receptors molecules, allowing for cross-talk between 
endothelial cells and podocytes, the most well studied being the VEGF/VEGF receptor 2 
(VEGFR2) system, crucial for glomerular development and renal homeostasis (31). In 
addition to signalling molecules, endothelial cells are also covered by a layer of glycocalyx 
as mentioned and shown in FIGURE 1-6. However, unlike podocyte glycocalyx (pGlx), the 
eGlx is believed to have a direct functional role in vascular permeability.   
1.3.1.2 The Glomerular eGlx and its Contribution to the Permeability Barrier 
The closely linked, mesh-like nature of the eGlx results in a strong interplay between all 
of its components and changes to even one component can compromise vascular 
permeability, and in the glomerulus this presents as albuminuria (32). In vitro studies 
performed by our group on glomerular endothelial cells (GEnC) show that removal of HS 
and CS, using the specific shedding enzymes heparanase and chondroitinase, results in 
removal of endothelial surface HS and CS and increases albumin flux in a GEnC monolayers 
(10,33). However, the eGlx also contributes to the restriction of solute flux of small 
molecules, as was shown in cannulated frog mesenteric vessels in which pronase was used 
to shed eGlx, resulting in increased hydraulic conductivity without damaging tight 
junctions (34). 
In humans, glomerular eGlx has not been well examined. In vivo models have been key to 
teasing out the functional role of eGlx in permeability. Treatment of mice with eGlx 
shedding enzymes heparinase III, hyaluronidase, and chondroitinase increased the 
frequency of close proximity intralipid droplets observed by EM (close proximity defined 
as 0-50nm from the GEnC), an indirect measurement of eGlx loss (35). In addition, albumin 
clearance measured in the urine was increased in chondroitinase treated mice, suggesting 
an increase in glomerular permeability (35).  More recent in vivo studies by our group 
have shown that treatment of healthy mice with hyaluronidase and chondroitinase 
resulted in decreased glomerular eGlx measured directly by EM, using Alcian blue, an 
electron dense stain that allows for visualisation of the eGlx (FIGURE 1-7, A-B) (36). A novel 




apparent albumin permeability in single capillaries (discussed in full in the methods), also 
demonstrated an increase in apparent glomerular albumin permeability when eGlx was 
shed (FIGURE 1-7, C) (36).  
Evidence for the eGlx’s contribution to permeability is further strengthened by indirect 
damage caused by less specific insults. For example, increased laminar shear stress in in 
vitro studies with GEnCs decreased the electrical resistance across the cell monolayer, 
indicative of increased permeability (37).  Activated inflammatory cells can also release 
reactive oxygen species and nitrogen species (ROS/RNSs) which possess the ability to 
degrade not only HS, but HA and CS as well (38). Importantly, ROS causes proteinuria with 
no ultrastructural changes in the GFB, leaving the eGlx as the most likely culprit in 
observed changes (39). This result, along with the aforementioned  studies have revealed 
the major role that the eGlx has on glomerular vascular permeability regulation (10,40–
42).  
Figure 1-7 Intravenous Treatment with eGlx Shedding Enzymes Sheds eGlx and Increases 
Glomerular Albumin Permeability  
 Mice were treated with vehicle or chondroitinase and hyaluronidase to shed eGlx. A. Electron 
micrographs of the GFB. After treatment mice were perfused with an anionic electron dense cation 
called Alcian blue that allows visualisation by EM. A fuzzy electron dense layer (arrows) can be seen on 
the glomerular endothelial cells (GEnC). Note the reduced eGlx layer in the enzyme group. The podocyte 
(Pod) and glomerular basement membrane (GBM) are also visible. B. Quantification of electron 
micrographs showe a decrease in eGlx coverage. C. Glomerular albumin permeability was measured 





1.3.2 Microvascular Permeability in the Retina  
1.3.2.1 Contributing Factors to the Blood Retina Barrier 
Unlike the filtration barrier in the glomerulus, the retina microvessels are continuous with 
no fenestrations and therefore constitutes a different type of vessel with its own mode of 
permeability regulation. The eye is a highly specialised organ that allows exterior visual 
input to ultimately come together as an image in our brain. This is only possible if all the 
separate components of the eye are functional. The eye can be most simply divided into 
three segments, the outer, middle, and inner segment which are surrounded by three 
transparent layers called the aqueous, lens, and vitreous (FIGURE 1-8) (43).The outer 
segment contains the cornea and sclera (FIGURE 1-8), and cumulatively help maintain 
structure,  prevent infection and damage to deeper parts of the eye, and refract and 
transmit light to the lens and retina (FIGURE 1-8) (43).  The middle segment contains the 
iris, the ciliary body, and the choroid (FIGURE 1-8). The iris determines how much light 
reaches the retina by controlling the pupil size, the ciliary body has roles in controlling 
lens shape and power and is also the site of aqueous production (43). The choroid is the 
vascular structure that provides nutrients and oxygen to outer retinal layers (FIGURE 1-8) 
(43). Lastly, the inner layer is the retina, the layered neuronal portion of the eye which is 
responsible for processing light into nerve impulses which are ultimately transmitted to 
the brain through the optic nerve (FIGURE 1-8) (43). Although all three segments are 
important in a healthy functioning eye, ultimately it is the retina which has one of the 
most important roles in fulfilling the functional role of the eye, i.e. sight.  
Figure 1-8 Anatomy of the Eye 
Schematic of transverse cross-section of human eye. Outer segments include cornea and sclera. 
Middle segments include iris, ciliary body, and the choroid. Inner segment is the retina. The aqueous 
humour, lens, and vitreous humour are transparent layers that surround these three layers. Image 




Blood is supplied to the inner and outer retina by two different sources, the retinal blood 
vessels and the choroidal blood vessels (FIGURE 1-9) (44,45). Since the outer layers of the 
retina are avascular as depicted in FIGURE 1-9, nutrients are obtained through diffusion 
from the choroid, which, like glomerular epithelium, is fenestrated (46).  
 
The inner retina however is much more tightly regulated, as the vessels in the retina are 
continuous, with the endothelium lacking fenestrations. The inner retina vascular 
endothelium is surrounded by the basal lamina which is covered by pericytes, astrocyte 
and Müller cell processes (FIGURE 1-10).  The tight structure of retinal vessels, which is 
highly selective, is known at the inner blood retina barrier (iBRB) (47) and due to its clinical 
relevance in diabetic retinopathy is the focus of the retina portion of this thesis.  
 
 
Figure 1-9 Structure of the Retina and Vasculature  
The retina can be divided into several cell layers (labelled on the left) made up of specialised cells. The 
ganglion cell layer is the inner most layer of the retina (toward the vitreous) and the retinal pigment 
epithelium (RPE) is the most outer cellular layer of the retina, (toward the choroid). The inner retina 
gets its blood supply from the retinal vessels, while the outer retina which is avascular is supplied by 





The iBRB is a physiological barrier that regulates ion, protein, and water flux in and out of 
the retina and is established by junctional complexes between retinal vascular endothelial 
cells (43,48). There are two ways in which vascular permeability is regulated, paracellular 
transport and transcytosis. Paracellular permeability is regulated through changes in 
junctional complexes which results in permeability changes around the cells (FIGURE 1-11) 
(48).  
Inner retina microvessels which form the inner blood retina barrier are continuous. Endothelial cells 
lack fenestrations, and are surrounded by a basal lamina, with pericytes, Müller, and astrocyte 
process that closely interact with each other. Image made using biorender.com  
Figure 1-10 Schematic of Inner Retina Microvessel  
Figure 1-11 Paracellular Transport in Retinal Endothelial Cells 
Examples of junctional complexes in the iBRB. Gap junctions, adherens junctions, and tight junctions 
which include claudins, JAM, and occludin family proteins. Junctional complexes regulate 
paracellular transport between two endothelial cells by junction reorganisation. Note the glycocalyx 





Junctional complexes include tight junctions and adherens junctions, made up of several 
proteins, some well-known protein families in each junction type being zonula occludens 
(ZO) and vascular endothelial (VE)-cadherins, respectively. Changes to the makeup of 
these complexes can have dramatic effects on permeability regulation. For example, 
knockdown of ZO-1 in tissue culture results in failure of cells to form tight junctions, and 
loss of ZO-1 correlates with vascular permeability in rat retinas (49,50). Similarly, 
increased retina permeability in diabetic rats coincides with reduced VE-cadherin, 
suggesting contribution to maintenance of the iBRB through paracellular transport (51). 
Transcytosis on the other hand is regulated through changes in the transport of molecules 
across the cell (FIGURE 1-12) (48). While some small lipophilic molecules have been shown 
to passively diffuse along the retinal endothelial membrane (52), larger or hydrophilic 
molecules require alternate transcytosis routes, like receptor mediated vesicular 
transport, non-receptor mediated pinocytosis, and pumps and transporters  (48) (FIGURE 
1-12). By changing transport molecules on both luminal and abluminal sides, retinal 
endothelial cells can alter transport of molecules across the cell and therefore regulate 
permeability (48).   
 
 
Figure 1-12 Types of Transcytosis Transport 
Examples of transcytosis pathways. Diffusion of small lipophilic molecules can happen freely. For 
larger or hydrophilic molecules, active transcytosis is required in an adenosine triphosphate (ATP) 
dependant manner. This includes receptor mediated transport, pinocytosis, or through 




As in the glomerulus, retinal endothelial cells are also covered in eGlx (53). Unlike the 
glomerulus, the contribution of the eGlx in the iBRB has not yet been investigated in detail, 
but there is now some evidence that the eGlx may have a role in maintaining iBRB integrity 
as discussed below. 
1.3.2.2 The Retinal eGlx and its Contribution to Permeability  
Despite the already demonstrated importance of eGlx in other vascular beds and the 
eGlx’s involvement in vascular diseases like diabetic nephropathy and cardiovascular 
disease (42,54–56) , the role of glycocalyx in retinal permeability has not been as 
extensively studied. Less than a hand-full of research articles have been published 
showing a reduction in retinal eGlx depth in disease (57–59), as will be discussed in section 
1.4.3.2, but the link between loss of eGlx in disease and permeability in the retina is 
lacking.  Recently, Leskova et al. showed that treatment of healthy C57BL/6 mice with 
hyaluronidase, resulted in a reduction of eGlx depth in retinal arterioles and an increase 
in retinal vascular leak, measured using TRITC-dextran and sodium fluorescein (59). A T1D 
rat model also showed that restoring eGlx in diabetic rats by overexpressing endomucin 
(EMCN) protected iBRB permeability, measured using FITC-dextran (60). To date, these 
are the only published articles directly suggesting a role for eGlx in retinal vascular 
permeability. However, the continued study of the eGlx in this type of vascular bed is 
important in not only understanding similarities and differences between eGlx in the 
retina and other types of microvessels such as the kidney, for example, but also allows us 
to better understand its role in disease and how it can be potentially targeted for 
treatment. 
 Changes in Microvascular Permeability in Diabetes  
1.4.1 Diabetes and Vascular Disease  
According to GOV.UK, 2015 data from the Public Health England National Cardiovascular 
Intelligence Network shows an estimated 3.8 million people in England are diagnosed with 
Type 1 (T1D) or Type 2 (T2D) diabetes. By the year 2035, 4.9 million people are estimated 
to have diabetes, demonstrating the crucial need for both preventative and effective 
therapeutic measures (61). T1D and T2D are characterized by high blood glucose levels, 
i.e. hyperglycaemia (62). In both cases, hyperglycaemia is caused by a defect in insulin 
signalling. In healthy individuals, circulating insulin signals to neighbouring organs to 
uptake glucose. In individuals with T1D or T2D, this signalling is altered. T1D is a chronic 




in the islets of Langerhans in the pancreas (62). Though the exact event that leads to T1D 
is still under debate, numerous studies suggest a variety of genetic and environmental 
factors lead to its development (62,63). Because -cells are the body’s insulin producing 
cells, T1D results in diminished insulin production resulting in decreased glucose uptake 
and increased hyperglycaemia. T2D on the other hand is caused by -cell dysfunction 
and/or the acquired resistance to insulin (64). A major risk factor for T2D is obesity. 
Because obesity causes a low but chronic level of inflammation, inflammatory 
molecules/processes lead to -cell dysfunction and eventual cell death (64). In addition, 
continuous increased levels of glucose and fatty acids in the blood stream persistently 
stimulates insulin production by -cells,  and subsequent development of insulin 
resistance by glucose recipient organs (65). Although T1D and T2D differ in their aetiology, 
outcomes of uncontrolled hyperglycaemia in both types results in various pathologies 
including macrovasculature and microvasculature disease (66).  
Macrovascular complications in diabetes stem primarily from the development of 
atherosclerosis, in which the arterial walls narrow, eventually leading to lipid-rich 
atherosclerotic lesions, which upon rupture can cause acute vascular infarction (66,67). 
Although there is evidence that demonstrates macrovascular and microvasculature 
complications are linked, the changes that occur in the microvasculature are typically one 
of the first observed, at times even before clinical signs of diabetes can be detected (66). 
Given the number of important processes microvessels are involved in, it is 
understandable how dysfunction of these small vessels can have large effects. Two of 
most common and severe microvasculature complications that occur during diabetes are 
diabetic nephropathy and diabetic retinopathy. As will be discussed, both involve 
endothelial cell dysfunction and loss of vascular permeability regulation, leading to 
pathology in the respective organ (68,69). 
1.4.1.1 Biochemical Alterations that Contribute to Microvascular Damage in Diabetes  
 Hyperglycaemia in diabetes is known to cause de-regulation of a series of processes such 
as inflammatory mediators and growth factors, many of which contribute to 
microvascular damage.  TABLE 1-1 gives a brief summary of some of the known molecules 
and pathways to be altered in diabetes and some of the known effects which result from 
its alteration (38,70–81). It should be noted that this is not an exhaustive list, and many 







A major inflammatory mediator listed in TABLE 1-1 is tumour necrosis factor α (TNF- α). 
TNF- α is an inflammatory cytokine produced by macrophages and monocytes, and is 
involved in a multitude of signalling events which result in necrosis and apoptosis (82). 
Elevated levels of TNF- α have been found in both T1D and T2D, which has been shown to 
promote insulin resistance in experimental diabetes (83,84). Additionally, TNF- α is 
thought to contribute to endothelial cell damage and hyperpermeability, as it is involved 
Table 1-1 Summary of Molecule and Pathway Alterations in Diabetes 
A brief summary of some of the known molecules and biological pathways which are altered in 
diabetes, and the effects resulting from such alterations. ↑= upregulating or activation ↓= 
downregulation. Advanced glycation end-products (AGEs), protein kinase C (PKC), hexosamine 
biosynthesis pathway (HBP), reactive oxygen species (ROS), Renin-Angiotensin-aldosterone 
system (RAAS), tumour necrosis factor α (TNF- α), interleukin (IL), vascular endothelial growth 




in endothelial cell activation resulting in alterations of adheren junctional complexes like 
VE-cadherin which are required for vascular barrier integrity, and will be discussed in later 
sections (76). Upregulation of TNF-α also results in increases of other cell damaging agents 
such as ROS (76), which as mentioned earlier also results in damage to eGlx components.  
Another well-known and extensively studied pathway, the renin-angiotensin-aldosterone 
system (RAAS), is activated in diabetes and contributes to the development of 
cardiovascular disease (85). RAAS is involved in a multitude of important physiological 
processing like maintenance of plasma sodium concentration and arterial blood pressure 
(85). As essentially every organ is affected by RAAS, activation of this system negatively 
impacts the vasculature on a systemic level. RAAS activation has been shown to result in 
glomerular, cerebral, and retinal vascular pathologies (86–88), and is a target of diabetes 
treatments as will be discussed later.  
Upregulation of growth factors in diabetes also contribute to vascular damage, and one 
of the most well studied is VEGF, previously mentioned. VEGF is important in 
development, as it has a role in proliferation and angiogenesis (89). In healthy adults, it 
has been shown to have a role in wound healing and bone repair, as well as angiogenesis 
in the uterus, ovaries, and breast, during the female reproductive cycle (89). In diseases 
such as diabetes, upregulation of VEGFA induces vascular endothelial cell proliferation 
and migration, and contributes to vasopermeability in many tissue types (80), and as will 
be discussed in more detail below, contributes to glomerular and retinal pathologies in 
diabetes.  
1.4.2 Microvascular Changes in the Kidney   
1.4.2.1 Changes to the Glomerular Filtration Barrier in Diabetic Nephropathy 
Diabetic nephropathy (DN) is characterised by increased passage of albumin into the urine, 
i.e. albuminuria. There are three categories of urine albumin excretion (UAE); 
normoalbuminuria (0-20ug/min), microalbuminuria (20-200ug/min), and 
macroalbuminuria (>200ug/min) (90,91). Increasing levels of albuminuria are generally 
correlated with DN progression, but not all those diagnosed with DN have albuminuria 
(92). This thesis focuses on early stages of DN, and therefore will focus on development 




The development of albuminuria is thought to result from ultrastructural changes in the 
GFB,  though such changes can also be found in patients without it (93). That being said, 
DN patients do have some characteristic changes to their glomeruli depicted in FIGURE 
1-13. One of earliest observed changes is increase in glomerular size and thickening of the 
glomerular basement membrane (GBM). Increase in glomerular size can be attributed to 
mesangial cell expansion as well as increased capillary size resulting from hemodynamic 
changes (90). Increased GBM thickness is thought to occur due to imbalances between 
synthesis and degradation of extracellular matrix components, contributed to by 
podocytes and endothelium (27,94,95). Other early signs include podocyte foot process 
effacement and therefore reduced podocyte slit diaphragm width (93), the outermost 
barrier in the GFB. Podocyte damage is likely caused by deregulation of crucial podocyte 
proteins like nephrin, podocin, and cluster of differentiation 2 (CD2) adaptor protein, 
amongst others (95). These proteins are crucial for maintaining the structural framework 
of the slit diaphragm, and genetic mutations of such proteins in mice and humans result 
in albuminuria, renal failure, and death (96,97). As VEGF also plays a role in regulating slit-
diaphragm signalling and podocyte structure, the observed upregulation of VEGF in DN 
contributes to these changes (98). However, the characteristic changes seen in DN does 
Figure 1-13 Changes to Glomerular Filtration Barrier in Diabetic Nephropathy 
Early changes in the GFB during DN include thickening of the basement membrane, loss of podocyte 
and podocyte effacement, loss of endothelial fenestrations and eGlx thinning which all contribute to 





not appear to be required for development of albuminuria, as is the case with 
approximately two thirds of type 2 diabetic (T2D) patients who have no changes in 
glomerular structure  (99–101). 
As previously mentioned, endothelial cells of the GFB are in closest contact with flowing 
blood. Due to the chronic exposure of endothelial cells  to high glucose, which itself can 
cause an increase in cell damaging agents like ROS and VEGF as discussed earlier (101), it 
is not surprising that the endothelial cell also fall victim to structural changes during 
diabetes. It has been reported in T1D and T2D that loss of fenestration density occurs 
during diabetes (FIGURE 1-13) and correlates better with albuminuria than does podocyte 
injury (102,103), pointing to endothelial dysfunction as a potential key event in DN 
progression. In agreement with these findings, the protective and functional layer that 
covers endothelial cells, the eGlx, is also damaged during diabetes and there is 
accumulating evidence that loss of eGlx may be an early and key event in the development 
of DN.  
1.4.2.2 Damage to the Glomerular Endothelial Glycocalyx   
During periods of inflammation, such as diabetes, changes to the cellular environment 
can cause dysregulation of a multitude of pathways which can ultimately cause damage 
to the eGlx (FIGURE 1-13) (104). For example, increased ROS occurs under hyperglycemic 
conditions, and in vitro studies show that ROS causes a reduction in cell surface HS, 
suggesting HS is shed (38). ROS also results in increased albumin passage in glomerular 
endothelial cell (GEnC) monolayers (38). An increase in active eGlx shedding enzymes, 
known broadly as sheddases, are also upregulated in diabetes. Both in vivo and human 
studies have shown increases in circulating hyaluronidase and matrix metalloproteinases 
(MMPs), HA/HS and proteoglycan core protein syndecan shedding enzymes, respectively 
(105–108). Active heparanase-1 (HPSE), which directly targets and degrades HS, is also 
upregulated in diabetics with DN (109,110), and presumably is a major factor in 
contributing to eGlx damage, which will be discussed in section 1.5.1.4.1.   
Studies measuring shedding of eGlx components have shown an increase in the serum of 
patients with T1D and T2D patients. Increased sydecan-1, an eGlx proteoglycan, was 
shown to be increased in serum from T1D (111). HA and CS have also been shown to be 
increased in serum from diabetics (104,112). In vivo diabetic rodent models have similarly 
shown increased shedding of eGlx components and sheddases, such as MMPs, HPSE, and 




examine functional and structural changes to the eGlx. Research done in our group using 
EM and fluorescently conjugated lectins that bind strongly to eGlx sugar components 
(FIGURE 1-14), show reduced glomerular eGlx in diabetic rodent models. This decrease 
also coincides with increased albuminuria and glomerular albumin permeability 
(36,108,116), indicating a role for eGlx in maintenance of vascular permeability. Reduced 
eGlx in sublingual and retinal vessels has also been shown in T2D, suggesting a more global 
loss of eGlx damage in multiple vascular beds (58), and therefore may be a key common 
step in the development of microvascular diseases.   
1.4.3 Microvascular Changes in the Eye 
1.4.3.1 Changes to Blood Retina Barrier in Diabetes  
Retinopathy is characterised by a breakdown in the iBRB which results in increased 
microvessel permeability. There are two defined stages of retinopathy, the early stage is 
non proliferative diabetic retinopathy (DR) and the more advanced stage, proliferative DR 
(PDR). This thesis focuses on early stages of disease in the microvessels and therefore will 
be focusing on the earlier stage, DR. The major criteria for diagnosis of DR, is the 
appearance of microvascular lesions (117). Techniques, such as ultrawide-field colour 
fundus photography and fluorescein angiographies, allow clinicians to non-invasively 
monitor changes in DR patients.  During DR, evidence of vessel leakage can be observed 
by imaging the back of the eye, i.e. the retina. Early changes can be seen in the form of 
microaneurysms, retinal haemorrhages, intraretinal microvascular abnormalities, lipid 
Figure 1-14 Diabetes Results in Glomerular eGlx Loss 
A T1D mouse model comparing eGlx in control and diabetic mice. A. Mouse kidney section stained with 
Marasmim oreades agglutinin (MOA) (green), a lectin that binds sugar moieties found in eGlx 
components. Cell membrane is stained red and nuclei blue.  B. Example of how eGlx depth was 
measured using lectin staining. The peak distance between the fluorescent intensity peak of the eGlx 
signal (green) and membrane signal (red) are measured and is representative of eGlx depth. C. A series 
of images were analysed and described in B. Comparison of control and diabetic mice show a significant 




exudates, and cotton wool spots resulting from neuronal infarcts due to capillary non 
perfusion (FIGURE 1-15) (117). 
 
The most common cause of blindness in both DR and PDR is macular oedema (DME) , 
caused by a breakdown in the blood retina barrier resulting in fluid and circulating protein 
leak into the retina (118,119). The use of optical coherence tomography (OCT) allows 
clinicians to measure changes in retinal thickness and has become a valuable non-invasive 
imaging technique used for monitoring the progression of DME. 
Long term clinical studies and histology on post-mortem human eyes have shown that DR 
lesions are preceded/accompanied by even earlier changes in retinal vasculature 
(120,121). This includes loss of pericytes, thickening of vascular basement membrane, and 
eventual endothelial cell death (120,121).  These early changes which can be seen prior 
to vascular lesions in humans, result in vascular integrity and loss of blood flow regulation 
in the retina, which is essential given the high metabolic activity of retinal neuronal cells 
(117). 
Increased vascular permeability in DR has also been associated with changes in junctional 
complexes and increased transcytosis. Frey et al. proposed tight junctions may be 
disrupted by increased ROS which can result in endothelial cell dysfunction as has been 
seen in the kidney, and increased cytokine and growth factors production by neural retinal 
cells caused by hyperglycaemia (72). In a T1D rat model, increased transcytosis, measured 
by horse radish peroxidase staining, was observed in retinal vascular endothelial cells 
Figure 1-15 Changes to the Eye in Diabetic Retinopathy 
Retinopathy causes loss of vessel integrity, leading to hemorrhages, abnormal growth of blood 
vessels, and hard exudates, amongst other complications. Image adapted from 




(RVECs) (122). The observed increase of VEGF in diabetes is also strongly implicated in 
increased vascular permeability, not only in the glomerulus but also in the retina. For 
example, in healthy monkeys injected with VEGF into the vitreous of the eye, increased 
microvascular leak was observed by fluorescein angiographies, and leaky vessels were 
interestingly associated with increased pinocytic vesicles (123). Additionally, VEGF 
induces profibrotic growth factors and extracellular matrix genes in vivo and in vitro (124), 
and likely contributes to the basement membrane thickening observed in early stages of 
the disease previously mentioned. Although the effect/contribution of the eGlx was not 
investigated in these studies, evidence from the kidney showing the effects of ROS, 
cytokines, and growth factors on eGlx loss and permeability, suggest that the similar 
observed changes in the eye can also be linked to early changes in the eGlx.  
1.4.3.2 Damage to Retinal Vascular Endothelial Glycocalyx 
As mentioned, the retinal eGlx in diabetes has not been extensively studied. One study in 
humans showed that retinal eGlx dimensions were decreased in T2D patients  (53). 
Diabetic rodent models have also demonstrated damage to eGlx. In T1D Wistar Kyoto rats,  
eGlx was reduced in retinal and choroidal vessels shown by EM (57), but eGlx staining was 
very patchy (FIGURE 1-16)  even in control animals and therefore may not be reliable.   
 
A study in Akita mice, a T1D model, also saw a reduction in retinal eGlx by measuring the 
difference in vessel diameter of the fluorescent peaks using TRITC-dextran and sodium 
fluorescein, which the authors suggest represents eGlx depth (59). However, these 
authors did not report if functional changes occurred in vascular permeability. Studies on 
T1D rats also demonstrated a reduction in retina eGlx depth by EM and an increase in 
Figure 1-16 Loss of Retinal eGlx in Diabetic Rats 
Electron micrographs of rats perfused with ionic colloidal iron stain. Albeit patchy, the eGlx can be 
visualised in nondiabetic control rats (black arrows), while diabetic rats show absence of eGlx.  




retinal vascular permeability using FITC-Dextran  (60) , though as in (FIGURE 1-16), the 
eGlx staining was also patchy, including in the control animals. In this same study, 
overexpression of EMCN in T1D rats  restored retina  eGlx and resulted in a significant 
decrease in permeability, indicating that protection of retinal eGlx in diabetes prevents 
permeability increase (60).  As in diabetic kidneys, HPSE has also been shown to be 
upregulated in the retinas of diabetic rats and epiretinal membranes of DR patients, but 
the effects on eGlx and HS were not investigated in these studies(125,126).  These data, 
along with the noted upregulation of eGlx damaging agents like ROS and cytokines, all 
point to a role for eGlx in the retina. However, the evident lack of research makes it clear 
that there is still much work that needs to be done in characterising the exact role of HS 
and eGlx in health and disease of the retina, which can be applied to the development of 
treatment of retinopathy and  microvascular complications.  
  Treatments in Diabetes  
1.5.1.1 Current Diabetes Treatments and Prevention of Vascular Disease  
Current treatments for T1D and T2D are aimed at maintaining blood glucose levels within 
the normal range, avoiding spikes or dips in glucose levels (127). For T2D, in addition to 
changes in diet, and physical activity aimed at weight loss, multiple treatments that 
increase insulin sensitivity are used in conjunction to target multiple organs (128). 
Treatments include metformin and thiazolidinediones (TZDs), which both act by inhibiting 
the increased hepatic gluconeogenesis in the liver, which causes elevated hepatic glucose 
production in T2D (129–131). Though this action helps in lowering blood glucose levels, 
the United Kingdom Prospective Diabetes Study (UKPDS) showed that over the course of 
fifteen years, metformin failed to provide any protective effects on -cell function and 
glycaemic control, which ultimately leads to progressive diabetic complications (132). 
Another common class of drugs used to manage blood glucose levels are sulfonylureas. 
Sulfonylureas work by binding to the sulfonylurea receptor on -cells, stimulating insulin 
secretion and lowering glycated hemoglobin (HbA1c), which directly correlates to blood 
glucose levels (131). Similarly to metformin, the UKPDS found that sulfonylurea did not 
help retain -cell function after 6-12 months of treatment, and in fact led to increased 
HbA1c levels due to progressive -cell loss (128). In contrast, studies have shown that 
TZDs do help maintain -cell function, but these class of drugs can also increase weight 
gain, fluid retention, and cause heart failure (131,133,134). Because T2D patients are at 
an increased risk of developing cardiovascular disease and both T2D and hypertension are 




to control blood pressure, like angiotensin converting enzyme inhibitors (ACEI), 
angiotensin receptor blockers (ARBs), RAAS blockers (135). Although various treatments 
have proven effective at preventing or slowing the process of DN and DR, the issue of 
blood glucose regulation remains and studies have shown, even with multiple types of 
treatment, target blood pressures are often not met, leaving an increased likelihood of 
developing cardiovascular disease (86).    
Although T1D treatment aims to control blood glucose levels just as in T2D, T1D is 
primarily treated with exogenous insulin or insulin analogues. Because T1D individuals 
have decreased -cells and therefore decreased insulin production, patients require 
insulin injections that allow glucose to be taken up by neighbouring organs. While 
exogenous insulin injections help regulate blood glucose levels, the inability of patients to 
physiologically respond to glucose spikes the way a healthy individual would, leads to 
hyperglycaemia episodes (136). These spikes contribute to complications previously 
mentioned, like nephropathy and retinopathy (136). In addition, exogenous insulin doses 
can also lead to episodes of hypoglycaemia, which has a mortality rate of 3-6% (137). 
Efforts have also been made using immune therapy, which aims to minimise the immune 
system’s destruction of -cells, slowing the progression of T1D (136,138). While this 
approach helps preserve patients’ remaining -cells, treatments used to accomplish this, 
like cyclosporine, have been shown to not only have short term effects, but also cause 
nephrotoxicity (136,138). In more extreme cases, whole pancreas, islet 
allotransplantation, and in some cases simultaneous pancreas/kidney transplantation, 
have been used successfully, but donor tissues are limited (139). With the added risk of 
required immunosuppressant to prevent tissue rejection, this is not a feasible treatment 
option except in the most severe cases (139). Given the increasing trend in diabetes 
diagnoses and the lack of fully effective treatments, most of which come with serious side 
effects or added complications, it has become increasingly important that a safe, effective, 
and accessible treatment be developed that can prevent complications associated with 
diabetes, like microvascular disease. 
1.5.1.2 Diabetic Nephropathy Targeting Treatments  
Unfortunately, there is currently no single treatment that is used to treat DN. Methods 
aimed at prevention and slowing progression are the main form of treatment, many of 
which have already been discussed in the previous section. However, treatments like ACE 
inhibitors may be favoured as they have shown to help lower albuminuria and blood 




in T1D and T2D by inhibiting aldosterone, which promotes fibrosis, ROS production, and 
endothelial cell dysfunction (142,143). The addition of calcium channel blockers (CCB) to 
RAAS blockers also appears to lower albuminuria in T2D (144).  Treatment of T2D and 
chronic kidney disease patients with sodium glucose transporter-2 (SLGT-2) inhibitors, 
which are typically used to lower blood sugar in T2D has also shown protective renal 
effects that lowers albuminuria and slows progression (145). Similarly, glucagon-like-
peptide-1 (GLP-1) receptor agonists, which are also used to lower blood sugar in T2D, have 
been shown to  reduce albuminuria (146). In more progressed stages of the disease, 
kidney dialysis may be used to aid loss of kidney function, but unfortunately this does not 
reverse damage or restore function, and compared to non-diabetic counterparts, dialysis 
patients have a higher mortality and morbidity rate (147).  
Of note, there are currently no treatments that specifically target the glomerulus 
therapeutically. And as discussed above, most of the current treatments have added side 
effects despite the benefit of lowering albuminuria, as is the case for some treatments. 
Therefore, an ongoing search for treatments that can safely and effectively target and 
prevent changes in DN is required   
1.5.1.3 Diabetic Retinopathy Targeting Treatments 
As with DN, DR treatments are firstly preventative with the same course of action as 
described above. However, DR does have some more targeted treatments to prevent DR 
progression. One of the most effective and widely used treatments for DR is anti-VEGF 
therapy. As previously discussed, VEGF is upregulated in diabetes and promotes loss of 
vascular integrity by promoting loss of pericytes and endothelial cell dysfunction, amongst 
other vascular deteriorating effects discussed above, which results in increased 
permeability (124). Additionally, VEGF is a pro-angiogenic protein which stimulates 
neovascularization. Although areas of the eye in retinopathy suffer damage due to 
hypoxia, VEGF actually promotes DR progression due to the uncontrolled and poor 
integrity of newly formed vessels, which leads to increased leak and DME (119). Anti-VEGF 
treatments are administered intravitreal, i.e. an injection directly into the vitreous of the 
eye. Though this treatment has proven effective in multiple studies, anti-VEGF agents 
have a short half-life and require DR patients to receive injections one to two times a 
month (119,148,149). Other treatments like anti-inflammatory corticosteroids, which 
target mediators of DR progression, like VEGF, TNF-α, and 
phosphorylation/destabilisation of tight junctions, are effective in preventing DR and 




into the vitreous, as with VEGF, but in a biodegradable capsule, thereby reducing the 
number of intravitreal injections required. Unfortunately, these treatments have 
increased side effects, including cataract development and elevated intraocular pressure 
(150,151). Non-steroidal anti-inflammatory drugs, which may have less side effects, are 
currently in clinical trials targeting IL-6 and integrin, one of the major proinflammatory 
cytokines and adhesion molecules promoting inflammation in DR patients, respectively 
(149). One of the older and most used therapies, second to anti-VEGF treatments, is laser 
photocoagulation. Panretinal photocoagulation involves creating multiple small burns in 
the retina, which results in reduced ischaemia, a major driving force for VEGF production 
in the retina, and promotes neovascularisation (152). Focal photocoagulation, another 
type of laser treatment, involves a strong but precise laser used to directly target and 
close microaneurysms, stopping vessel leak (153). The obvious draw-back to these 
treatments, despite advances in laser technology, is the likelihood for permanent laser 
damage causing loss of mild central vision and  reduced night vison (154). While DR clearly 
has more effective and targeted therapies, they do not come without both side effects 
and difficulty of administration as discussed. Additionally, these targeted treatments are 
given once increased permeability and changes in the eye have already been detected, 
and do not help the wider issue of initial development and progression of microvascular 
disease.  
1.5.1.4 Glycocalyx Targeting Treatments  
The role of eGlx in maintenance of vascular permeability, along with data showing that 
changes in the cellular components of the GFB ultrastructure  are not required for the 
development of microalbuminuria, suggests that an early intervention targeted at 
restoring the eGlx may help slow or stop the progression of microvascular complications 
like DN and DR.  
One of the approaches that has been tested experimentally as a therapeutic to restore 
eGlx and mitigate the negative effects diabetes has on the vasculature is the use of growth 
factors known to upregulate eGlx components. Our group has shown that in tissue culture, 
VEGF-C treatment increased production of highly charged GAGs by GEnC (33). In 
agreement with this, we showed in a transgenic T1D mouse model, mice whose podocytes 
overexpressed VEGF-C had slowed progression of DN (116). It has also been demonstrated 
that in a diabetic mouse model with a systemic injection of VEGF-A165b, an isoform of 
VEGF, protected against DN and helped restore the eGlx (155). Additionally, Schott, U. et 




such as hydrocortisone and albumin (41), however these experiments were performed in 
vitro/isolated organ models and the effects this would have in vivo are unclear. While 
many of these treatments remain promising, they primarily target the eGlx through 
alternate pathways that lead to its restoration, and the complexity of diabetes associated 
vascular disease requires a multitude of available treatments.  
In humans, some progress has been made in the direction of directly targeting the eGlx in 
diabetic patients. The eGlx is a crucial structure which contributes to 50% of the overall 
hydraulic resistance of the GFB (156), and likely contributes significantly to vascular 
barrier functions in other vessel beds as well, as has been demonstrated in cardiovascular 
diseases (56). Because the eGlx is a tightly bound network and HS is the most abundant 
GAG, it is not surprising that loss of HS may have detrimental effects on the integrity and 
functionality of the eGlx. To combat this, Sulodexide, a mixture of low-molecular weight 
heparin (80%) and dermatan sulphate (20%), has been used to treat DN and DR. Initially, 
several studies showed success in using Sulodexide as a therapeutic, showing an increase 
in sublingual and retinal glycocalyx dimensions (58), and decrease in albuminuria 
(157,158). Unfortunately, two larger randomized double-blinded placebo control studies 
later showed that treatment with Sulodexide did not reduce albuminuria when compared 
to placebo and had no renoprotective effects (157,159). Despite negative results however, 
there is still value that has come from these studies. The initial success of Sulodexide has 
made it a drug that continues to be studied for use in vascular diseases, with positive 
effects seen with long-term low-dose treatment in nephropathies and peripheral artery 
diseases (160,161). A one year study in patients with mild to moderate DR also showed 
reduction in  macular hard exudates which result from lipid and protein leaking from 
vessels, though eGlx was not addressed in this study (53).  The continual positive results, 
using Sulodexide, shows that treatment with a compound that has been shown to restore 
the eGlx has potential, and perhaps the use of a different and more potent compound 
with a similar end result could be successfully used to protect from microvasculature 
complications during diabetes.  
Interestingly, an in vitro study by the same group who showed protection from DN in 
diabetic patients with Sulodexide, published a potential mechanism for DN protection 
(162). The group showed that Sulodexide can act as a HPSE inhibitor, exclusively due to 
its heparin component (162). Though not specifically addressed in this study, it is possible 





1.5.1.4.1 HPSE as a Potential Target for eGlx Restoration in DN and DR 
Briefly mentioned in earlier sections, the HS shedding enzyme, HPSE, is elevated in 
diabetes. HPSE is an endo-β-ᴅ-glucuronidase and is the only known enzyme in humans 
that cleaves HS. Another protein, Heparanase-2 (HPSE-2), which has a similarity of 40% 
with HPSE, lacks enzymatic activity and actually inhibits HPSE (163). HPSE cleaves HS at 
specific sites, β(1,4) glycosidic linkage between GlcA and GlcNS, which generates small 5-
10kDa HS fragments (164). These fragments have themselves been shown to have 
biological activity. For example, in melanoma studies, HPSE-cleaved HS from melanoma 
cells promoted cell migration and angiogenesis in rodent studies (165). In vitro studies 
also show HS fragments generated by HPSE stimulate cytokine production in peripheral 
blood mononuclear cells (166). Similarly, shed HS fragments from patients who 
underwent aortic bypass surgery also had the ability to directly activate leukocytes and 
platelets (167), in turn releasing more HPSE.  
The investigation into HPSE in disease for the most part has been in its involvement with 
cancer metastasis (168). But HPSE is also upregulated in many inflammatory and 
proteinuric diseases like IgA nephropathy, minimal change disease, dense deposit disease, 
membranous glomerulopathy, and DN (169). In T2D patients, increased HPSE staining in 
kidney biopsies was correlated with overt DN (109). Interestingly, HPSE may also be 
required for the development of DN, as was shown in a recent article in which T1D HPSE 
knockout mice failed to develop DN, compared to T1D wild type (WT) controls (114). The 
same authors also demonstrated reduced albuminuria in WT T1D and T2D mice when 
treated with the HPSE inhibitor SST0001, but did not investigate the effect on eGlx (114). 
In DR, upregulated HPSE in the vitreous of PDR patients has been observed (125). In 
agreement with this, high glucose was found to stimulate HPSE expression in human 
retinal endothelial cells, in vitro (126). As added evidence for a role of HPSE in DR, retina 
flat mounts from T1D rats had increased HPSE expression and was reduced by treatment 
with the HPSE inhibitor phosphomannopentaose sulphate (126). However, functional 
studies to determine if inhibiting HPSE reduced vascular leak, or if eGlx was impacted, 
were not carried out and therefore requires further investigation. Despite this, there 
appears to be accumulating evidence for a role of HPSE in DN and DR, and it is possible 




 Hypothesis and Aims  
1.6.1 Endothelial Glycocalyx Heparan Sulphate as a Therapeutic Target in Diabetic 
Nephropathy and Retinopathy  
Although the presence and dominating abundance of HS in the eGlx is well established, 
most of the work on HS has been focused on its role in the extra cellular matrix and 
basement membrane, but the functional and structural role it plays in the eGlx has not 
been looked at in detail, particularly  in vivo.  In vivo studies in mice glomeruli in which 
mice were treated with heparinase III, an HS shedding enzyme derived from 
Flavobacterium, suggested a perm-selectively role  for HS in the eGlx, but the method of 
EM fixation did not allow for direct visualisation of eGlx (170).  Heparinase III treatment 
of bovine aortic endothelial cells in vitro show that HS acts as a mechanotrasducer for 
fluid sheer stress, crucial to vascular endothelial cell function, but the direct effect on 
permeability and eGlx structure was not studied (171). Therefore, more work is required 
to establish the functional and structural role HS has in the eGlx.  
Damage to the eGlx in disease, and most relevant to this thesis, in diabetes, has also been 
well established in both humans and in vivo laboratory experiments, albeit not in all vessel 
beds. However, the role of HS specifically in the eGlx and in disease has not been studied 
in depth. Staining on human kidney biopsies in DN patients have shown a reduction in 
glomerular HS staining (109), although the antibody used primarily detected GBM HS. 
However, loss of HS in the same glomerulus also coincided with an increase in HPSE 
expression (109). Given the upregulation of HPSE in both DN and DR, it may serve as a 
target to prevent eGlx damage and slow progression or development of DN and DR. 
1.6.2 Hypothesis 
The previously published studies have led me to the following hypothesis: 
Heparan sulphate has a structural and functional role in the endothelial glycocalyx and is 
damaged in diabetes. Prevention of heparan sulphate shedding in diabetic mice will 
ameliorate endothelial glycocalyx damage and restore barrier function in glomerular and 






1.6.3 Aims  
To test my hypothesis, I have conducted experiments with the following aims in mind.  
Aim 1: Demonstrate the Importance of Endothelial Glycocalyx Heparan Sulphate in Kidney 
and Retinal Vasculature  
I will perform in vivo and ex vivo studies to test if reduced HS, by enzymatic removal or 
use of a transgenic mouse model, results in structural damage to the eGlx and loss of 
function in the glomerulus and retinal vasculature. Damage to the eGlx structure will be 
assessed by imaging techniques such as electron microscopy and immunofluorescence 
staining. Functional studies in the glomerulus will use the ex vivo technique developed by 
Desideri et al., to determine changes in apparent glomerular albumin permeability (36). 
In the eye, sodium fluorescein angiographies will be performed and used to develop an 
‘apparent solute flux’ assay.  
Aim 2: Determine if the Endothelial Glycocalyx is Damaged in a Type 2 Diabetic Mouse 
Model in the Glomerulus and Retinal Vasculature  
In vivo studies will be performed in a T2D mouse model using db/db mice. Damage to eGlx 
in the glomerulus and the retina will be determined using the same techniques described 
in Aim 1. Similarly, the same functional studies described in Aim 1 will be performed to 
address changes in eGlx function in the glomerulus and retina during diabetes.  
Aim 3: Demonstrate That Prevention of HS Shedding by Inhibiting HPSE in a Type 2 Diabetic 
Mouse Model Will Restore eGlx Structure and Function  
In order to prevent HS shedding and damage to the eGlx, db/db mice will be treated with 
either vehicle or a novel HPSE inhibitor OVZ/HS-1638 and restorative effects of treatment 
determined using the same structural and functional assays described in Aim 1 and Aim 
2. Non-diabetic controls treated with vehicle will act as healthy controls.  
1.6.4 Potential Outcomes 
This investigation of the role of HS in the eGlx takes place in two spatially (kidney vs eye) 
and functionally (fenestrated vs continuous) different vascular beds. This allows a more 
global investigation into determining if therapeutically targeting HS eGlx in diabetes has 
beneficial effects on microvascular permeability. If successful in both vascular beds, the 
use of this novel inhibitor has the potential to be used for treatment of all early 




 Methods and Materials  
These methods are not inclusive. Methods pertaining specifically to experiments in 
specific chapters can be found in the methods section of that chapter.  
 In Vivo Work  
2.1.1 Animal Licence  
I obtained a personal license (PIL No.: I167CEA42) for all work involving live animals. All 
animal work was performed in compliance with The University of Bristol’s guidelines and 
the Animal (Scientific Procedure) Act 1986 on Dr. Rebecca Foster’s project license (PPL 
No.: 30/3048 and P855B71B4), approved by UK Home Office.    
2.1.2 Animals 
FVB and C57BL/6 mice were ordered from Charles Rivers (Charles Rivers Laboratories, 
Wilmington, MA). Ext1 mouse colony is maintained in Barn 1 at the University of Bristol 
Animal Service Unit (Bristol, England). Five-week-old and 7-week-old BKS.Cg-
+Leprdb/+Leprdb/OlaHsd (db/db) and lean littermate controls (lean) were ordered from 
Envigo (Envigo, Cambridgeshire, England, UK). 
2.1.3 Anaesthesia  
Isoflurane was used as anaesthetic for all the following procedures at 2.5%, 1.5 litre/min 
unless otherwise specified: retro orbital injections, tail vein injections, cardiac perfusions, 
and OCT/fluorescein angiographies.  
2.1.4 Measurement of Mouse Weights 
Electric scales were used to measure mouse weights when appropriate, or daily in diabetic 
studies. Scales were zeroed with weight bucket and individual mice placed in bucket and 
weight recorded.  
2.1.5 Urine Collection for Albumin Creatinine Ratios  
Unless otherwise specified, all mouse urines were collected in metabolic cages allowing 
separation of solid and liquid waste. Mice were provided with drinking water and 
enrichment. Mice were left in metabolic cages for a maximum of 6 hours.  
2.1.6 Measurement of Blood Glucose in Mice  
Blood was obtained weekly in diabetic studies from end of tail prick with 18G needle for 




standard glucometer (range 0-40mmol/L) with Accu-Check AVIVA test strips (Roche 
Diagnostics Limited, West Sussex, England).   
2.1.7 Treatment of Mice with Heparinase III for HS Shedding  
6 week old FVB (EM and glomerular permeability studies) or C57BL/6  (fluorescein 
angiographies) mice were given 0.1ml retro orbital injections of heparinase III from 
Flaviobacterium (H8891, Sigma-Aldrich, St. Louis, MO) reconstituted in Phosphate 
Buffered Saline (PBS) (137mM NaCl, 27mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4) at 
8.2u/kg or PBS only for vehicle. Dose required for shedding of eGlx was previously 
optimised following the same procedure using vehicle, 8.2, or 82u/kg of enzyme (FIGURE 
2-1). Mice were kept under light anaesthetic for 30 min on a heating pad. To prevent 
drying of the eyes, drops of eye lubricant gel were put on both eyes. After 30 min, mice 
were prepared for cardiac perfusions or sodium fluorescein angiographies described in 
2.1.10 and 2.1.11 below.  
 
Figure 2-1 Heparinase III Pilot Experiment 
A. Representative retina microvessel EM images of vehicle or enzyme treated mice perfused with Alcian 
blue/ glutaraldehyde. EGlx (arrowhead) is visibly thinner and patchy in 8.2u/kg treated mouse  B. 
Quantification of eGlx depth (left) and eGlx coverage (right). Note, does not represent a real statistical 
difference. N=1 mouse per group, three capillaries analysed per mouse. Statistics performed on capillaries 




2.1.8 Administration of HPSE Inhibitor in Diabetic Studies 
HPSE inhibitor OVZ/HS-1638 (Olga Zubkova, Ferrier Research Institute, Victoria University 
of Wellington) was reconstituted in PBS and stored at -20°C until time of use. Inhibitor 
was administered once daily through subcutaneous (s.c.)  or intraperitoneal injection (i.p.) 
at 20mg/kg for 14 days starting at 7 weeks or 9 weeks of age, respectively. Vehicle mice 
were administered only PBS. 
2.1.9 Alcian Blue Cardiac Perfusions for Electron Microscopy of Kidney and Eye 
Tissue   
Mice were anaesthetised until no pain response was evident using tail and foot pad pinch 
method. Mice were cardiac perfused at 100mmHg with 30ml of Ringer’s solution pH 7.4 
(132mM NaCl, 4.6mM KCl, 1.27mM MgSO4(7H2O), 2mM CaCl2(2H2O) with 5.5mM D-
glucose, 3.07mM HEPES acid, 1.9mM HEPES base), followed by 30mL of Alcian blue  in 
fixative solution composed of 0.15M sodium cacodylate pH 7.4 (NaCa Buffer), 2.5% 
glutaraldehyde, and 0.01g/mL of Alcian Blue 8GX (75881-23-1, Santa Cruz Biotechnology, 
Dallas, TX) in water. Fixed kidney was removed, cut into small pieces and put into fixative 
solution until processing. Mouse eyes were enucleated and put into fix solution until 
processing (SECTION 2.2). 
2.1.10 Cardiac Perfusion for Ex Vivo Glomerular Permeability Assay  
Mice were anaesthetised until no pain response was evident as above and cardiac 
perfused with Ringer’s solution as above to remove red blood cells. Renal artery was 
clamped with metal clip and kidney removed and placed into ice cold Ringer’s solution 





2.1.11 Optical Coherence Tomography (OCT) and Sodium Fluorescein 
Angiographies (FA)  
A Micron IV imaging system (Phoenix Research Labs, Pleasanton, CA) was used for OCT 
and FA retinal imaging. Initial training was given by Dr. David Copland (Bristol 
Ophthalmology, The University of Bristol). Thirty minutes prior to imaging, mouse pupils 
were dilated with Tropicamide 1%w/v (Bausch and Lomb, Rochester, NY). Mice were 
anesthetized with isoflurane unless otherwise stated. Mouse nose cone which allows 
access to the eyes was used (SOMNO-0801, Kent Scientific Corporation, Torrington, CT).  
To prevent drying of the eye, drops of eye lubricant gel were put on both eyes for duration 
of imaging and recovery. Schematic of setup shown in FIGURE 2-2. Mice were positioned 
on the imaging stage for OCT imaging and images were taken averaging 30 frames per 
second. The following camera settings were used for FAs: Gain-10, User defined-2, exciter 
filter wheel- 2, barrier wheel-2. Camera settings were kept the same for duration of FA 
imaging for all mice, intensity and focus knobs changed as needed prior to start of video. 
Mice were given 50µl of 10% Sodium Fluorescein (NaF), sterile filtered with 0.22μm pore 
filter and diluted in water, by i.p. injection or intramuscular injection (i.m.) as specified. 
Recording began after NaF injection. All settings remained unchanged for all recordings. 
Analysis of images is described in SECTION 2.2. Once completed, mice were allowed to 
recover on a cage placed on top of a heating pad before being placed in original cage.  
 
Mouse is put onto stage where mouse nose cone lays and is connected to isoflurane rig. Mouse 
eye is focused with camera and OCT image is taken. Once ready, recording begins and sodium 
fluorescein injection is given while mouse remains in situ and under anaesthetic.   
 




 Ex Vivo and In Vitro Work, and Analysis  
2.2.1 Immunofluorescence with anti-HS Phage Display Antibodies in Paraffin 
Embedded Kidney  
Kidney harvested from respective mice were fixed in 4% paraformaldehyde (PFA) for 
minimum of 24 hours and were paraffin embedded and sectioned at 5m at The 
University of Bristol Histology Lab. For immunofluorescence, slides were deparaffinized 
two times in Xylenes for 10 min. Slides were rehydrated by sequential 5min incubations 
in decreasing ethanol concentrations: 100% twice, 95%, 70%, and 50%. Slides were 
incubated in deionized water for 5min followed by a 15min incubation in PBS. Slides were 
blocked for 30min in block solution (3%BSA/0.3% Triton-X in PBS). Anti-HS phage display 
antibodies (gift from Jerry Turnbull, The University of Liverpool) were diluted 1:5 and 
incubated at 4°C overnight. The following antibodies were screened for eGlx staining 
(HS3A8V, HS4C3V, LKIV69V, EV3C3V, MPB49V) (172). These antibodies  were previously 
shown to identify distinct HS epitopes in embryonic rat lung, but due to the nature of HS 
binding flexibility, distinct binding epitopes have not been determined (173) . Slides were 
washed three times for 5min in PBS. Secondary anti-VSVG (A190-131A, Bethyl 
Laboratories, Inc., Montgomery, TX) was added for one hour at room temperature 1:50. 
Slides were washed three times for 5min in PBS. Tertiary anti-rabbit 488 (A-11001, 
ThermoFisher Scientific, Waltham, MA) was added for 1 hour at 1:500. Slides were 
washed three times for 5min in PBS. Tissue was counterstained in 300nM 4’,6-Diamidino-
2-Phenylindole, Dihydrochloride (DAPI) (D1306, ThermoFisher Scientific) for 5min 
followed by 15min membrane stain with Octadecyl Rhodamine B Chloride (R18) (O246, 
ThermoFisher Scientific) diluted 1:1000 in PBS. Slides were washed in PBS for 5min and 
coverslip mounted with Pro long gold (P10144, ThermoFisher Scientific).  
2.2.1.1 Confocal Imaging  
Multi-Laser CLSM Leica SP5 provided by University of Bristol Wolfson Bioimaging Facility 
was used for confocal imaging unless otherwise specified. Slides were imaged using 100X 
oil immersion lens for eGlx analysis.  
2.2.1.2 Analysis of Total Glomerular HS Staining in Mouse Kidney  
Images were analysed on FIJI image analysis software (174). To measure total glomerular 
HS, the freehand selection tool was used to draw around glomeruli perimeters. The 
“analyse” tool was used to obtain area, mean grey values, and integrated density values 




mean grey value mean was calculated for each image by average the background mean 
grey values.  To calculate Corrected Total Cell Fluorescence (CTCF) the following equation 
was used: 
𝐶𝑇𝐶𝐹 = 𝐼𝑛𝑡𝐷𝑒𝑛 − (𝑎𝑟𝑒𝑎 𝑜𝑓 𝑟𝑒𝑔𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑥 𝑚𝑒𝑎𝑛 𝑓𝑙𝑢𝑜𝑟𝑠𝑐𝑒𝑐𝑒 𝑜𝑓 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑚𝑒𝑎𝑛𝑠) 
Equation 2-1 
A minimum of three glomeruli per mouse were measured, and CTCF values for each group 
were averaged. Statistics performed on mouse number.  
2.2.2 Urine Albumin Creatinine Ratios (uACR) 
Urine ACR for each mouse was calculated by determining the amount of albumin (mg/L) 
and creatinine (mmol/L) in the urine. Ratio was calculated by dividing albumin 
concentration by creatinine concentration to obtain uACR (mg/mmol). Urine was 
centrifuged at 13,000rpm for 30 seconds to remove debris prior to analysis.  
2.2.2.1 Mouse Urine Albumin Enzyme-Linked Immunosorbent Assay (ELISA)  
Albumin levels in mouse urine were obtained using the Mouse Albumin ELISA 
Quantitation Set (E90-134, Bethyl Laboratories, Inc.) following manufactures instructions. 
If needed, urine samples were diluted in sample/conjugate diluent solution to obtain an 
optical density reading within the linear range of the assay FIGURE 2-3 and actual 
concentration was back calculated from dilution factor.   
 
 
Figure 2-3 Example of Standard Curve for Albumin ELISA 
Example of standard curve for ELISA albumin assays. Dotted line shows the linear 




2.2.2.2 Urine Creatinine 
Mouse urines were sent to Langford Vets Diagnostic Laboratories (The University of 
Bristol) for creatinine measurements using an Enzymatic Creatinine Assay (ThermoFisher 
Scientific). 
2.2.3 Isolation of Retinas from Enucleated Mouse Eyes  
Mouse retinas for retinal flat mounts and EM were isolated from enucleated eyes. Under 
a dissection microscope, an incision was made along the eye to separate anterior and 
posterior cups of eye (FIGURE 2-4 A). Once separated, lens and anterior cup were 
discarded (FIGURE 2-4 B,C).  
 
To remove the retina from eye cup, cup was turned over to allow visualisation of retina. 
Small tweezers were used to carefully separate retinal pigment epithelium and choroid 
layer (FIGURE 2-5 A,B). This was continued until retina could be easily separated (FIGURE 
2-5 C). In unperfused vessels or Alcian blue perfused eyes, some faint vessels may be 
visible as shown in FIGURE 2-5 D. 
Figure 2-4 Dissection of Mouse Eye for Retinal Isolation 
A. Image of enucleated eye from mouse under dissection microscope. Orientation of eye labelled. B. 
View of back of eye, arrow points to optic nerve entrance. C. Image of eye cut in half into posterior and 






2.2.4 Electron Microscopy Processing and Sectioning for Alcian Blue Tissue  
All processing and sectioning of EM samples were completed by me. Training and 
processing were completed at the Wolfson Bioimaging Facility at The University of Bristol. 
EM samples were removed from fixative buffer and washed in 0.1M sodium cacodylate 
(NaCa) buffer three times for 5min. Samples were switched to 1% OsO4 in 0.1M NaCa 
Buffer for 1 hour and washed in NaCa buffer again three times for 5min followed by a de-
ionized water wash. Samples were incubated in 3% aqueous uranyl acetate (UA) in the 
dark for 30mins and washed with de-ionized water. Samples were dehydrated through a 
series of increasing concentration of ethanol washes (70%,80%,90%,96%,100%) followed 
by propylene oxide washes for 10min, three times. Samples were then incubated 
overnight in a 1:1 mixture of Epon and propylene oxide overnight. Samples were switched 
over to fresh 100% Epon and incubated overnight on a rocker. Samples were embedded 
in fresh Epon in silicon moulds and allowed to cure for 72 hours at 60°C. Blocks were 
trimmed and sectioned using the ultramicrotome Leica EM UC7 (Leica Microsystems, 
Milton Keynes, England, UK) first at 1000nm using homemade glass knives to confirm area 
of interest and then at 70nm with DiATOME diamond knife (Electron Microscopy Sciences, 
Hatfield, PA). Sections were mounted on copper grids and stained in UA for 10 min 
followed by two 5min washes in de-ionized water. Grids were stained once more with a 
lead stain made by mixing of 1mL Sodium citrate, 1mL lead nitrate, and 0.38mL of NaOH. 
Grids were incubated in stain for 10min followed by two 5min washes in de-ionized water. 
Grids allowed to dry before imaging.  
Figure 2-5 Isolation of Retina from Eye Cup 
A. Image of inside of posterior part of eye. B. Enlarged image shows retina layer separating from 
choroid layer, as well as area where optic nerve attaches to retina.  C. Image of isolated retina once 





2.2.5 Imaging and Quantitative Electron Microscopy Analysis  
2.2.5.1 Electron Microscopy Imaging 
EM images were taken on FEI Tecnai 12 120Kv BioTwin Spirit transmission electron 
microscope (ThermoFisher Scientific, Hillsboro, OR) provided by the Wolfson Bioimaging 
Facility. High power images (49,000x magnification) used for EM analysis.  
2.2.5.2 Glomerular Filtration Barrier Measurements 
A minimum of three capillaries per glomerulus were measured for each animal. Analysis 
was done using FIJI image processing program using the measurement tool. Examples of 
how measurements were taken are shown in (FIGURE 2-6). GBM thickness was measured 
by averaging a minimum of ten measurements per image. Number of endothelial 
fenestrations were determined by counting the number of fenestrations per image and 
normalizing to total length of GBM measured. Slit diaphragm (SD) width and podocyte 
foot process (PFP) width was measured from relevant lipid bilayer to lipid bilayer.  
 
Glycocalyx depth and coverage was analysed only where the phospholipid bilayer was 
easily distinguishable, to allow for accurate measurements. To eliminate bias 
measurements, two steps were taken. First, all images were blinded for analysis. Second, 
images were covered in a grid and where intersecting grid lines also intersected lipid 
bilayers, glycocalyx measurements were taken (FIGURE 2-6, B). Glycocalyx depth was 
Figure 2-6 Analysis of Glomerular Filtration Barrier Ultrastructure and eGlx 
A.  Red lines indicate how measurements for each parameter are taken. Measurements are made from 
lipid bilayer to lipid bilayer of next point. Number of fenestrations are counted and divided by length of 
basement membrane (BM) measured. B. A grid is placed over the image to be analysed and Glx (arrow 
heads) measurements for endothelial cells and podocytes are made where intersecting grid marks lay 





calculated by averaging all depth values for that capillary. Percent coverage was 
calculated as follows:  
% 𝐺𝑙𝑦𝑐𝑜𝑐𝑎𝑙𝑦𝑥 𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = 1 − (
𝑡𝑜𝑡𝑎𝑙 𝑚𝑒𝑎𝑠𝑟𝑢𝑚𝑒𝑛𝑡𝑒𝑠 𝑙𝑒𝑠𝑠 𝑡ℎ𝑎𝑛 10𝑛𝑚
𝑡𝑜𝑡𝑎𝑙 𝑚𝑒𝑎𝑠𝑢𝑟𝑚𝑒𝑛𝑡𝑠
) 𝑥 100% 
2.2.5.3 Retina Microvessels Measurements  
A minimum of three microvessels were measured per animal, and a minimum of five 
images were analysed per microvessels. Retinal basement membrane thickness was 
measured by averaging a minimum of ten measurements per image FIGURE 2-7. 
Glycocalyx measurements were taken as described above for glomerular filtration barrier, 







Figure 2-7 Analysis of Retina EM Images 
A.  Red lines indicate how measurements for basement membrane (BM) thickness are measured. 
Measurements are made from lipid bilayer to lipid bilayer of next point. B. A grid is placed over the 
image to be analysed and eGlx (red arrow heads) measurements are made where intersecting grid 
marks fall on lipid bilayer (red crosses). Glx is measured from endothelial lipid bilayer to end of Glx 




2.2.6 Glomerular Albumin Permeability Assay and Analysis 
To determine changes in permeability, our lab recently developed an assay allowing us to 
measure fluorescently labelled albumin permeability across a single glomerular capillary 
wall. This assay is more sensitive and allows for direct measurement of glomerular 
albumin permeability in the absence of other physiological processes that contribute to 
variations in measurements of albuminuria. To do this, glomeruli were perfused with 
Ringer’s solution as described above, to clear capillaries of red blood cells and other debris 
that could interfere with permeability measurement. Glomeruli were isolated from 
kidneys in 4%BSA ringer by using a series of sieves with decreasing pore size 
(425,180,125,100,71m) and a 5mL plunger to push glomeruli through. Glomeruli were 
isolated from 75µm sieve. Glomeruli were resuspended in 1mL of 4% BSA ringer 
containing 36.5µg/mL R18 (O246, ThermoFisher Scientific, Waltham, MA) and incubated 
in the dark for 15 min on ice to label cell membranes. Glomeruli were poured onto a 40µm 
pore sieve and washed with 4%BSA ringer and isolated in 1mL of 4%BSA ringer containing 
30µg/mL of AlexaFluor 488 BSA (BSA-488) (A13100, ThermoFisher Scientific) and allowed 
to incubate in the dark for 15 min on ice to allow fluorescently labelled BSA to diffuse into 
capillaries. Using a pulled glass capillary tube made with a magnetic pipette puller, a single 
glomerulus (free of Bowman’s capsule) was trapped on a glass plate (FIGURE 2-8), fitted 
with plastic capillaries attached to a peristaltic pump, to allow washing of BSA-488 bath 
in which glomeruli were in. Nikon TI inverted confocal microscope (Nikon Instruments Inc 
(Nikon), Melville, NY) was focused so that the maximum number of capillaries for each 
glomerulus met the following criteria: capillary was on outer edge of glomerulus, had clear 
R18 membrane staining (under TRITC filter), interior was free of red blood cells or any 
other particles (bright field), BSA-488 intensity was equal both inside capillary and outside 
capillary in the BSA-488 bath (under FITC filter) (FIGURE 2-8 A). Once correct focus was 
chosen, recording commenced for 3 min. During recording, pump was turned on and bath 
was washed with 4%BSA ringer until bath was black and free of BSA-488 (FIGURE 2-8), 










Using NIS Elements software (Nikon), loops which met criteria previously mentioned were 
selected as regions of interest, and fluorescent intensity profiles were measured over time 
(FIGURE 2-8 A (RIGHT IMAGE) AND B). One minute after the wash was determined in 
previous studies as the most accurate window for analysis (36). 
Because this is an ex vivo measurement which is also static (no fluid flow in the capillaries) 
Starlings principles cannot be accurately applied. As a result, using Fick’s first law of 
diffusion, the following formula, whose derivation is explained further ny Desideri et al., 
was derived to calculate apparent albumin permeability (Ps’alb): 
𝑃𝑠′𝑎𝑙𝑏 = −𝑘𝑅/2 
In this equation, k, the filtration coefficient, which is the negative slope of the relationship 
obtained from calculating the natural log of fluorescent intensity and time, where raw 
Figure 2-8 Albumin Glomerular Permeability Assay 
A. An individual glomerulus labelled with R18 to define capillary loops and perfused with BSA-488 
(labelled albumin) is isolated containing loops free of debris and red blood cells (left image). The 
bath is then washed with non-labelled BSA until bath is black (upper right image). B Immediately 




values are obtained from fluorescent intensity profiles (FIGURE 2-8) (36). R is the radius of 
the capillary being analysed which is measured on the NIS Elements software. Using this 
formula allows for calculation of Ps’alb for a single capillary. A minimum of three 
capillaries were measured per glomerulus and values averaged per glomerulus. A 
minimum of three glomeruli were analysed per animal. Statistics performed on mouse 
number.   
2.2.7 Sodium Fluorescein Angiography Analysis (Optimisation and Application)  
The method of using FAs to measure apparent solute flux in the retina, was obtained from 
Professor David Bates at The University of Nottingham with his permission (unpublished 
method) as well as collaboration with Dr. Kenton Arkill at The University of Nottingham, 
and its application has been further optimised by myself. Analysis was first optimised 
using FIJI imaging processing program, and later used for the development of an 
automated program in collaboration with a Computer Science masters student Kwan Ho  
Ho, under the supervision of Dr. Neill Campbell (Faculty of Engineering, The University of 
Bristol), which will be discussed in 2.2.7.2 
2.2.7.1 Optimisation of Manual Analysis  
Once the NaF is injected, recording began and the vessels begin to fill over time as shown 
in FIGURE 2-9. 
In FIJI, fluorescent intensity is measured in the main vessel (box 1) as well as in the 
exchange vessels (box 2) every 10 frames (FIGURE 2-10 A,B), ensuring that if eye 
movement occurs, measurements are still within the same box, and therefore may 
require manual movement of boxes. A modified version of Fick’s Law derived by Professor 
David Bates is used to calculate solute flux:  
Figure 2-9 Example of Fluorescein Angiography in Mouse Retina 
Shortly after injection of the mouse with sodium fluorescein, fluorescent signal appears in the main vessels. Over 
time, exchange vessels become visible and fluorescent intensity builds. Yellow signal in the main vessels in the 





                                                           𝑃 = 𝛥𝐼𝑓 𝛥𝑡⁄ /(𝛥𝐶 𝑥 𝐴) 
Equation 2-2 
where permeability is equal to solute flux (If/t), which is the change in fluorescence 
intensity (If) over the change in time (t), divided by the product of the change in 
concentration (C) of solute and the area measured (A).  The use of this equation in solute 
flux measurements makes the following assumptions: 
1. Area of exchange vessels (in box 2) does not change from week to week (if 
multiple solute flux measurements are being taken on the same animal).  
2. Solute flux is diffusive, not convective.  
3. Plasma concentration does not decrease during measurements. 
4. The interstitial concentration is a small fraction of plasma concentration, and 
therefore the slope is linear. 
5. Only exchange vessels are in box 2. 
To account for any potential variations in total fluorescent intensity that may be due to 
varied acquisition settings, the fluorescent intensity ratio between box 2:box 1 is taken 
for each measurement at that given time point, and then plotted against time (FIGURE 
2-10 C). This yields a line where the equation from a linear fit of the line, represents the 
relationship between If  and t, where the slope of the line (If/t) is solute flux, as 
described in EQUATION 2-2 above.  Therefore the solute flux measurement in FIGURE 2-10 
C is 0.0014 µm/second(s) or 14 x 104 cm/s.  It should be pointed out that measurments of 
solute flux using this assay is still a work in progress, and therefore we are using change 
in fluoescent intesnsity over time so represent solute flux (cm/s). This method of 







An issue that can arise when comparing one animal to another, is the variability in 
fluorescent profiles in the main vessel which, as mentioned, is used as a way to account 
for potential variations in fluorescent intensity due to difference in acquisition settings, 
fluorescein batch variations, etc. For example, FIGURE 2-11 shows the fluorescent 
intensity profiles for the main vessel and exchange vessels for two different animals, 
injected either through i.m. or i.p. Both mice were healthy C57BL/6 mice litter mates with 
Figure 2-10 Measurement of Fluorescent Intensity from Angiography Videos 
Fluorescent intensity measurements are taken over time for the length of the video. A. Snapshot of 
fluorescein angiography at time x. B. Enlarged image from white box in A shows area of measurements, 
box 1 in the main vessels and box 2 in the exchange vessels. Boxes of equal size are placed in main vessel 
and exchange vessels, and fluorescent intensity is measured approximately every 10 frames. C. Graph 
of ratio box2/box1 of exchange vessel intensity and main vessel intensity is plotted over time from 
determined time frame. Y axis in arbitrary unites (a.u.). A line of best fit is applied, and linear equation 





the same age, sex, and similar weights of 26.5g and 26.2g. The main vessel profile for 
animal 2 shows a delayed vessel filling compared to animal 1. Therefore, use of data points 
at the same time frame (those between the dotted red lines) to calculate solute flux 
(If/t)  would not be accurate in animal 2, as the main vessel is still filling and that time 
frame is not comparable to animal 1.  
 
 
Betteridge et al. demonstrated the fluorescent intensity profile for a single vessel located 
in the rat mesentery perfused with Alexa Fluor 488-labelled BSA (175). As shown in FIGURE 
2-12, there is an initial filling of the vessel represented by ΔIf0, followed by a steady linear 
increase in fluorescent intensity (If) represented by the solid horizontal line, and an 
eventual drop in fluorescence as the Alexa Fluor 488-labelled BSA is cleared (175).  
Betteridge et al. used this rate of fluorescent intensity change [dIf/dt]0 to represent the 
rate of solute flux across the vessel wall. 
Figure 2-11 Fluorescent Intensity Profiles for Two Different Animals  
Main vessel and exchange vessel intensity profiles shown for each animal. Animal 1 was injected with 
sodium fluorescein through i.m. whereas animal 2 was injected through i.p. Note that animal 2 has a 
delayed filling in the main vessel and begins to reach a steady state at a later time point. Red dotted 






Therefore, in order to circumvent differences in rates of vessel filling between animals 
that may confound results, I used the steady state linear increase portion of the 
fluorescent intensity profile in the main vessel as the time frame to calculate solute flux 
for any given animal. To determine the exact point at which the main vessel reaches a 
linear steady state in an objective manner, I chose to fit a linear line to the main vessel 
profile and calculate where the R2 value was the highest. This is demonstrated in 
calculation A vs B in FIGURE 2-13 where the cut off in B (184 seconds) yields the highest 
R2. This point would therefore be used as the cut off for where the main vessel has 
reached a steady state. 
Figure 2-12 Determining Solute Flux in Rat Mesentery  
A. A rat mesenteric vessel perfused with Alexa Fluor 488-labelled BSA is used to measure changes in 
permeability as the labelled BSA crosses the vessel (red arrows). B. The fluorescent intensity profile 
measured upon perfusion with labelled BSA shows a rapid increase in fluorescence followed by a steady 
state (horizontal line). The slope of the steady state line represents solute flux. Image adapted from 
(Betteridge et al, 2017)(175).   
Figure 2-13 Determining Point at Which Steady State Begins for Solute Flux Measurement 
Time frame used for analysis is determined based on where the main vessel intensity approaches a 
steady state, i.e. the most linear part of the curve determined by highest R2 value. A. Example of R2 





If we apply this method to both animal 1 and animal 2 in FIGURE 2-13  to determine when 
the steady state is reached in the main vessels, and then plot the ratio of the exchange 
vessel and the main vessel over time to calculate solute flux as in FIGURE 2-10 C  for both 
animals, we obtain the graphs in FIGURE 2-14. Note that slopes of the line, i.e. solute flux 
are both 0.0014. This is a good indication that this method of analysis is consistent as 














Figure 2-14 Solute Flux Comparison in Animal 1 and Animal 2 
Analysis performed on two different mice with the same age and background show similar results for solute 




2.2.7.2 Automated Analysis of Solute Flux  
Manual analysis of these videos was very time consuming, as videos can have over a 
thousand frames, and great attention needs to be given during the analysis process. As 
these mice are under anaesthesia during the recording, rolling of the eye as well as 
movement due to heartbeats required changing of the position of box 1 and box 2 for 
fluorescent intensity measurements so that they remained in place. Additionally, 
movement of the eye also caused occasional frames to become out of focus (FIGURE 2-15), 
therefore skewing the fluorescent intensity measurements.  
 
In collaboration with a Computer Sciences MSc student, Kwan Ho Ho whom I co-
supervised with Dr. Neill Campbell in the Computer Sciences, Faculty of Engineering, we 
developed software with a user-friendly interface which allowed for automated analysis, 
with the ability to exclude frames which were out of focus, from analysis. A more in-depth 
description of the program and the computer science techniques used to develop it can 
be found in Kwan Ho Ho’s MSc thesis (176).  I will describe how the software analyses the 
videos in order to calculate solute flux.  
In the program, the video is loaded and a snapshot of the video opens. Here, the region 
of interest (ROI) for analysis is selected (FIGURE 2-16).Note that the ROI is no longer a box 
in the main vessel and a box in the exchange vessels as in FIGURE 2-10. Instead, the 
Figure 2-15 Example of Out of Focus Frame 
Movement of the eye during recording can cause vessels to go in and out of focus, giving 
fluorescent intensity measurements that are not accurate. White arrowheads point to 




program was designed to distinguish between ‘bright’ and ‘dark’ pixels, and in this way 














Figure 2-16 Loading and Selection of ROI in FA Analysis Program  
The video to be analysed is first loaded. 2. A window with a snapshot of the video allows you to select 




The program can distinguish blurry frames and remove them from the data points used 
for analysis. FIGURE 2-17 A shows fluorescent intensity ratio plotted against time for the 
entire video, in which data points which deviate significantly from the curve are apparent 
(arrow). These points were confirmed to represent blurry frames in FIGURE 2-17 C, as 
blurry frames have a smaller “edgesharpness” value. FIGURE 2-17 D shows a graph for 
which values are deemed sharp, or in focus. These frames are then removed from  FIGURE 
2-17 A to give the graph in  FIGURE 2-17 B, representing the values which can be used to 
calculate solute flux without data from blurry frames.  
 
 
Figure 2-17 Removal of Blurry Frames from Analysis 
Graphs produced from video ROI measurement. A. The fluorescent intensity ratio over time for the 
entire video. The arrow points to fluorescent intensity values which deviate from the curve produced 
from the other data points. Arrowhead points to the clustered values which appear to deviate less. 
B. Results from removing deviating data points, which were deemed as blurry frames, based on data 
from C. C. Graph of edge sharpness vs seconds indicating which frames are considered blurry, as 
blurry frames have lower edge sharpness values (arrow) compared to the majority (arrowhead).  D. 





The program then allows you to select the time frame from which data points should be 
used to calculate solute flux. As in FIGURE 2-13, the point at which the main vessel begins 
to reach a steady is determined and the time frame is selected on the main vessel graph 
(FIGURE 2-18).  
 
Once selected, the program produces a graph plotting the ratio of the exchange vessel 
and main vessel over time, as is done in manual analysis, and displays the calculated slope 
from the line (FIGURE 2-19).   
Figure 2-18 Selection of Analysis Time Frame 
The program produces fluorescent intensity profiles for the main vessel (large vessel) and exchange 
vessels as with manual measurements. B. Once the point at which the main vessel reaches a steady state, 
the time frame used for analysis can be selected (red highlighting). 
Figure 2-19 Calculation of the Slope of the Line Representing Solute Flux 
The program uses the data selected as the time frame for analysis excluding blurry data points and plots 
a line of the ration of the exchange and main vessel fluorescent intensity vs time. B. From this line, the 




To confirm that the automated method of analysis yields similar results to the manual 
method, Kwan Ho Ho validated a series of videos from which manual analysis was done 
as well as automated analysis. An example of the results from the same video, manual 
measurements versus automated measurements are shown in  FIGURE 2-20. As shown, 
the slope of the line is 0.0021 for both methods (FIGURE 2-20), confirming that automated 
analysis is consistent with manual analysis.  
 
In addition to being consistent with manual measurements, this method of analysis has 
added benefits. Because the area of analysis is bigger, and no longer just a very small 
portion of the main vessel and exchange vessel as in FIGURE 2-10, this method is likely a 
more accurate representation of solute flux in the retina rather than very local changes 
which would result from measuring a smaller area of the retina. Additionally, manual 
measurements were taken every 10 frames due to the large volume of frames in each 
video. These videos have an imaging rate of 2 frames per second, meaning manual 
measurements were taken every 5 seconds. Automated analysis takes a measurement 
every frame (i.e. every 0.5 seconds), therefore gathering more data points to which a line 




Figure 2-20 Manual Versus Automated Measurements for Solute Flux 
Manual and automated measurements for the same video. A. The fluorescent intensity ratio over time 
for manual measurements yields a slope of 0.0021. B. The fluorescent intensity ratio over time for 





GraphPad Prism version 5.00 for Windows was used for all statistical analyses (GraphPad 
Software, La Jolla California USA, www.graphpad.com). Statistical test for each set of data 
can be found in figure legends of corresponding data. For data comparing two groups for 
statistical differences, unpaired Student’s t- test was used, or where appropriate paired t-
test, as indicated in figure legends. One-way ANOVA followed by Tukey’s multiple 
comparisons test, which is recommended when comparing a mean with every other mean, 
was performed for comparing more than two groups for statistical differences (177). All 
data are presented graphically as the mean + standard error of the mean. If P values 
were >0.05 for a given set of data, the data was considered not statistically significant. For 







 Importance of Endothelial Glycocalyx Heparan 
Sulphate in the Kidney 
 Introduction  
3.1.1 Structure and Biological Role of Hepran Sulphate in the Glomerular 
Filtration Barrier  
Heparan sulphate (HS) belongs to a family of linear polysaccharides called 
glycosaminoglycans (GAGs). HS is one of the most complex GAGs, made of alternating D-
glucuronic acid (GlcA) or L-iduronic acid (IdoA) and D-glucosamine (GlcNac), with 
variations of N-sulphation or N-acetylation (178). HS should not be confused with heparin. 
Although both are comprised of the same back-bone disaccharides, heparin has higher 
levels of N- and O-sulphation and is differentially localized with different functions (179). 
Although HS was originally identified in commercial preparations of heparin as low 
sulphation heparin, years of research have identified unique biological function for HS 
(178). HS is most commonly referred to in the context of HS proteoglycans (HSPGs), 
because HS is covalently bound to different proteoglycans, which are membrane bound 
on cell surfaces or in the extra cellular matrixes/ basement membrane of all tissues. 
Syndecans and glypicans are the two main families of membrane bound HSPGs, while 
perlecan is a major HSPG in basement membranes (180). HS has been shown to have roles 
in cell growth and differentiation, host defence and viral infections, lipid transport, 
inflammation, cell-cell and cell-matrix signalling, and cancer (179). Because different 
HSPGs are differentially distributed, HS can have different functions in each tissue type, 
depending on its location.  
In the glomerulus, HS is widely expressed in podocytes, GBM, and the eGlx. In podocytes, 
expression of HS may help in adhesion and motility, demonstrated by in vitro experiments  
where podocytes which lacked HS had reduced motility and focal adhesion formations 
(181). In agreement with this, in vivo studies show that loss of podocyte HS in a mouse 
model resulted in  podocyte effacement and reduced GBM HS (182). For years it was 
believed that that HS in the GBM contributed to charge selectivity, since the high levels 
of N- and O- sulphation make HS a highly negatively charged molecule , but a study 
showing that loss of some HS epitopes in the GBM, and consequently reduction of anionic 
charge sites, led to no structural change to GBM or large increases in albuminuria 




studies have confirmed that loss of agrin and perlecan HS in the GBM has no effect on the 
GFB (185,186), so whether or not GBM HS has a role in charge selectivity remains under 
debate, but has largely been debunked. There is, however, evidence suggesting a role of 
GBM HS in modulating local compliment activation by recruiting and binding Factor H 
from the plasma, a major inhibitor of the alternative compliment pathway, and part of 
the innate immune system’s defence against infections (187). However, the role of HS in 
the glomerular eGlx has not been fully elucidated.   
3.1.1.1 Heparan Sulphate in the Glomerular eGlx 
On GEnC, prominent HSPGs include sydecans-1,-2,-4 and glypican-1, all of which form part 
of the eGlx (188), but there remains to be conclusive evidence in the form of images 
showing HS is in fact in the glomerular eGlx. Rops et al. showed that immunofluorescence 
on mouse kidney sections using HS targeting antibodies had an endothelial cell staining 
pattern in the glomerulus, but the authors did not show conclusive evidence that this was 
eGlx staining and not just basement membrane staining (189). Functionally, there is 
evidence that eGlx HS acts as a mechanotransducer in glomerular capillaries, resulting in 
regulation of the nitric oxide (NO) response, a modulator of vasodilation (190). HS in the 
eGlx may also serve as a regulator of inflammatory responses. Specific ‘inflammatory’ N- 
and 6-O-sulphated HS domains have been identified to be upregulated after GEnC 
activation in vitro and during nephritis in vivo (189). Furthermore, a mouse with a 
conditional endothelial knockdown of these inflammatory domains had increased renal 
function measured by plasma creatinine concentration and blood urea nitrogen 
concentration (189). Knockdown mice also had less glomerular injury during anti-GBM 
nephritis, due to reduced leukocyte infiltration (189). Therefore, variation in HS domains 
in the eGlx may help modulate the inflammatory response, not only by acting as a 
reservoir for chemokines as has been previously discussed, but also by variations in its 
composition. Interestingly, alteration of HS sulfation patterns does not seem to negatively 
impact GFB function, as mice who are deficient in the modifying enzyme N-deacetylase-
N-sulfotransferase 1 and 2 (Ndst-1 and Ndst-2) do not have increased albuminuria 
(189,191).   However, presence of eGlx HS does seem to play a role in the GFB function, 
as isolated perfused kidneys from mice treated with heparinase III have a significant 
increase in albumin clearance (35), but because these studies were performed ex vivo and 
the eGlx was not directly visualised, the effect of HS shedding on eGlx structure and 




3.1.2 Synthesis of Hepran Sulphate in the Cell  
HS is synthesised in the Golgi, where attachment of a linkage region of four 
monosaccharides to the core protein occurs (192). This chain is extended by addition of 
GlcA and GlcNac to the protein core, which is accomplished by two glycosyl transferases, 
exotosin 1 (Ext1) and exotosin 2 (Ext2), which form a heterodimer referred to as HS-
polymerase (FIGURE 3-1) (192). Once the chain has been extended, though likely occurs 
simultaneously as well, a series of enzymes such as   NDSTs, and 2-O,3-O and 6-O 
sulfotransferases (2OSTs,3OSTs,6OSTs) modify the nascent HS chain (FIGURE 3-1)  (193). 
Upon completion of HS synthesis, membrane HSPGs are transported in cytoplasmic 
vesicles to the cell surface (178).  
 
Interestingly, although Ext1 and Ext2 both have GlcA and GlcNac transferase activity, in 
the absence of Ext1, Ext2 does not have any significant glycosyltransferase activity (194). 
Additionally, mutation in either gene causes hereditary multiple exotoses (HME), a 
Figure 3-1 Synthesis and Modification of HS 
Example of HS synthesis and chain modification. Ext1/Ext2 complex is involved in HS chain 
formation and elongation, adding repeating GlcA, GlcNAc, and IdoA units. HS chain 
modifications are then made by a series of enzymes (NDSTs, epimerase, 2OST, 6OST, 3OST). 
Modifications include:  N-sulphated GlcN (NS), 6-O-sulphated GlcN (6S), 2-O-sulphated IdoA 




disorder that leads to skeletal abnormalities, and in some instances osteosarcomas (195). 
This suggests that, despite structural homology, Ext1/Ext2 are not functionally redundant 
and both are required for normal HS synthesis. Importantly, this means that genetically 
modified mice which have a knockout of just one of these genes should be sufficient to 
prevent HS synthesis, which will be of use for the experiments discussed in this chapter.   
3.1.3 Heparan Sulphate Degrading Enzymes  
There are two groups of known HS-degrading enzymes. One group is the mammalian 
endoglucuronidase, HPSE, which will be discussed in detail in CHAPTER 4. The second is a 
family of bacterial lyases isolated from Flavobacterium heparinum. This group of enzymes 
have been useful in studying heparin and HS, as affinities for heparin or HS differ between 
members of the enzyme family. Heparinase I and II have the ability to degrade heparin 
and HS (196,197). Heparinase III is more specific to HS, acting on regions of low sulphation 
and therefore having little activity against heparin (196,197). Heparinase III primarily acts 
on non-sulphated GlcNac domains, while S-domains on HS which are highly sulphated 
remain resistant (196). Due to its specificity, Heparinase III has been used in countless 
studies to investigate the role of HS in biological systems, including in the eGlx 
(10,170,184,198,199), and is used as a tool for enzymatic removal of vascular eGlx HS in 
this chapter.  
3.1.4 Chapter Aims and Experimental Approaches  
The aim of this chapter is to show the importance of HS in the glomerular eGlx, which is 
accomplished in two parts.  
1. Show that that HS is present in the glomerular eGlx using immunofluorescence.  
2. Show that removal of HS from glomerular eGlx increases vascular permeability. I 
used two approaches for this aim. The first was to directly target HS by treatment 
with the HS shedding enzyme Heparinase III, allowing me to investigate if HS 
contributes structurally and functionally to the glomerular eGlx in healthy mice. 
The second approach was the use of a transgenic mouse model in which 
endothelial Ext1 was knocked out, in an inducible manner, in healthy mice. This 
allowed me to study the effects of reduced HS synthesis on the glomerular eGlx 






These methods are not inclusive. The methods described in this section are those that 
pertain specifically to this chapter or have been adapted for experiments in this chapter. 
All other methods are described in the CHAPTER 2 METHODS AND MATERIALS.   
3.2.1 Generation of Ext1 Knock Down Mice  
Set up of Ext1 colony and partial characterisation of this inducible Ext1 mouse model was 
previously done by a previous PhD student in the Bristol Renal group, Dr. Hesham E 
Hussien Elhegni. A more in-depth discussion on the creation of the Ext1 model and 
characterisation can be found in his thesis (200). Briefly, due to the embryonic mortality 
in homozygous Ext1 knockout mice, an inducible knockdown was created by combining 
the Tet-O-Cre-Loxp systems on a C57BL/6 background. Doxycycline (an analogue of 
tetracycline) controlled expression of reverse tetracycline trans-activator (rtTA) under the 
Tie2 (endothelial specific (201)) promoter (Tie2 rtTA). This drove Cre recombinase 
expression, the bacteriophage P1 recombinase (201), in endothelial cells. The Cre 
recombinase target LoxP sites were inserted in the 5’ untranslated region of exon1 and 
the second in the intron downstream of exon1 (Ext1flx/flx). Excision of Ext1 can therefore 
be induced by treatment of triple transgenic mice Tie2+/Cre+/Ext1flx/flx  with doxycycline. A 





Figure 3-2 Excision of Ext1 in Extflx/flx Mice 
1. Treatment of mice with doxycycline (Dox) leads to Dox binding to rtTA.  2. Binding of Dox allows for 
Cre recombinase expression. 3. Cre recombinase target sites (flox) which are on both sides of Ext1, are 




To obtain Tie2+/Cre+/Ext1flx/flx  Ext1 conditional knock out (Ext1CKO) mice, breeding pairs 
were set up as shown in FIGURE 3-3  in the Animal Service Unit, Barn 1, at the University 
of Bristol. Offspring were genotyped for the three transgenes. Ext1CKO were used as 
experimental mice while littermate control mice (LMC) had the requirement of lacking at 
least one of the transgenes. For example, Tie2+/Cre+/Ext1wt/wt , Tie+/Cre-/ Ext1wt/flx, and Tie-




















Figure 3-3 Schematic of Breeding Pair Set Up for Generation of Ext1CKO Mice 
 
Breeding pairs were set up to generate triple transgenic mice as well as litter 





3.2.2 Animal Genotyping  
Ear notches were digested in 100μl of 50mM NaOH for 1 hour at 95°C. 20µl of 1M Tris-
HCl pH 8.0 was added to neutralise. For reactions, The PCRBIO HS Taq Mix (PB10.22-02, 
PCRBIOSYSTEMS, London, England, UK) was used following manufacture instructions. 
Samples were genotypes for Tie2 rtTA (Tie2), Cre, and Ext1flx/flx. A list of primer sequences 
and program protocols can be found in  TABLE 3-1  and  TABLE 3-2 .  6X PCR loading dye 
(B7024S, New England BioLabs (NEB), Ipswich, MA)  was added to 1X to all samples, and 
samples were run on a 2% Agarose gel for 1 hour and 100V with 100bp ladder (N0457S, 
NEB) and imaged to determine product sizes, listed in TABLE 3-2.  
Table 3-1 Ext1 Mouse Genotyping Primers  
 











3.2.3 Inducing Ext1 Knockdown with Doxycycline 
Prior to the start of experiments, litter mate controls (LMC) and Ext1CKO (6 weeks to 9 
months, age matched) were given 2mg/ml doxycycline (D3447, Sigma-Aldrich) in drinking 
water for three weeks supplemented with 5% sucrose to encourage drinking and prevent 
dehydration due to bitterness of doxycycline (FIGURE 3-4). Water was provided in blacked 
out plastic bottles to protect doxycycline water from light. Fresh doxycycline water was 








3.2.4 Fluorescence Activated Cell Sorting (FACS) Cytometry for CD31 Positive 
Cells  
This work was performed by Dr. Sarah Fawaz, a member of the group. Glomeruli were 
isolated from 75µm pore sieve (see main methods). Glomeruli were digested with 
1mg/mL collagenase I,V,and VI ( Sigma-Aldrich) for 1 hour at 37°C with constant rotation. 
Digest was passed through 35μm mesh cell strainer (353355, BD Falcon, Thermo Fisher 
Scientific) to remove cell clumps. Cells were washed three times and cell pellet 
resuspended in HBSS with 1mM EDTA, 0.1µl/ml DNAse and 0.3% BSA. Cells were 
incubated with PE Rat anti-mouse CD31 (550083,BD Pharminigen, San Jose, CA) 1:50 for 
1 hour at 4°C. Cells were washed again three times and FACS sorted/collected for CD31 
(an endothelial cell marker) positive cells using Becton Dickinson Influx Cell Sorter (BD 
Biosciences, San Jose, CA) at the University of Bristol Flow Cytometry Core Facility.  
3.2.5 RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction 
(qPCR) for EXT1 
This work was performed by Dr. Sarah Fawaz. RNA was extracted from isolated cells using 
RNeasy Mini Kit (Qiagen, Manchester, UK) following manufacturer’s instructions. A total 
of 2µg of RNA was converted to cDNA using high-capacity RNA to cDNA conversion kit 
Figure 3-4 Induction of Knockdown in Ext1CKO Mice Prior to Experimental Procedures 
 
LMC and Ext1CKO mice were given 2mg/ml of Doxycycline drinking water (Dox water) 
for 3 weeks followed by experimental procedures (urine collection, perfusions, 





(Applied Biosystems, Foster City, CA) following manufacturer’s instructions. For qPCR , 
SYBR Green Master Mix was used (S-4438, Sigma-Aldrich) following manufacturer’s 
instructions using StepOne 96-well plate real-time PCR system (Life Technologies- Applied 
Biosystems, Foster City, CA). Ext1 and β-Actin, primer sequences in TABLE 3-3. Relative 








3.2.6 Urine Collection for L-Lysine Experiments  
All urine was collected on hydrophobic sand (LabSand, Animalab, Poznan, Poland) unless 
otherwise specified. To collect urine on hydrophobic sand, mice were placed in a cage 
with a thin layer of sand and solid waste removed immediately to prevent contamination 
of urine. Clean urine which was freshly voided was collected with pipette into an 
Eppendorf tube. Any urine that came into contact with solid waste was deemed 
contaminated. See main methods for uACR measurements. 
3.2.7 Blocking Tubular Reabsorption with L-Lysine in FVB Mice  
Upon pre-treatment urine collection, all mice receiving L-Lysine were injected via 
intraperitoneal (i.p.) route 2g/kg with freshly made L-Lysine (L5751, Sigma-Aldrich) 
dissolved in PBS, a dose previously shown to be effective in mice (202). Post treatment 
urine was collected over the following 2 hours in metabolic cages with enrichment to 
allow access to water.  
3.2.8 Treatment with eGlx Shedding Enzymes Chondroitinase and Hyaluronidase  
After pre-treatment urine collection, mice were anaesthetised (2.5 % isoflurane, 1.5 
litre/minute) and administered 0.087mU/g Chondroitinase (C3667, Sigma-Aldrich) and 
15mU/g Hyaluronidase (385931, Sigma-Aldrich) via tail vein (t.v.) injection in a volume of 
100uL, a dose previously shown to shed eGlx and increase glomerular albumin 




permeability (116). Mice receiving L-Lysine were administered this treatment as described 
above. Mice were allowed to fully recover (approximate time required - 10 minutes) 
before collection of post treatment urines over the following one to two hours in 
metabolic cages, with enrichment, to allow access to water. A schematic of the 













Figure 3-5 Visual Representation of Enzyme + Lysine Experimental Set Up 
Pre-treatment urines were collected immediately followed by enzyme +/- L-Lysine treatment. 





3.2.9 Blocking Tubular Reabsorption in Ext1CKO Mice  
LMC and Ext1CKO mice were given doxycycline water as described above. Pre-treatment 
urine was collected on hydrophobic sand and upon urine collection mice were treated 
with L-Lysine as previous. Mice were then placed in metabolic cages with enrichment to 
allow access to water, and urine collected for the following one to two hours. A schematic 
of experimental design is shown in FIGURE 3-6. 
 
 
Figure 3-6 Experimental Design for Albuminuria Measurements and Tubular Reabsorption Inhibiting 
Treatments in Ext1CKO Mice. 
LMC and Ext1CKO mice were given 2mg/ml of doxycycline drinking water for 3 weeks. Urine was 
collected after 3 weeks immediately followed by 2g/kg of L-Lysine. Post-treatment urine was 






3.3.1 Presence of Heparan Sulphate in Glomerular eGlx 
3.3.1.1 Heparan Sulphate is Present in the Glomerular eGlx 
 To show conclusively that HS is present on the eGlx of glomeruli, I used paraffin 
embedded BKS lean kidney tissue and performed IF staining for HS with epitope specific 
phage display antibody anti-HS3A8V or no primary as a control. HS staining was present 
throughout the kidney and glomerulus but absent in the no primary control (FIGURE 3-7). 
Magnification of a single capillary showed that, although HS staining was present in the 
GBM and/or podocytes, HS staining on the luminal side of the capillary was clear 









Figure 3-7 HS is Present in the Glomerular eGlx  
 
Mouse kidney tissue stained with anti-HS HS3A8V phage display antibody (green), R18 cell membrane 
stain (red), and DAPI nuclear stain (blue). Left: 100x image of mouse glomerulus Middle: Zoomed in 
image from white box in left panel of single capillary. Basement membrane (BM) in red separates HS 
staining (white arrow heads) on luminal side (L) of endothelial cell. Right: No primary control indicating 





3.3.2 Heparinase III Treatment Studies  
3.3.2.1 Heparinase III Treatment Results in Loss of Glomerular eGlx 
Having established the presence of HS in the glomerular eGlx, further investigation was 
required to determine if HS has a structural role in the eGlx in the glomerulus. It has been 
previously shown that mice treated with heparinase III have a significant reduction in 
kidney eGlx depth measured by the distance of intralipid droplets from the endothelial 
cell on EM (170), but this is an indirect measurement of eGlx. To more directly measure 
the effect that an HS shedding enzyme would have on the eGlx, FVB mice were treated 
with systemic heparinase III or heat inactivated enzyme and 30mins later were perfused 
with glutaraldehyde and Alcian blue, allowing for direct visualisation of eGlx by EM. Mice 
treated with inactive enzyme had visible eGlx on both podocyte and endothelial cells, 
while mice treated with active enzyme had a noticeable decrease in eGlx (FIGURE 3-8 A). 
Quantitative EM showed a significant reduction in both eGlx depth and coverage on GEnC, 
indicating that treatment with HS shedding enzyme damages and causes loss of eGlx 











Figure 3-8 Treatment of Healthy FVB Mice with HS Shedding Enzyme Results in Loss of eGlx 
A. Representative EM images of GFB from mice treated with active or inactive enzyme. Podocyte 
(P), basement membrane (BM), endothelial cell (E) shown. Arrow points to pGlx and arrowheads 
point to eGlx. B. EM images were analysed for eGlx depth (left) and eGlx coverage (right) and C. 





3.3.2.2 Heparinase III Treatment Does Not Affect GFB Structure    
Changes in the GFB coincide with increases in albumin permeability. This includes some 
of the previously discussed characteristic changes observed in DN, such as podocyte foot 
process effacement, increased GBM thickness and loss of GEnC fenestrations (101).To 
confirm that treatment with heparinase III did not have any off-target effects that would 
result in permeability increases unrelated to HS shedding, quantitative EM was used to 
measure changes in the GFB ultrastructure. Treatment with active enzyme had no effect 
on podocyte foot process width or slit diaphragm width (measures of foot process 
effacement), fenestration density, or basement membrane thickness compared to 





Figure 3-9 Heparinase III Treatment Does Not Affect GFB Structure 
EM images were analysed for changes in: A. Podocyte foot process (PFP) width. B. Slit diaphragm 
(SD) width. C. Endothelial cell fenestration number. C. Basement membrane (BM) thickness. 





3.3.2.3 Heparinase III Treatment Increases Glomerular Albumin Permeability  
To examine if the observed loss of eGlx resulting from heparinase III treatment also 
resulted in functional changes, FVB mice were treated with inactive or active enzyme as 
before. Thirty minutes later, mice were perfused, and glomerular albumin permeability 
assays performed. Treatment with active enzyme resulted in a significant increase in 
apparent albumin permeability (Ps’alb) (FIGURE 3-10) indicating that HS shedding 



















Figure 3-10 Heparinase III Treatment Increases Glomerular Albumin Permeability  
 
Ringer perfused mice, previously treated with inactive or active Heparinase III, and 
glomerular albumin permeability was measured. On x-axis (mouse number 
(glomeruli analysed)). Stats performed on animal numbers. Unpaired Student’s t-





3.3.3 Endothelial Ext1CKO Mouse Model 
3.3.3.1 Ext1CKO Mice Have Reduced Ext1 mRNA Expression 
Although this mouse line was partially characterized by Dr. Elhegni, confirmation of Ext1 
knock down was not performed at the time of his thesis submission, therefore 
confirmation was required prior to using the model in further studies. This following work 
was completed by Dr. Sarah Fawaz. Experimental mice Ext1CKO and LMC mice were treated 
with doxycycline water to induce knockdown of Ext1. In order to confirm that Ext1 mRNA 
expression was reduced after doxycycline treatment, glomeruli from LMC or Ext1CKO mice 
were isolated and CD31+ cells FACS sorted and collected. QPCR was performed on FACS 
sorted endothelial cells to confirm knockdown. As expected, Ext1CKO mice had a significant 
reduction in Ext1 mRNA compared to control mice, indicating that Ext1 is reduced in 








Figure 3-11 Ext1CKO Mice Have Reduced Ext1 mRNA Expression 
Ext1CKO mRNA quantified with regard to (w.r.t.) β-Actin from FACS sorted CD31+ endothelial cells 
from LMC and Ext1CKO mice. N=3 mice, unpaired Student’s t test indicated, **p<0.01. This figure is 





3.3.3.2 Changes in HS Cannot Be Detected by Anti-HS Phage Display Antibody in Ext1CKO  
As mentioned, Ext1 is part of the HS-polymerase complex, and is required for HS chain 
elongation. It therefore stands to reason, that reduced Ext1 activity would result in 
reduction of HS expression in endothelial cells and eGlx. To determine if this was the case 
in Ext1CKO mice, kidneys from LMC and Ext1CKO mice were harvested 3wk post doxycycline 
treatment and I performed immunofluorescence on kidney sections using the same phage 
display antibody, anti-HS HS3A8V, as used previously. With this antibody, no detectable 







Figure 3-12 Changes in HS Cannot be Detected by anti-HS Phage Display Antibody 
A. Representative images from mouse kidney section from LMC and Ext1CKO mice, stained with anti-
HS HS3A8V phage display antibody (green), R18 cell membrane stain (red), and DAPI nuclear stain 






3.3.3.3 Ext1CKO Mice Have Loss of Glomerular eGlx 
Immunofluorescence on Ext1CKO mice did not confirm knockdown of HS. To confirm that 
the eGlx was impacted when HS synthesis was reduced, changes to the eGlx were 
measured in Ext1CKO and LMC mice using EM as previous. Perfusions and images were 
completed by Dr. El Hengi and analysis was done by me. LMC mice had visible glomerular 
eGlx and appeared more abundant compared to Ext1CKO mice (FIGURE 3-13 A). In 
agreement with this, quantitative EM showed a significant reduction in eGlx depth and 
coverage in Ext1CKO compared to LMC mice confirming that there was reduced glomerular 
eGlx in Ext1CKO mice (FIGURE 3-13 B). There were no changes in pGlx depth or coverage 
(FIGURE 3-13 C). 
 
A. Representative EM images of GFB from mice treated with active or inactive enzyme. Podocyte 
(P), basement membrane (BM), endothelial cell (E) shown. Arrow points to podocyte glycocalyx 
and arrowheads point to eGlx. B. EM images were analysed for eGlx depth (left) and eGlx coverage 
(right). C. pGlx depth (left) and eGlx coverage (right). N=3 mice, unpaired Student’s t-test 
indicated, *p<0.05. This figure is from work completed by Dr. Elhegni and me.  




3.3.3.4 Ext1CKO Mice Do Not Have Changes in GFB Structure 
To confirm that Ext1CKO mice did not have changes in GFB that are not specific to eGlx, 
quantitative EM was used to measure changes in the GFB ultrastructure. Ext1CKO mice had 
no significant changes in  podocyte foot process width or slit diaphragm width, 
fenestration density, and basement membrane thickness compared to LMC mice (FIGURE 
3-14 A-D), indicating knock out of endothelial Ext1 does not affect the GFB ultrastructure. 






Figure 3-14 Ext1CKO Mice Do Not Have Changes in GFB Structure 
EM images were analysed for changes in: A. Podocyte foot process (PFP) width. B. Slit diaphragm (SD) 
width. C. Endothelial cell fenestration number. C. Basement membrane (BM) thickness. Minimum of 3 





3.3.3.5 Ext1CKO Mice Have Increased Glomerular Albumin Permeability Compared to 
Control Mice  
Previous results show that loss of HS by treatment with heparinase III results in reduced 
eGlx and increased glomerular permeability. To test if reduced HS synthesis in Ext1CKO 
similarly resulted in increased glomerular albumin permeability, mice were perfused, and 
permeability assays were performed on LMC and Ext1CKO after doxycycline treatment. This 
work was completed by Dr. El Hegni, Dr. Sara Fawaz, and contributed to by me. 
Comparison of the two groups showed that Ext1CKO mice had a significant increase in 










Figure 3-15 Ext1 Knockdown Mice Have Increased Glomerular Albumin Permeability 
Glomeruli were isolated from Ringer perfused control and Ext1CKO mice and glomerular albumin 
permeability was measured. On x-axis (mouse number (glomeruli analysed)). Unpaired Student’s t-




3.3.3.6 Ext1CKO Mice Do Not Have Increased Albuminuria Compared to Control Mice 
To confirm that Ext1CKO had increased albuminuria,  uACR was measured in LMC and 
Ext1CKO mice after doxycycline treatment. Surprisingly, Ext1CKO did not have a significant 
increase in albuminuria compared to control mice as expected (FIGURE 3-16), despite the 













Figure 3-16 Ext1CKO Mice Do Not Have Increased Albuminuria 
Control and Ext1CKO mice were given doxycycline for 3 weeks and albuminuria was measured. N= 7-





3.3.3.7 Optimisation of the Tubular Reabsorption Inhibitor, L-Lysine, In Vivo  
The contradicting results observed in Ext1CKO showing increased Ps’alb, but no increase in 
albuminuria, were not expected. Under normal conditions, the GFB regularly leaks out 
small amounts of protein but is almost completely reabsorbed by the proximal tubules 
(203). Only when the system is overwhelmed with a heavy albumin load, such as in DN, is 
an increase in albuminuria is observed (203). I therefore examined whether blocking 
tubular reabsorption would have any effect on control and Ext1CKO mice. L-Lysine has been 
used as a potent tubular reabsorption inhibitor in humans and rodent models, and 
therefore I optimised this for use in these experiments (202,204). I first examined the 
effect of L-Lysine on FVB mice to determine if blocking tubular reabsorption in normal 
mice had any effect. Baseline urines were collected and immediately followed by L-Lysine 
injection given i.p., followed by a post L-Lysine urine collection. A significant increase in 
albuminuria was observed in post L-Lysine treated urines, suggested tubular reabsorption 








Figure 3-17 L-Lysine Blocks Tubular Reabsorption in Normal Mice 
Baseline and post L-Lysine uACR measurements were taken in healthy FVB mice. N=6 mice, paired t 




Previous work by a member of our group, Dr. Kai Betteridge, showed that a long term 
treatment of mice with chondroitinase and hyaluronidase using implanted minipumps did 
not result in increased albuminuria (unpublished data), but mice did have significantly 
increased Ps’alb (116), similar to Ext1CKO mice. I therefore wanted to determine if lack of 
albuminuria in these studies was due to tubular reabsorption. To do this, I examined if 
treatment with eGlx shedding enzymes would result in increased albuminuria after 
tubular reabsorption was blocked. This would also serve as a proof of concept experiment 
for blocking tubular reabsorption in Ext1CKO, as treatment with chondroitinase and 
hyaluronidase are known to increase glomerular permeability. If blocking tubular 
reabsorption is responsible for lack of albuminuria, I would expect to see an increase in 
albuminuria after L-Lysine treatment. To this end, baseline urines were collected from 
eight mice. Mice were then evenly and randomly assigned to enzyme only group or 
enzyme + L-Lysine group, briefly anesthetized and given chondroitinase and 
hyaluronidase via t.v. injection. Additionally, enzyme + L-Lysine group received an L- 
Lysine injection i.p. after enzyme treatment. Post treatment urines were then collected. 
One mouse from the enzyme only group was excluded due to a high baseline uACR. 
Although a modest increase in uACR was observed in the enzyme only group, it was not 
significant. However, mice treated with enzyme and L-Lysine had a significant increase in 
uACR (FIGURE 3-18). This indicates that L-Lysine successfully blocks tubular reabsorption 
and allows measurements of permeability changes which can only be observed with when 
tubular reabsorption is not active, such as in glomerular albumin permeability assays. 
 
Figure 3-18 Blocking Tubular Reabsorption in eGlx Shedding Enzyme Treated Mice Increases 
Albuminuria 
Baseline and post treatment uACR measurements were taken before and after treatment with 
chondroitinase/hyaluronidase with or without L-Lysine. One-way ANOVA, Tukey’s multiple 




3.3.3.8 Ext1CKO Mice Have Increased Albuminuria When Tubular Reabsorption is Blocked  
To investigate if tubular reabsorption of albumin masked increased albuminuria in Ext1CKO, 
LMC and Ext1CKO were treated with doxycycline as before. Pre-L-Lysine treatment urines 
were collected, followed by L-Lysine injection, i.p. Post treatment urines were then 
collected. As expected, a modest increase in uACR was observed in control mice after L-
Lysine treatment, though not significant (FIGURE 3-19). However, Ext1CKO mice had a 
significant increase in uACR after L-Lysine treatment  (FIGURE 3-19), indicating that tubular 









Figure 3-19 Ext1CKO Mice Have Increased Albuminuria When Tubular Reabsorption is Blocked. 
Albuminuria was measured in LMC mice and Ext1CKO mice before treatment (pre) and after 






 Discussion  
3.4.1 Heparan Sulphate is Present in Glomerular eGlx 
It is well established that HS plays an important role in many biological functions ranging 
from angiogenesis to modulator of inflammatory responses. However, the structural and 
functional role that HS plays in glomerular eGlx in health has not been addressed. Our 
group has shown that in tissue culture, GEnC expression of HS is present on the surface of 
cells shown by immunofluorescence (10). This signal is decreased when cells are treated 
with heparinase III (10), suggesting that HS is present in GEnCs surface, but whether this 
translated into tissue was not known. I therefore confirmed the presence of HS in 
glomerular eGlx in mouse kidney sections using immunofluorescence with a phage display 
anti-HS specific antibody. Staining showed a clear HS signal on the luminal side of 
endothelial cells in glomerular capillaries, confirming the presence of HS. While HS 
staining in glomeruli has been shown a number of times (109,186), to my knowledge, this 
is the first time that conclusive evidence of HS on the glomerular eGlx has been shown 
and is an important first step in investigating the role of HS in the eGlx.  
3.4.2 Loss of HS Reduces Glomerular eGlx and Increases Permeability  
3.4.2.1 Removal of Heparan Sulphate by Heparinase III 
Once the presence of HS was established in the glomerular eGlx, confirmation of the 
functional and structural role that HS has was required to determine if HS contributed to 
the eGlx’s barrier properties in vascular permeability.  I found that mice treated with 
heparinase III had a significant reduction in eGlx depth and coverage, but no changes in 
pGlx. This damage suggests that HS plays a structural role in the eGlx. Furthermore, 
heparinase III treated mice had a significant increase in glomerular Ps’alb compared to 
the inactive enzyme treated group, indicating that loss of HS in the eGlx results in loss of 
glomerular barrier function.  These results are in agreement with previously mentioned 
work showing that isolated kidneys from mice treated with heparinase III have a 
significant increase in albumin clearance (35). However, the glomerular albumin 
permeability assays and eGlx measurements by quantitative EM presented in this thesis 
are a more direct measurement of definitive eGlx loss and glomerular permeability 
changes. Loss of eGlx HS contributes to loss of barrier function in other organs as well, as 
was demonstrated in isolated perfused heart models, showing that loss of eGlx with 
heparinase III resulted in reduced endothelial barrier function (205,206). It is likely that 




can be observed either experimentally or in disease, such as the retina. Changes in GFB 
ultrastructure that may contribute to the observed increase in permeability, such as 
podocyte effacement, fenestration density, or basement membrane thickening were also 
measured and no significant changes were observed with active enzyme, confirming that 
the observed changes in permeability can be attributed to loss of HS. It should be noted 
that as potential changes in HS expression in the GBM were not measured, I cannot 
conclude that that loss of HS after heparinase III treatment occurs only in the glomerular 
eGlx. However, since there is evidence suggesting that HS does not contribute to GBM 
filtration properties (183–185), and the data presented show no changes in GBM 
structure along with damage to eGlx, it is reasonable that glomerular permeability can be 
attributed to loss of glomerular eGlx HS. This suggests that HS not only plays a structural 
role in the eGlx, but also a functional role, establishing the importance of HS in the eGlx. 
3.4.2.2 Reduction of HS Synthesis in Ext1 Mouse Model  
As a second method of investigating the importance of HS in the eGlx as well as a way to 
dismiss potential off target effects by enzyme treatment, an inducible transgenic mouse 
model, in which HS synthesis in endothelial cells can be knocked out by targeting Ext1, 
was used. A similar mouse model has been previously used, in which Ext1 was knocked 
out in podocytes, with Cre expression driven by the podocin promoter, a podocyte specific 
promoter (182,207). Although reduced HS staining was observed in the glomerular 
capillary wall, the researchers did not observe changes in albuminuria (182). I  investigated 
if reduced endothelial HS synthesis had any effect on barrier function. Previous work by 
Dr. Sarah Fawaz showed that Ext1 mRNA was significantly reduced in the Ext1CKO mice 
after treatment with doxycycline, evidence of a working model. Surprisingly, 
immunofluorescence staining for HS in Ext1CKO mice did not show an obvious decrease in 
HS signal in Ext1CKO compared to LMCs. The reasons for these results are not clear, 
however there are some explanations as to why this may be the case. Firstly, the Ext1 
enzyme is involved in chain elongation, as mentioned earlier. The HS3A8V antibody was 
originally raised against bovine kidney HS (173),  but since the exact HS epitope that this 
antibody recognises in mouse tissue is not known, it’s possible that the antibody is 
detecting segments of HS that are still expressed, such as the GlcNac residues which are 
present prior to elongation by Ext1 (208). Therefore, in Ext1CKO mice, this pre-elongation 
segment may be recognised by the antibody. Perhaps a more broad HS staining antibody, 
such as the antibody clones JM403 and 10E4, which recognize common epitopes on HS 




that this method of HS detection simply is not sensitive enough to detect changes, as this 
is a conditional knockout, and therefore HS is still likely present in a population of 
endothelial cells. In addition, other glomerular cells such as podocytes and mesangial cells 
still have the capacity to synthesise HS, which may prevent changes in HS expression from 
being easily observed. Lastly, it is possible that HS synthesis is not reduced, but the 
structural and functional results that followed suggest that this is likely not the case.  
EM results showed that Ext1CKO mice had a significant reduction in glomerular eGlx depth 
and coverage but not pGlx, suggesting a structural role for HS in the eGlx and is in 
agreement with heparinase III treatment studies. Additionally, Ext1CKO had no changes in 
GFB unstructured, indicating that knockout of Ext1 did not negatively impact the GFB 
ultrastructure. Ext1CKO mice also had a significant increase in glomerular Ps’alb, again 
agreeing with the heparinase III studies and the indication that HS contributes to 
glomerular eGlx barrier function.  
Interestingly, when albuminuria was measured in Ext1CKO, there was no significant 
increase compared to LMC. Because an increase in permeability was observed in the ex 
vivo glomerular permeability assays in Ext1CKO mice, we argued that changes in 
albuminuria were masked by tubular reabsorption and therefore confounded results. In 
line with this thought, the previously mentioned heparinase III whole perfused mouse 
kidney studies in which increased albumin clearance was observed,  kidneys were kept at 
8°C to inhibit tubular function (170). Similarly, the same authors observed increased 
albumin clearance in mice treated with hyaluronidase and chondroitinase using the same 
technique, but unpublished work by our group showed long term exposure of mice to 
these enzymes did not yield changes in albuminuria. These two contradicting results may 
be due to the fact that our studies were performed under conditions in which tubular 
function was normal, and no treatment was given to inhibit tubular reabsorption, whereas 
in the perfused mouse kidney study, tubular function was inhibited  by cooling the kidney. 
 To test this theory, I first optimised treatment with L-Lysine in normal FVB mice. Although 
several studies have used L-Lysine and it is acknowledged as a potent tubular reabsorption 
inhibitor (204,211,212), the exact mechanism remains unknown. There is some evidence 
suggesting that L-Lysine acts by binding to negative sites on the tubular cell surface (213). 
This may inhibit the proposed initial event required for tubular reabsorption, in which a 
positive amino- or guanidino- group from proteins binds to the negative sites on tubular 




to be absorbed. In FVB mice, I confirmed that treatment with L-Lysine successfully blocked 
tubular reabsorption, as an observed increase in albuminuria was seen after L-Lysine 
treatment. I also treated FVB mice with eGlx shedding enzymes to investigate potential 
changes in albuminuria when tubular reabsorption was blocked, and indeed observed 
that mice treated with enzyme + L-Lysine had a  significant increase in albuminuria 
compared to baselines, while the enzyme only treated group did not, suggesting that 
tubular reabsorption masked increases in albuminuria in the previous enzyme treatment 
work by our group. Of note, mice treated with L-Lysine and enzymes were treated with L-
Lysine while still under anaesthesia, therefore results from the initial FVB and L-Lysine 
only treated mice discussed above cannot be directly compared. It would be beneficial to 
this study to have an additional L-Lysine only treatment group in which mice are treated 
under the same conditions.  
In the Ext1 model, Ext1CKO mice treated with L-Lysine had a significant increase in 
albuminuria compared to pre-treatment urines, while LMC mice did not. This may explain 
why in the absence of tubular reabsorption, as is the case with the ex vivo glomerular 
permeability assays, Ext1CKO mice did show an increase in albumin permeability.  However 
in vivo, where tubular reabsorption is active, this data suggest that increased levels of 
albuminuria are sufficiently reabsorbed by the proximal tubules to mask an observable 
increase in the urine but can be revealed by blocking tubular reabsorption. Together, 
these data serves as evidence for a structural and functional role of HS in the glomerular 
eGlx and demonstrates that loss of HS can have detrimental effects on glomerular barrier 
function.  
3.4.3 Conclusions and Significance 
The work presented in this chapter establishes an important role for HS in the glomerular 
eGlx which was previously not known. This work shows for the first time, that HS is present 
in the glomerular eGlx. Additionally, the structural and functional studies looking at the 
effects of the loss of HS, both by enzymatic removal and by use of a transgenic mouse 
model, demonstrate that loss of HS is detrimental to the eGlx and GFB integrity, resulting 
in increased permeability. This work lays a foundation for investigating the role of HS in 
vascular diseases in the kidney, such as diabetic nephropathy, where damage to the eGlx 






 Loss and Restoration of Glomerular Endothelial 
Glycocalyx Heparan Sulphate in a Type 2 Diabetic Mouse 
Model   
 Introduction  
4.1.1 Mouse Models of Diabetic Nephropathy  
4.1.1.1 Motivations for Choice of Diabetic Mouse Model  
As stated in CHAPTER 1, the goal of this thesis is to determine if preventing HS degradation 
in diabetes prevents the development of associated microvascular diseases such as DN 
and DR. As the ultimate goal is to find a therapeutic treatment that can be used for all 
microvascular complications in diabetes in the same patient, it was important to choose 
a mouse model which recapitulated aspects of both DR and DN seen in humans. Since the 
focus of this thesis is the role of HS in eGlx permeability barrier, increased permeability in 
the respective vessel beds was a major focus for choosing a mouse model in which both 
microvascular diseases can be studied. Therefore, although there exist good  models for 
studying DN and DR individually, I chose a model in which the hope was that both diseases 
could successfully be investigated in parallel. 
4.1.1.2 Common Mouse Models of Diabetic Nephropathy  
While tissue culture techniques are valuable and necessary in studying cellular responses 
to stimuli, mouse models have become an invaluable tool in many research fields, 
allowing researchers to investigate the complexity of various disease in a living organism 
and the development of novel treatments. In diabetes research, inducible and genetic 
models of diabetes are used to study the development and treatment of this disease. This 
section will cover mouse models of DN, however it should be noted that there are many 
models that are used in diabetes research and these are only a few of the common models 
used in DN research.  
 One of the most common inducible models used to study diabetes is streptozotocin (STZ) 
induced diabetes. This involves injecting rodents with STZ, a chemical that leads to the 
destruction of β-cells. In humans, T1D is a chronic autoimmune disorder, caused by the 
body’s immune system attack on the -cells located in the islets of Langerhans in the 
pancreas (62).  Because -cells are the body’s insulin producing cells, T1D results in 




hyperglycaemia. The STZ model therefore serves as a classic model for T1D. Importantly, 
the mouse background chosen for this model has a substantial effect on the phenotype 
observed. For example, the DBA/2 strain of mice are widely used for DN, and exhibit 
albuminuria 5 weeks after of induction of diabetes with STZ, and continue to progress, 
showing more marked albuminuria by 25 weeks (214). This model also exhibits classic 
pathological features associated with DN in humans, including GBM thickening, severe 
mesangial expansion, and glomerulosclerosis by 25 weeks of diabetes (215). STZ DBA/2 
mice also have a high mortality rate of 40% after 25 weeks (215). The common laboratory 
mouse strain, C57BL/6, on the other hand is largely resistant to DN and renal injury, 
developing only mild to moderate albuminuria 6 months after development of diabetes 
(216). Pathological features such as glomerular hypertrophy, GBM thickening, and mild to 
moderate mesangial expansion are observed more than 6 months after diabetes is 
induced and mice can live for more than 45 weeks after the onset of hyperglycaemia  (214), 
making it a less severe model of DN. However, one drawback to the STZ model is the non-
specific kidney toxicity that can occur 6 to 48 hours after STZ injections (217). Researches 
have combatted this by giving multiple low dose injections of STZ rather than one large 
dose, and while this does seem to mitigate some of the toxicity observed in the high dose 
model, adjustments for individual strains have to be made as susceptibility to β-cell injury 
and non-specific toxicity can vary (218,219) 
A common genetic model for T1D is the Insulin-2 Akita mouse (Ins2Akita). This model has a 
mutation in the Insulin-2 gene, resulting in misfolding of insulin-2, which consequently 
causes β cell-selective proteotoxicity (220). Mice with homozygous mutations die within 
1 to 2 months, but heterozygous mice develop hyperglycaemia  and polyuria at 3-4 weeks 
of age (217).  As with the STZ model, the background on which the Ins2Akita mutation is 
used determines the susceptibility to DN. On a C57BL/6 background, mice are mildly 
resistant to DN and the associated glomerular changes that are seen in humans, with only 
mild development of albuminuria (221). Alternatively, on a DBA/2 or FVB/NJ background, 
mice develop substantial albuminuria, with some changes to renal structure in the FVB/NJ 
mouse such as mesangial expansion, but not in DBA/2 mice (222).   
LepRdb /LepRdb mice (db/db) are another genetic model of diabetes, where mice 
homozygous for the leptin receptor point mutation results in susceptibility to obesity and 
insulin resistance (223). In humans, major risk factor for T2D is obesity. Because obesity 
causes a low but chronic level of inflammation, inflammatory molecules/processes lead 




of glucose in the blood stream persistently stimulates insulin production by -cells,  and 
subsequent development of insulin resistance by glucose recipient organs (64,65). Db/db 
mice are therefore a model of T2D. Db/db mice develop many of the phenotypes observed 
in T2D, including hyperglycaemia, hyperinsulinemia, and morbid obesity by 4-8 weeks of 
age (224). Again as with previous mentioned models, severity of disease and phenotype 
vary from strain to strain and can also be dependent on sex, in part due to differences in 
estrogen levels which plays a role in insulin sensitivity (225), with male mice exhibiting 
more robust diabetic phenotypes (217). Male mice  on a C57BLKS/J (BKS) background 
develop symptoms of early stages of DN such as moderate albuminuria by 8 weeks of age, 
while C57BL/6 mice have minimal changes (215,226). However, unlike other more severe 
models of DN such as the DBA/2 T1D model, db/db mice on a BKS do not have a consistent 
increase in albuminuria, as levels remain similar from 8-25 weeks (227,228). Additionally, 
BKS db/db (db/db) mice have a 20-30% increase in glomerular size by 2 to 4 months of 
age. As in humans, this is likely due to early changes in glomerular hemodynamics that 
coincide with hyperfiltration and mesangial expansion (90,229). Loss of podocytes and 
GBM thickening have also been reported in this model by 12 weeks 16 weeks, respectively 
and   (230,231) , serving as further indications of changes in the GFB. These mice, however, 
fail to develop any of the more advanced features of DN such as mesangiolysis, nodular 
mesangial sclerosis, and tubulointerstitial fibrosis, which  therefore makes db/db mice a 
good model for early changes in DN. Importantly for this thesis, in which the goal is to 
show protection from early changes in microvascular disease in different vessel beds, 
db/db mice also develop some early signs of DR, which will be discussed in detail in 
CHAPTER 6.  In addition, T2D is now considered a global epidemic affecting all parts of the 
world, and is also major economic burden, costing the NHS £8.8 billion a year, alone 
(61,232). It is therefore crucial to find both preventative and effective therapeutic 
treatments for T2D, with the aim that treatment can be translated to T1D. Therefore, 
given the evidence for T2D db/db mice serving as a good model for early DN as well as DR, 
I chose to use this model for my investigations. Because I am interested in early changes 
in the microvasculature, I used two times points of 9 weeks and 11 weeks of age to 
investigate loss and restoration of eGlx, as the literature suggest mice at these ages 
develop early signs of DN with moderate albuminuria and some structural changes 




4.1.2 Heparanase and Its Role in Health and Disease  
4.1.2.1 Heparanase Synthesis  
As mentioned in CHAPTER 1, heparanase (HPSE) is the only known mammalian 
endoglycosidase that directly targets HS for degradation. HPSE is encoded by the gene 
HPSE1,and is synthesised as an enzymatically inactive 68kDa pre-proHPSE, which is 
targeted to the endoplasmic reticulum through its N-terminal signal peptide (25). Here, it 
is cleaved to produce the 65kDa proHPSE, which still lacks enzymatic activity. ProHPSE is 
then shuttled to the Golgi apparatus and secreted (233). Secreted proHPSE is capable of 
binding to extracellular components such as HSPGs and mannose-6-phosphate receptors, 
causing it to be internalized into the cell into latent endosomes and lysosomes (234).  It is 
in the lysosomes where the active enzyme HPSE is activated by lysosomal cathepsin L, 
which excises a 6kDa linker peptide on proHPSE, forming a noncovalent heterodimer 
(8kDa and 50kDa) (235). Studies show that the 8kDa peptide is required for enzymatic 
activity, as the 50kDa chain is not active on its own (236). HPSE is then largely retained in 
intracellular compartments in fibroblasts and neutrophils, where it can be released upon 
internal or external signals either in health or disease.   
4.1.2.2 Heparanase in Health  
In normal conditions, active HPSE is expressed in few tissues and does not seem to have 
any essential roles. ProHPSE has a role in angiogenesis, cell proliferation, and 
tumorigenesis, through its binding of receptors on the cell surface which can lead to Akt, 
p38, and Src activation (237). Active HPSE however is largely restricted to placental and 
skin tissue (238,239). In placental tissue HPSE plays an important role in angiogenesis, 
embryo implantation, and placentation (239). It is also active in blood-borne cells such as 
platelets, neutrophils, monocytes, and mast cells, where it is stored in granules and is 
implicated in diapedesis and extravasation of immune cells (164,240–242).  Because of its 
HS degradation activity, HPSE expression and activity is tightly regulated, as degradation 
of HS in extracellular matrixes and eGlx can release a pool of cytokines, growth factors, 
and enzymes which can affect cell and tissue function (187,240).  HPSE expression and 
activation is also largely modulated by pathophysiological conditions, such as pH. In 
neutral conditions, HPSE is essentially inactive (243). However, under acidic conditions 
such as those found in inflammatory states, enzymatic activity is increased, with pH 5-6 
being optimal for enzymatic activity (243). Because of its restricted expression and lack of 





4.1.2.3 Heparanase in Diabetic Nephropathy  
A large part of HPSE research has focused on its role in cancer progression, and 
upregulation of HPSE has been shown in a number of cancers, associated with increased 
metastasis (244). However, HPSE is now known to be upregulated in several diseases and, 
as previously mentioned, includes inflammatory and proteinuric diseases such as IgA 
nephropathy, membranous glomerulopathy, and DN (169). HPSE is now known to be 
upregulated in diabetes and increased levels have been found in urine and plasma from 
T1D and T2D (110,245,246). It is also upregulated in renal biopsies from DN patients in 
glomeruli and proximal tubules and increased HPSE activity was found in podocytes from 
T1D patients (109,247). Furthermore, reduced GBM HS is associated with increased HPSE 
expression in DN (248), but the effect on the eGlx HS has not been investigated.  In 
laboratory studies, HPSE is increased in T1D and T2D DN rodent models (114,249,250). A 
previously mentioned study in CHAPTER 1 showed that HPSE knock out mice did not 
develop DN when diabetes was induced with STZ, and had reduced albuminuria (114). 
Additionally, pre-treatment with Hyperoside, an active flavone glycoside, in T1D mice 
prevented progression of DN, showing reduced albuminuria and inhibition of increased 
HPSE expression in podocytes (249). As with humans, HPSE expression is associated with 
reduced glomerular HS in rodent models, but no work has been published looking at its 
effect on eGlx (109,249). Together, this data is strong evidence for the role of HPSE in DN 
and its contribution to the development of increase glomerular permeability. However, 
the focus of these studies has been largely on GBM HS, and the effect of HPSE on eGlx in 
diabetes, which is known to contribute to vascular permeability, has yet to be elucidated.   
4.1.3 Use of Heparnase Inhibitors in Disease  
4.1.3.1 Use of Currently Available Heparanase Inhibitors in Disease  
HPSE inhibitors are currently a popular topic in the treatment of malignant and metastatic 
tumours. Two major events that occur during metastasis are the breakdown of the ECM 
and the development of new blood vessels, i.e angiogenesis, that nourish the tumour and 
allow it to survive and grow (251). HPSE is involved in both processes and is upregulated 
in many types of cancers such as myelomas, gliomas, and breast cancers, and is associated 
with poor prognosis (252–254). In fact, HPSE expressing tumour cells show an increase in 
metastatic potential (251,255). Importantly, because HPSE is not typically expressed in the 
majority of non-diseased tissue, treatment with inhibitors have so far shown to have 
minimal side effects (168,256). Indeed, transgenic C57BL/6 mice that have HPSE knocked 




no prominent pathological alterations (257), suggesting HPSE may be a good target in 
disease.  
Use of the HPSE inhibitor SST0001 has shown to slow tumour progression in  myeloma 
studies, both in in vivo laboratory models as well as in vitro (258) . The same inhibitor was 
also shown to have antitumor effects in a lymphoma and paediatric sarcoma mouse 
models (259). Similarly, PG545, PI-88, and M104 have all been used in in vitro or in vivo 
laboratory studies and shown antitumor effects  (260–262).  
Although the upregulation of HPSE in diabetes is also well established, there are fewer 
studies which have investigated the benefits of HPSE inhibitor treatment for DN.  SST0001 
has been used in T1D and T2D DN models showing reduced albuminuria in inhibitor 
treated animals (114).  PI-88 was also used in a non-obese diabetic (NOD) T1D model and 
showed that treatment reduced the incidence of diabetes by 50% (263). Sulodexide, a 
therapeutic drug made from a mixture of heparin and dermatan sulphate,  has also been 
used to treat T1D  rats, resulting in reduced urine protein excretion as well as a decrease 
in pathological changes due to DN, compared  to untreated rats (264). Although 
Sulodexide is not classified as a HPSE inhibitor, it does appear to possess some enzymatic 
inhibition properties due to its heparin component (162). However, none of these studies 
have specifically addressed the impact of HPSE inhibitor treatment on the GFB eGlx and 
HS.  
4.1.3.2 Structure of Currently Available Heparanase Inhibitors  
Most of the available HPSE inhibitors are modified natural heparin molecules or semi 
synthetic compounds which have been designed to closely resemble heparin’s structure, 
a linear polysaccharide, while removing its anticoagulant activity (265). For example, the 
HPSE inhibitor PI-88 is isolated from yeast, which is comprised of a mixture of chemically 
highly sulfonated mannan oligiosaccharides (262,266,267). PI-88 has shown 
antiangiogenic and antimetastatic activity, and has gone through several phase I and 
phase II trials (256). SST0001 and M402 are modified natural heparin molecules, which 
have been altered to remove most of the anticoagulant activity and  have also undergone 
clinical trials showing antimetastatic and antitumor effects (168,256). PG545 is regarded 
as the most potent inhibitor, likely attributed to the two sites on HPSE to which it can bind 
and inhibit HPSE enzymatic activity (268).  Though so far proven effective, currently 
available HPSE inhibitors still have some major pitfalls. PG545 and M402 still retain 




mixtures, and methods required to characterise batch-to-batch variation for FDA approval 
are costly (271) . These factors have led the development of new and improved HPSE 
inhibitors with unique structures that allow for more uniform and cost-effective 
production while retaining potency. 
4.1.3.3 New Dendrimer Heparanase Inhibitors  
The development of dendrimers for drug delivery has gained interest as they are versatile 
in drug delivery with high functionality (272). Unlike linear polysaccharides, dendrimers 
are known for their defined structures (272) (FIGURE 4-1)(273), which lend themselves to 
not only function as will be discussed, but also ease of characterisation for batch-to-batch 
variation. 
  
Dendrimers are highly branched ‘’globular’’ structures, which have layers between each 
cascade point known as ‘’generations’’ (FIGURE 4-2) (272). With each generation, the size 
Figure 4-1 Evolution of Polymer Structure  
Linear and hyperbranched polymers have disorganized structures, whereas dendrimers have 
highly defined organized structures. Image adapted from (Zheng et al. 2015)(273).  
Figure 4-2 Structure of Dendrimer Molecules 
The highly branched dendrimer structure has layers referred to as generations, between each 
cascade point (arrowheads). Each generation increases the number of surface terminal groups 




of the molecule and terminal surface group is increased, allowing for multiple points of 
interaction with the target molecule (272,274).  
Our collaborator, Dr. Olga Zubkova at Victoria University of Wellington, has developed a 
dendrimer, OVZ/HS-1638, in which the dendrimer itself has HPSE inhibitory properties, 
without acting as a drug delivery system. The inhibitor is made of single-entity HS 
glycomimetic clusters, capped with sulphated saccharides, glucose, and maltose (FIGURE 
4-3) (271). Importantly, this inhibitor was shown to have similar potency as PG545, with 
IC50 values of 11nM and 8nM respectively, and with a significant lack of anticoagulant 
activity compared to other inhibitors such as PG545 and M410 (271). It was also tested  in 
vivo in an aggressive myeloma mouse model and resulted in a significant reduction in 
tumour spread (271). Given the role of HPSE in DN and the initial success/ apparent 
superior properties of this inhibitor, we investigated if use of this novel inhibitor would 
prevent eGlx damage and associated increase in microvascular permeability by preventing 
HS degradation. Additionally, if proven effective, the work on other HPSE inhibitors 
already in clinical trials has paved the way for the use if this type of therapy in humans, 




Figure 4-3 Structure of OVZ/HS-1638 
OVZ/HS-1638 is a dendrimer heparanase inhibitor. This compound is highly branched, allowing for 
multiple interaction points. The compound is capped with sulphated groups which contribute to its 




4.1.4 Chapter Aims and Experimental Approaches  
The aim of this chapter is to show that loss of HS, and consequently damage to eGlx due 
to upregulated levels of HPSE in DN, can be prevented by treatment with a novel HPSE 
inhibitor, OVZ/HS-1638. The aims to accomplish this were as follows: 
1. Show that glomerular eGlx is damaged in a T2D mouse model which results in loss 
of eGlx function and associated increased glomerular permeability. This was done 
at two different timepoints, 9 weeks of age and 11 weeks of age.  
2. Show that damage to the glomerular eGlx can be restored by preventing HS 
degradation through treatment with OVZ/HS-1638, resulting in restored eGlx 
function and decreased glomerular permeability. This was done at two different 






These methods are not inclusive. The methods described in this section are those that 
pertain specifically to this chapter or have been adapted for experiments in this chapter. 
All other methods are described in the CHAPTER 2 METHODS AND MATERIALS.   
4.2.1 Study Design Nine-Week-Old Time Point  
At 7 weeks of age, lean control and db/db control mice were administered vehicle 
treatment (PBS), daily for two weeks subcutaneously (s.c.). Similarly, OVZ/HS-1638 group 
received daily injections for two weeks of OVZ/HS-1638 dissolved in PBS at 20mg/kg, s.c. 
Blood glucose was measured weekly and urine was collected at end point for uACR 
measurements as described in CHAPTER 2. Mice were anesthetised and perfused as 
described in CHAPTER 2 for glomerular permeability studies and EM imaging. A schematic 








Figure 4-4 Study Design for Nine-Week-Old Time Point 
At 7 weeks five lean and five db/db mice were treated with vehicle s.c. Five db/db mice were treated 
with 20mg/kg OVZ/HS16-38 heparanase inhibitor (HI) in vehicle, also by s.c. At 9 weeks mice were 




4.2.2 Study Design for Eleven-Week-Old Time Point 
At 9 weeks of age, lean control and db/db control mice were administered PBS vehicle 
treatment daily for two weeks i.p. Similarly, OVZ/HS-1638 group received daily injections 
for two weeks of OVZ/HS-1638 dissolved in PBS at 20mg/kg by i.p. Blood glucose was 
measured weekly and urine was collected at end point for uACR measurements as 
described in CHAPTER 2. Mice were anesthetised and perfused as described in CHAPTER 2 
for glomerular permeability studies and EM imaging. A schematic of the experimental 
design is shown in FIGURE 4-5.   
 
 
4.2.3 Immunofluorescence for HPSE in Mouse Kidney 
Kidneys were flash frozen in liquid nitrogen, embedded in O.C.T. Compound (23-730-571, 
Fisher Scientific), and sectioned at 5µm on cryostat and mounted onto superfrost slides 
for staining. Slides were airdried for 15 minutes and fixed in 4% PFA for 15min and washed 
in PBS, three times for 5min. Sections were blocked in 3%BSA/0.3% Triton-X for an hour. 
Primary antibody anti-HPSE Rabbit 1:100 (16673-1-AP, Proteintech) and matched rabbit 
IgG control was added in block solution at 4°C overnight. Slides were washed in PBS, three 
times for 5min. Secondary goat anti-rabbit Alexa Fluor 594 (A-11037, ThermoFisher) was 
applied for 1 hour at 1:200 at room temperature. Slides were washed in PBS, three times 
for 5min and counterstained with DAPI as described in main methods. Slides were washed 
two times for 5min and coverslips were mounted with Vectashield (H-1400, Vector 
Laboratories).  
Figure 4-6 Study Design for Eleven-Week-Old Time Point  
At 9 weeks five lean and five db/db mice were treated with vehicle by i.p. injection. Five db/db mice were 
treated with 20mg/kg OVZ/HS16-38 in vehicle, also by i.p. At 11 weeks mice were cardiac perfused and 




4.2.3.1 Imaging and Analysis of Total HPSE in Mouse Kidney 
Images were taken on Leica DM2000 microscope (Leica Microsystems) using 20X 
objective, using TRICT filter (HPSE staining) and DAPI filter (nuclear staining). Images were 
analysed on FIJI. On DAPI images, the entire image was measured for area, mean gray 
value, and integrated density (IntDen) using a rectangular selection tool. Four background 
measurements were taken as well. CTCF was calculated as described in CHAPTER 2. The 
same measurements were taken for corresponding TRITC images and CTCF calculated for 
HPSE as previous with DAPI. To calculate total kidney HPSE, CTCF values for HPSE were 
normalised to DAPI. CTCF values were averaged for each group. A minimum of three field 
of view were taken for each animal.  
4.2.4 Periodic Acid-Schiff Staining on Mouse Kidney 
Kidney was fixed in 4% PFA for minimum of 24 hours, paraffin embedded, and sectioned 
at 5m at The University of Bristol Histology Lab. For immunofluorescence, slides were 
deparaffinized two times in Xylenes for 10 minutes. Slides were rehydrated by sequential 
5min incubations in decreasing ethanol concentrations: 100% twice, 95%, 70%, and 50%. 
Slides were incubated in deionized water for 5min. Periodic Acid-Schiff (PAS) kit (395b-
1KT, Sigma-Aldrich) was used to stain slides following manufacturer’s instructions. Slides 
were coverslip mounted in DPX Mountant (06522-100ML, Sigma-Aldrich).  
4.2.4.1 PAS Slide Imaging and Analysis  
Bright field images were taken on Leica DM2000 microscope (Leica Microsystems) with 
40X objective. Images were quantified with FIJI using the H-PAS colour deconvolution 
plugin. Pink images were inverted and converted to 8-bit images. Using the Freehand 
selection tool, glomeruli perimeters were traced and the Analyse tool was used to obtain 
area, mean gray value, and integrated density value for each image. Four background 
values were obtained similarly, and the background mean grey value was calculated for 
each image. CTCF values were calculated as previous. Minimum of six glomeruli were 
analysed per mouse, and mean CTCF values were calculated for each mouse.  
4.2.5 Heparan Sulphate Depth Measurements on Heparan Sulphate Stained  
Mouse Kidney  
The technique described has been previously used and validated against EM to measure 
changes in eGlx depth with lectin staining (108). Briefly, confocal images were taken using 
the Multi-Laser CLSM Leica SP5 provided by University of Bristol Wolfson Bioimaging 




set to 2048x2048. Images were analysed using FIJI and a macro developed by a PhD 
student in the lab, Dr. Colin Down, M.D. with technical support from University of Bristol 
Wolfson Bioimaging Facility. FITC filter images (HS staining) and TRITC filter images (R18, 
cell membrane staining) were opened on FIJI. Using the macro, the centre of the capillary  
was marked by measuring the longest and shortest diameter of the capillary (FIGURE 4-8 
A). The macro then took 200 measurements (number set by user) of peak intensity 
profiles for the R18 and HS staining around the entire capillary (FIGURE 4-8 B). The 
distance of the two peaks were then calculated and is representative of eGlx depth, or in 










Figure 4-7 Analysis of HS Depth from HS Immunofluorescence.  
A. The longest diameter (d1) and shortest diameter (d2) is set by user, which results in a marking of 
the centre of the capillary (yellow x). B. The macro takes 200 measurements (m1, m5) of peak intensity 
in at increments of equal distance around the entire capillary. C. Example of peak intensity profiles for 
green signal (HS) and red signal (cell membrane). The distance between the two peaks represents HS 





4.2.6 Diabetic Mice at Nine Weeks of Age 
4.2.6.1 Db/db Mice Have Increased Weight which is Not Affected by OVZ/HS-1638 
To ensure that diabetic mice were progressing as expected, mouse weights were taken 
daily from the time of treatment. As expected, db/db mouse weights were higher 
compared to lean controls (FIGURE 4-9). Additionally, treatment with OVZ/HS-1638 did 
not affect mouse weights in db/db mice compared to db/db mice treated with vehicle 

















Figure 4-9 Db/db Mice Have Increased Body Weight and is Not Affected by HPSE Inhibitor Treatment 
Mouse weights taken daily from 7 to 9 weeks of age in non-diabetic(lean), diabetic (db/db) mice, and 




4.2.6.2 Db/db Mice Have Increased Blood Glucose which is Not Affected by OVZ/HS-1638 
Treatment   
To determine whether db/db mice had become hyperglycaemic and confirm that 
treatment with OVZ/HS-1638 did not affect it, blood glucose levels were taken weekly for 
all mice. As shown in FIGURE 4-10, db/db mice had a significant increase in blood glucose 










Figure 4-10 Db/db Mice are Hyperglycemic which is Not Affected by HPSE Inhibitor Treatment   
Blood glucose levels were measured weekly in non-diabetic (lean), diabetic (db/db) mice, and db/db 
mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) to ensure all db/db mice were 






4.2.6.3 Nine-Week-Old Db/db Mice Show No Changes in GFB Ultrastructure  
To determine whether db/db mice had developed changes in GFB ultrastructure 
associated with DN, EM images from glutaraldehyde/Alcian blue perfused mice were 
taken and analysed. Db/db mice did not have any changes in podocyte foot process width, 
slit diaphragm width, fenestration density, or basement membrane thickness (FIGURE 







Figure 4-12 Nine-Week-Old Db/db Mice Do Not Show Changes in GFB Consistent With Diabetic 
Nephropathy 
Non-diabetic (lean), diabetic (db/db) mice, and db/db mice treated with OVZ/HS-1638 HPSE inhibitor 
(db/db+HI) EM images were analysed for changes in: A. Podocyte foot process (PFP) width B. Slit 
diaphragm (SD) width. C. Endothelial cell fenestration number. D. Basement membrane (BM) 
thickness. Minimum of 3 capillaries per mouse measured. N= 5 mice, one-way ANOVA, Tukey’s 





4.2.6.1 Db/db Mice Do Not Have Reduced Glomerular eGlx at 9 Weeks of Age 
To determine whether db/db mice had changes to the glomerular eGlx at 9 weeks of age, 
eGlx depth and coverage was measured using quantitative EM images from 
glutaraldehyde/Alcian blue perfused mice. Contrary to what was expected, vehicle and 
OVZ/HS-1638 treated db/db mice had no changes glomerular eGlx depth or coverage 
compared to lean ( FIGURE 1-9A,B). Furthermore, treatment with OVZ/HS-1638 had no 
significant effect on eGlx depth or coverage. Similarly, there were no significant changes 



















Figure 4-13 Nine-Week-Old Db/db Mice Have No Changes in eGlx or pGlx 
 A. Representative EM images of GFB from non-diabetic  (lean), diabetic (db/db) mice, and db/db mice 
treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI). Podocyte (P), basement membrane (BM), 
endothelial cell (E) shown. Arrow points to podocyte glycocalyx and arrowheads point to eGlx. B. EM 
images were analysed for eGlx depth (left) and eGlx coverage (right). C. EM images were analysed for 
pGlx depth (left) and pGlx coverage (right). Minimum of three capillaries measured per animal. Minimum 






4.2.6.2 Nine-Week-Old Db/db Mice Have Increased Albuminuria, which is Not Affected by 
OVZ/HS-1638 Treatment  
Ultrastructural measurements by EM showed no changes that were suggestive of early 
signs of DN, as would have otherwise been expected. To determine whether db/db mice 
had any changes to GFB function, albuminuria was measured at end point at 9 weeks of 
age. Vehicle and OVZ/HS-1638 treated db/db mice had a significant increase in 
albuminuria compared to lean controls, and no significant changes were observed 
between vehicle and OVZ/HS-1638 treated mice (FIGURE 4-14). This data indicates that 
db/db mice do have changes in GFB function, despite no changes in GFB ultrastructure, 








Figure 4-14 Nine-Week-Old Db/db Mice Have Increased Albuminuria which is Not Affected by OVZ/HS-
1638 Treatment   
 Endpoint albuminuria was measured for non-diabetic (lean), diabetic (db/db) mice, and db/db mice 
treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) . N= 5 mice, one-way ANOVA, Tukey’s multiple 





4.2.6.3 Vehicle Treated Db/db Mice but Not OVZ/HS-1638 Treated Mice Have Increased 
Glomerular Albumin Permeability  
As db/db mice had increased albuminuria, it would be expected that an increase in 
glomerular albumin permeability would be observed. To further investigate, glomerular 
permeability assays, which are more sensitive than uACR measurements, were performed 
on Ringer perfused isolated glomeruli from lean and db/db mice treated with vehicle or 
OVZ/HS-1638. In agreement with albuminuria data, vehicle treated db/db mice had a 
significant increase in Ps’alb compared to lean controls (FIGURE 4-15). Surprisingly, db/db 
OVZ/HS-1638 treated mice did not have a significant increase in Ps’alb, though a modest 
increase was observed compared to lean mice (FIGURE 4-15). Treatment with OVZ/HS-















Figure 4-15 Vehicle Treated Db/db Mice but Not OVZ/HS-1638 Treated Mice Have 
Increased Glomerular Albumin Permeability  
Glomeruli were isolated from ringer perfused non-diabetic (lean), diabetic (db/db) mice, 
and db/db mice treated with HPSE inhibitor (db/db+HI) and glomerular albumin 
permeability was measured. On x-axis (mouse number (glomeruli analysed)). One- way 





4.2.7 Diabetic Mice at Eleven Weeks of Age 
4.2.7.1 Db/db Mice Have Increased Weight which is Not Affected by OVZ/HS-1638 
Treatment 
Data from the 9-week-old cohort suggested that mice had not developed DN to the stage 
that allowed for detection of eGlx changes. I therefore decided to conduct a similar 
experiment using a later time point, where db/db mice were treated from 9-11 weeks of 
age. As with the earlier 9-week-old cohort of mice, weights were measured daily from the 
start of OVZ/HS-1638 treatment to confirm that db/db mice were progressing as expected 
and determine whether OVZ/HS-1638 treatment had any effect on weight gain. As before, 
both vehicle and OVZ/HS-1638 treated db/db mice had increased body weight compared 
to lean controls (FIGURE 4-16). OVZ/HS-1638 treatment also had no effect on weight gain 






Figure 4-16 Db/db Mice Have Increased Body Weight, which  is Not Affected by OVZ/HS-1638  
Treatment 
Weights were taken daily post treatment (age) to monitor growth progression in non-diabetic  





4.2.7.2 Db/db Mice Have Increased Blood Glucose which is Not Affected by OVZ/HS-1638  
To confirm that db/db mice were hyperglycaemic and remained so for the duration of the 
experiment, weekly blood glucose was taken at the start of treatment. As with the 9-
week-old cohort, all db/db mice had elevated blood glucose which remained elevated for 
the duration of the experiment with and without OVZ/HS-1638 treatment, compared to 











Figure 4-17 Db/db Mice are Hyperglycaemic which is Not Affected by OVZ/HS-1638  Treatment  
Blood glucose levels were measured weekly for non-diabetic (lean), diabetic (db/db) mice, and db/db 
mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) to ensure all db/db were hyperglycaemic. 




4.2.7.3 Eleven-Week-Old Db/db Mice Have Increased HPSE Expression in Kidney Tissue 
It is well established that HPSE expression is upregulated in diabetes. To confirm that HPSE 
was elevated in this mouse model at this time point, I performed immunofluorescence 
staining for HPSE in kidney sections from lean and all db/db mice. Staining confirmed that 
HPSE levels were increased in db/db mice compared to lean controls, while db/db mice 
treated with OVZ/HS-1638 had only a modest increase (FIGURE 4-18 A). Images were 
quantified by measuring CTCF. As shown in FIGURE 4-18 B, and in agreement with 
representative images, db/db mice treated with vehicle had a significant increase in HPSE 
signal compared to lean controls. Interestingly, OVZ/HS-1638 treated mice did not have a 
significant increase in HPSE signal compared to leans, but was not significantly reduced 




Figure 4-18 Eleven Week Old Db/db Mice Have Increased HPSE Levels in Kidney Tissue  
A. Representative immunofluorescent images of HPSE (red) and DAPI nuclear stain (red) in kidneys from 
non-diabetic  (lean), diabetic (db/db) mice, and db/db mice treated with OVZ/HS-1638 HPSE inhibitor 
(db/db+HI) . B. Total HPSE CTCF was measured and normalised to DAPI. Minimum of three fields of view 





4.2.7.4 Eleven-Week-Old Db/Db Mice Have Ultrastructural Changes Consistent with Early 
Diabetic Nephropathy 
To determine whether db/db mice had characteristic ultrastructural changes in the GFB 
at 11 weeks, and therefore an indication that mice had developed DN, podocyte foot 
process width, slit diaphragm width, fenestration density, and GBM thickness were 
measured as before using quantitative EM. Db/db mice treated with vehicle had a 
significant increase in podocyte foot process width and decrease in slit diaphragm width, 
a sign of podocyte effacement (FIGURE 4-19 A,B). While db/db mice treated with OVZ/HS-
1638 did not have a significant increase in podocyte foot process width, mice did have a 
modest increase, and had a significant decrease in slit diaphragm width (FIGURE 4-19 A,B). 
There were no significant changes measured between any groups in fenestration density 
and GBM thickness.  
 
 
Figure 4-19 Eleven-Week-Old Db/db Mice Show Changes Consistent with Diabetic Nephropathy  
Non-diabetic  (lean), diabetic (db/db) mice, and db/db mice treated with OVZ/HS-1638 HPSE inhibitor 
(db/db+HI) EM images were analysed for changes in: A. podocyte foot process (PFP) width B. Slit 
diaphragm (SD) width C. Endothelial cell fenestration number D. Basement membrane (BM) 
thickness. Minimum of 3 capillaries per mouse measured. N= 5 mice, one-way ANOVA, Tukey’s 





4.2.7.5 Db/db Mice Have Reduced Glomerular eGlx, which is Restored by OVZ/HS-1638 
Treatment  
Nine-week-old db/db mice did not show changes in eGlx depth or coverage, but also 
showed no ultrastructural changes suggestive of DN.  The data so far for 11 week-old-
mice suggest a more progressed level of DN compared to the 9-week-old mice. I therefore 
measured eGlx depth and coverage in 11-week-old mice using quantitative EM as before. 
As shown in   FIGURE 4-20 A, db/db mice had reduced eGlx compared to lean, with eGlx 
appearing thinner and more patchy. This was confirmed by quantitative EM, with a 
significant reduction in depth and coverage FIGURE 4-20 B. OVZ/HS-1638 treated mice 
appeared to have thicker and more evenly spread eGlx, more similar to lean mice. In 
agreement with this, quantified images showed no significant decrease in eGlx depth or 
coverage compared to leans, and in fact had a significant increase in eGlx measurements 
compared to db/db mice treated with vehicle (FIGURE 4-20 B) . There were no significant 










Figure 4-20 Db/Db Mice Have Decreased Glomerular eGlx depth and coverage, which is 
Restored by OVZ/HS-1638  Treatment  
A. Representative EM images of GFB from non-diabetic  (lean), diabetic (db/db) mice, and db/db 
mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) . Podocyte (P), basement membrane 
(BM), endothelial cell (E) shown. Arrow points to podocyte glycocalyx and arrowheads point to 
eGlx. B. EM images were analysed for eGlx depth (left) and eGlx coverage (right). C. EM images 
were analysed for pGlx depth (left) and pGlx coverage (right). Minimum of three capillaries 
measured per animal. Minimum of 50 measurements per capillary. N= 5 mice, one-way ANOVA, 




4.2.7.6 Changes in Heparan Sulphate Cannot be Detected by HS Phage Display Antibody 
in Db/db Mice 
As HPSE is increased in 11-week-old db/db mice and was associated with decreased eGlx, 
I investigated whether mice also had reduced HS in glomerular eGlx. To do this, kidney 
sections were immunostained with anti-HS3A8V, previously determined to stain eGlx HS 
(CHAPTER 2). There were no visible changes between lean, db/db, and db/db treated with 
OVZ/HS-1638 mice (FIGURE 4-21 A). As a way to quantify eGlx HS depth,  fluorescent peak-
to-peak measurements were taken for eGlx HS, a technique which has been previously 
used  by our group to quantify changes in eGlx using lectins and was validated with EM 
(108). There were no detectable changes in eGlx HS depth, nor in total glomerular HS 




Figure 4-21 Changes in HS Cannot be Detected by Anti-HS Phage Display Antibody in Db/db Mice 
A. Representative images of mouse kidney tissue from non-diabetic  (lean), diabetic (db/db) mice, and 
db/db mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) stained with anti-HS HS3A8V phage 
display antibody (green), R18 cell membrane stain (red), and DAPI nuclear stain (blue). B. eGlx HS depth 
measurements taken for individual capillaries. Minimum of 3 glomeruli (3 capillaries each) measured 
per mouse. N=3 mice, one-way ANOVA, Tukey’s multiple comparison test, not significant. C. CTCF was 
calculated for total glomerular HS. Minimum of 3 glomerular measured per mouse. N=3 mice, One-way 





4.2.7.7 Eleven-Week-Old Db/Db Mice Have a Significant Increase in Albuminuria, which  
is Prevented by OVZ/HS-1638 Treatment  
The results presented so far indicate development of DN in db/db mice. Furthermore, 
reduced glomerular eGlx, as was seen in db/db mice, is associated with increased 
albuminuria (36,108,116). To determine whether db/db mice had changes in GFB function 
and examine whether treatment with OVZ/HS-1638 had any effect on this, uACR 
measurements were taken at end point for all mice. Db/db mice had a significant increase 
in albuminuria compared to lean mice (FIGURE 4-22). OVZ/HS-1638 treated mice did not 
have a significant increase in albuminuria, and had a modest but not significant decrease 
in albuminuria compared to db/db mice treated with vehicle (FIGURE 4-22). It should be 
noted that one urine sample from db/db and one urine sample from db/db treated with 







Figure 4-22 Eleven-Week-Old Db/db Mice Have Increased Albuminuria and is Prevented by 
OVZ/HS-1638 Treatment  
 Endpoint albuminuria was measured for non-diabetic (lean), diabetic (db/db) mice, and db/db 
mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI) . N= 4-5 mice, one-way ANOVA, Tukey’s 





4.2.7.8 Db/db Mice Have Increased Glomerular Albumin Permeability, which is Reduced 
by OVZ/HS-1638 Treatment  
Albuminuria and eGlx data for 11-week-old mice showed an increase in uACR and 
decreased in eGlx depth and coverage, suggesting loss of GFB function. To further confirm 
this data, glomerular albumin permeability assays, with greater statistical power and 
sensitivity  than uACR, were performed to determine whether glomeruli isolated from 
db/db mice had increased albumin permeability and determine whether treatment with 
OVZ/HS-1638 had any therapeutic effect. As expected, db/db mice had a significant 
increase in Ps’alb compared to lean mice, as was observed in 9-week-old db/db mice 
(FIGURE 4-23). Additionally, OVZ/HS-1638 treated mice had no significant increase in 








Figure 4-23 Eleven Week Old Db/db Mice Have Increased Glomerular Albumin Permeability which is 
Reduced by OVZ/HS-1638 Treatment  
Glomeruli were isolated from non-diabetic (lean), diabetic (db/db) mice, and db/db mice treated with 
OVZ/HS-1638 HPSE inhibitor (db/db+HI) ringer perfused mice and glomerular albumin permeability was 
measured. On x-axis (mouse number (glomerular analysed)). Statistics performed on mouse number, 




4.2.7.9 Glomerular Permeability Negatively Correlates with eGlx Depth and Coverage 
To determine whether eGlx was correlated with permeability, and therefore suggestive 
of a causal relationship, I plotted eGlx depth and coverage against permeability and 
performed correlation studies. As shown in FIGURE 4-24, both eGlx depth and coverage 
was significantly correlated with glomerular permeability, with increasing eGlx negatively 
correlating with reduced permeability. This indicates a potential causal relationship 
between eGlx and permeability. 
 
 
Figure 4-24 Glomerular Permeability Negatively Correlated with eGlx Depth and Coverage  
A. Relationship between permeability and eGlx depth. B. Relationship between eGlx coverage and 




4.2.7.10 Glomerular Fibrosis is Increased in Db/db Mice, which  is Reduced by OVZ/HS-
1638 Treatment  
Because db/db mice exhibited changes in GFB ultrastructure and function, I investigated 
whether db/db mice had developed other signs associated with DN, such as glomerular 
fibrosis. Additionally, I wanted to determine whether the protective effects of OVZ/HS-
1638 on eGlx structure and GFB function extended further than the GFB. To do this, I used 
the histological stain PAS, a stain which detects deposition of glycogen, glycoproteins, 
glycolipids, and mucins in tissue (275). Db/db mice treated with vehicle had increased PAS 
intensity staining compared to lean mice, which appeared decreased in OVZ/HS-1638 
treated mice (FIGURE 4-25 A). In agreement with this, quantification of CTCF in PAS 
stained kidney showed that db/db mice had a significant increase in fibrosis staining which 
was significantly reduced in OVZ/HS-1638 treated mice (FIGURE 4-25).  
 
Figure 4-25 Glomerular Fibrosis is Increased in Db/db Mice which  is Reduced in by OVZ/HS-1638 
A. Representative bright field images of PAS stained kidney from non-diabetic  (lean), diabetic (db/db) 
mice, and db/db mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI). Arrowheads point to 
fibrosis staining in pink. B. Total glomerular CTCF was measured. Minimum of six glomeruli measured 





 Discussion  
4.3.1 Nine-Week-Old Diabetic Mice Do Not Show Signs of eGlx Damage in Early 
Stages of Diabetic Nephropathy  
The aim for this chapter was to show that eGlx is damaged in a T2D mouse model using 
db/db mice, and to show that microvascular changes that occur in early DN could be 
prevented by treatment with a novel HPSE inhibitor, OVZ/HS-1638. I therefore used an 
early time point of 7-9 weeks of age, at which time db/db mice are recognized to be 
hyperglycaemic and have increased albuminuria. In agreement with previous reports 
using this model, db/db mice treated with vehicle had increased weight and blood glucose 
levels by 7 weeks of age compared to lean controls treated with vehicle, and remained 
elevated for the duration of the experiment. This suggested that the mouse model was 
progressing as would be expected for a T2D model, resembling aspects of the disease in 
humans. Treatment with OVZ/HS-1638 also had no effects on weight or blood glucose 
levels, indicating that the inhibitor itself was not having any off-target effects that 
changed metabolic processes. Interestingly, T1D models have shown that HS is highly 
expressed in mouse islets, and is essential for β-cell survival (276), suggesting preventing  
HS loss in mouse islets may help prevent T1D diabetes. Indeed, T1D mice treated with the 
heparanase inhibitor PI-88, had a delayed development of diabetes by 10 weeks (276). 
However, as this is a T2D mouse model in which tissues become insulin resistant, any 
protective affects which OVZ/HS-1638 may have on β-cell survival, may not impact blood 
glucose in the same way. This may explain why no differences are observed in blood 
glucose levels when comparing vehicle and OVZ/HS-1638 treated db/db mice.   Examining 
changes in GFB ultrastructure, all db/db mice showed no significant changes that would 
have been expected if mice had developed early changes associated with DN. But it is 
likely that this was too early of a time point to observe such changes as previous reports 
of podocyte effacement and GBM thickening for example, did not occur until 12 and 16 
weeks of age, respectively (230,277).  Measurements of eGlx depth and coverage were 
also unchanged in db/db mice compared to lean controls, further evidence that this was 
too early of a time point to detect changes in eGlx structure. Surprisingly, db/db mice did 
have a significant increase in albuminuria at 9 weeks of age. Although this is in line with 
the literature, which reports a moderate increase in albuminuria by 8 weeks of age 
(217,277), I expected this to be associated with changes in eGlx. It is possible that small 
changes in eGlx did occur, but with moderate changes, a larger sample size is required to 




to-perfusion and depth can be further affected by EM processing due to dehydration and 
rehydration steps (10). Bigger changes however are more evident despite slight variations 
in perfusions and EM processing. It is of course also possible that there are simply no 
changes in eGlx at this time point. However, glomerular albumin permeability assays also 
showed a significant increase in permeability in db/db mice, which our group has shown 
is associated with loss of eGlx in other diabetic models such as STZ mice and rats (36,108). 
Increased permeability is further evidence that mice have changes in their GFB function, 
despite the lack of ultrastructural changes. Additionally, although Ps’alb was not 
significantly reduced by OVZ/HS-1638 treatment at 9wk compared to vehicle treated 
db/db mice, it was not significantly increased compared to lean controls. This contradicts 
the albuminuria results showing that both sets of db/db mice had increased albuminuria. 
However, the glomerular permeability assay is a more sensitive and direct measurement 
of glomerular permeability, therefore it is possible that it is able to distinguish smaller 
changes in glomerular permeability that  are not detectable by the ELISAs used to measure 
albumin in the urine.  
As there were no changes in eGlx depth or coverage, it cannot be concluded wheather or 
not treatment with OVZ/HS-1638 is protective at this time point. Albuminuria data 
suggest that functionally, OVZ/HS-1638 treatment is not protective. However, there are 
several factors that can affect albuminuria. First, as discussed in CHAPTER 3, tubular 
reabsorption plays a major role in reabsorbing low levels of albumin that is leaked out by 
the glomerulus. Although these mice were all treated the same, slight differences in 
kidney physiology in individual mice could affect albuminuria. Indeed, a study performed 
on diabetic children showed that diabetic subjects had a significant increase in tubular 
reabsorption of sodium, glucose, and calcium, compared to non-diabetic children (278). 
Additionally, an STZ rat model showed that rats in early stages of diabetes had reduced 
tubular reabsorption of albumin (279), which may explain the large variability observed in 
all db/db mice. Additionally, time and methods of urine collection has been shown to have 
effects on albuminuria results. Human studies report that the first morning void is better 
for investigating changes in albuminuria in patients, versus the 24-hour collection or spot 
collection method (280). Unfortunately, the nature of these experiments did not allow for 
collection of urines at a specific time for each mouse, which may also contribute to 
variabilities in albuminuria that could be masking protective effects of the inhibitor. It 
should also be noted that the route of injection for OVZ/HS-1638 in this study was 




Professor Jerry Turnbull at University of Liverpool, who had positive results using this 
route of injection with OVZ/HS-1638 in myeloma studies. However, efficacy may vary 
depending on the model and disease being investigated, and it is possible a different route 
of injection would increase efficacy. Ultimately, an end point of 9 weeks of age in db/db 
mice did not provide conclusive evidence that glomerular eGlx structure and function is 
deteriorated, and therefore potential protective effects with OVZ/HS-1638 treatment 
could not be established.  
4.3.2 Loss of eGlx Structure and Function in Eleven-Week-Old Mice is Restored by 
Treatment with OVZ/HS-1638  
As the 9-week timepoint did not yield conclusive evidence, likely due to a small sample 
size and too early of a time point. Based on ultrastructural data, I decided to use a later 
time point in hopes that changes in db/db mice would be more robust and therefore more 
easily measurable. I also changed the OVZ/HS-1638 administration to i.p., in hopes this 
would be a more effective route for HPSE inhibition.   For this later timepoint, experiments 
began at 9 weeks of age with vehicle or OVZ/HS-1638 treatments for two weeks and an 
endpoint of 11 weeks. As before, weights and blood glucose were measured in db/db mice, 
showing that diabetic mice were progressing as expected, and treatment with the 
OVZ/HS-1638 had no effects on either parameter.  
Although an increase in circulating HPSE and expression in diabetic kidneys is well 
established and has been shown in a number of animal and human studies 
(109,247,250,281), including db/db mice (114), I wanted to confirm our cohort of db/db 
mice at 11 weeks had increased HPSE expression. Using immunofluorescence on mouse 
kidney sections, I confirmed that HPSE expression was significantly increased in db/db 
mice as measured by CTCF. Of note, HPSE staining was primarily tubular in the kidneys of 
db/db mice. Although unexpected, this is in agreement with HPSE staining in human 
studies, which showed a significant reduction in glomerular HS, despite HPSE signal being 
primarily in the tubules (109). It is possible that loss of glomerular HS occurs due to 
circulating active HPSE, which may not be directly sourced from glomerular cells. Indeed, 
as mentioned previously, leukocytes and platelets have been shown to be sources of 
active HPSE (84). Surprisingly, OVZ/HS-1638 treated mice had a decrease in HPSE 
expression in their kidneys, though not significant. The supposed mechanism of action for 
this inhibitor is inhibition by binding to HPSE in a way that prevents catalytic cleavage of 
HS molecules (271). However, it has been shown that HS shed from eGlx can activate 




is stored in granules and can be released upon intracellular or extracellular signals. This 
may explain why mice treated with the inhibitor have reduced HPSE expression, as 
presumably eGlx HS shedding is inhibited, preventing inflammatory cell activation and 
HPSE release.  
In agreement with the literature for this mouse model which showed reduced podocytes 
by 12 weeks (230), db/db mice had a significant increase in podocyte foot process width 
and decrease in slit diaphragm width, consistent with podocyte effacement, an early sign 
of DN seen in both humans and mice. A significant increase in GBM thickening was not 
observed, however there was a modest increase in db/db mice compared to lean controls, 
and possibly would become significant were it not for the greater variation observed in 
diabetic mice. No changes were observed in fenestration density, however this becomes 
more prevalent  in slightly later stages of DN (103), and therefore may not be apparent at 
11 weeks. Inhibitor treated mice also had a significant increase in podocyte foot process 
width suggesting podocyte effacement, though no changes were observed in slit 
diaphragm width. Additionally, no changes were observed in pGlx between any groups. 
This has been observed by our group in many diabetic studies (116,155). Though it is not 
entirely clear why, it is likely due to the fact that the pGlx is not the first point of contact 
with flowing blood containing the highest concentrations Glx damaging agents.   
In contrast to the 9-week model, measurement of eGlx in db/db mice did showed a 
significant decrease in depth and coverage at 11 weeks of age. Notably, treatment with 
OVZ/HS-1638 prevented eGlx damage and was significantly increased compared to db/db 
mice treated with vehicle. This suggests that the OVZ/HS-1638 is having protective effects 
on eGlx structure by preventing HS degradation.  To confirm this, I performed 
immunofluorescence on kidney sections from these mice staining for HS using the same 
antibody described in CHAPTER 3. Unfortunately, there were no detectable changes in eGlx 
HS depth, measured using the validated and published method which uses lectin staining 
to determine the distance between fluorescent profile peaks (peak-to-peak) by confocal 
microscopy imaging to measure changes in eGlx depth (108). Additionally, total 
glomerular HS measured by CTCF also showed no changes. With regard to the peak-to-
peak analysis, in retrospect it is likely that this method of analysis is not appropriate for 
the type of staining obtained using this antibody. The reason is that lectin staining of eGlx 
generally gives a very uniform signal around the capillary and was originally used to 
optimise the macro for analysis. However, this HS antibody gives very punctate staining 




in inaccurate eGlx HS depth measurements. However, as total glomerular HS is also not 
reduced in db/db mice it is likely that this antibody is not suitable for detecting eGlx HS 
changes and faces the same issues in this model as in Ext1CKO mice discussed in CHAPTER 3. 
Indeed, a study performed on human kidney tissue showed that staining with different 
antibodies yielded different results in terms of loss of HS in glomeruli. For example, 
staining with the HS antibodies JM403, HS4C3, and EW3D10 which target specific N-
unsubstituted glucosamine residues or sulphated heparan sulphate domains, all showed 
a significant decrease of HS in glomeruli from DN tissue (282). However, the antibody K5, 
which recognises unmodified heparan sulphate domains with N-acetylglucosamine-
glucuronic acid residues (the HS precursor domains) did not show differences in 
glomerular HS between control and DN tissue (282). The authors suggest that this may be 
due to remaining HS remnants or that non-modified HS side chains were still present (282). 
Therefore, applying this knowledge to these experiments, more work is required to 
determine whether HS is lost in glomerular eGlx in db/db mice and if treatment with 
OVZ/HS-1638 restores it. However, the observed increase in HPSE expression in these 
mice which coincided with a loss of eGlx measured by EM, strongly suggest that HS is likely 
degraded. Recall that CHAPTER 3 showed that treatment of healthy mice with heparinase 
III caused a loss of eGlx, supporting the theory that increased HPSE expression in diabetes 
would also cause eGlx damage. Despite the further work needed to confirm loss and 
restoration of HS specifically, this is the first time that restoration of glomerular eGlx with 
a HPSE inhibitor has been demonstrated. Protection of eGlx appears to be not only 
structural but also functional, as db/db mice had a significant increase in albuminuria 
compared to lean mice, which  was prevented by OVZ/HS-1638 treatment. This is in line 
with previous work by Gil et al., who showed that treatment of db/db mice with the HPSE 
inhibitor SST001 significantly reduced albuminuria from 10 to 18 weeks of age, compared 
to vehicle treated db/db mice (114). The same was shown for STZ T1D mice at 12 weeks 
of age (114). These studies suggest that HPSE has a role in the development of albuminuria 
and can be prevented by treatment with a HPSE inhibitor, but eGlx was not examined in 
either of these models.  
Following the albuminuria data presented in this chapter, db/db mice also had a 
significant increase in glomerular albumin permeability, which was significantly reduced 
by treatment with the OVZ/HS-1638. These data suggest that OVZ/HS-1638 restores GFB 
function by restoring glomerular eGlx, most likely by preventing eGlx HS degradation. 




and permeability, revealed that there was a significant negative correlation between the 
two. Of course, this does not prove a causal relationship between eGlx and permeability 
but does serve as a good indication that damage to the eGlx results in increase 
permeability.   
To see whether the protective effect on eGlx and GFB function more widely impacted 
glomerular health, I performed PAS staining to observe changes in glomerular fibrosis. 
Glomerular fibrosis results from an accumulation of extracellular matrix proteins such as 
collagen and fibronectin, resulting from increased synthesis by mesangial cells in response 
to pro-fibrotic signals from cytokines and growth factors derived from podocytes, 
endothelial cells, leukocytes, and mesangial cells themselves (283,284). This results in 
mesangial cell expansion, and early sign of DN which  has a clear link with progression to 
diabetic kidney disease (284). Quantification of PAS stained kidney sections showed that 
db/db mice had a significant increase in PAS staining, evidence of glomerular fibrosis. 
Db/db mice treated with OVZ/HS-1638, however, did not have a significant increase in 
staining, and had significantly reduced fibrosis staining compared to db/db mice treated 
with vehicle. We have seen similar results in T1D model in which VEGFC overexpression 
was used to therapeutically targeting eGlx.  VEGFC overexpressing diabetic mice had  
reduced PAS staining compared to control diabetics, which may be due to reduced tubular 
toxicity as a result of reduced albumin filtration (116). This suggests that restoration of 
eGlx structure and function not only has beneficial effects on the GFB, but also has a wider 
effect on glomerular health, as fibrosis is prevented with treatment.  
4.3.3 Conclusions and Significance  
The work presented in this chapter reveals a novel HPSE inhibitor as a potential treatment 
to therapeutically target HS during DN. Though loss of HS in the eGlx specifically could not 
be established, increase HPSE coincided with a loss of eGlx, increased glomerular albumin 
permeability, and glomerular fibrosis. These changes were prevented by treatment with 
OVZ/HS-1638 that is not only clinically relevant, but also has the added benefit of having 
similar potency to the most potent HPSE inhibitor currently available, as well as reduced 
anticoagulant activity, a major hurdle for HPSE inhibitors in clinical use. This work also 
shows for the first time that glomerular eGlx damage can be prevented by treatment with  
OVZ/HS-1638, and ameliorates associated microvascular changes in DN, with the 





 The Importance of Endothelial Glycocalyx Heparan 
Sulphate in the Inner Blood Retina Barrier 
 Introduction  
5.1.1 Biological Role of Heparan Sulphate in the Retina 
The structure and synthesis of HS was discussed in detail in CHAPTER 3 and applies to the 
eye as well. CHAPTER 3 also provided discussion and evidence for the role of HS in the 
glomerulus, HS however is ubiquitously expressed throughout the body and plays an 
important role in the retina. HS and heparan sulphate proteoglycans (HSPG) are present 
throughout all layers of the retina and much of the work exploring their role in the retina 
has been on the development of the neuronal retina (285). Studies in rats showed that 
syndecan HSPG were spatiotemporally expressed during retinal development, which the 
authors suggested means that syndecan may play a role in the formation of neural 
networks (286). In zebrafish, knockdown of the HSPG agrin, results in microphthalmia, a 
condition in which the eye is abnormally small and fails to develop properly (287). In fact, 
agrin mRNA was found at various stages of retinal development such as retinal ganglion 
cell differentiation and stages in which laminated retina is formed and synaptic 
connections are established not only in zebrafish, but also rats, mice, and chickens (287–
289). Retinal lamination is the process in vertebrates in which neuronal cell bodies are 
organised into distinct layers based on function, giving the retina its layered appearance, 
and disturbance of this process results in impaired function (290). HS and other GAGs also 
have a role in angiogenesis in development of the retina, as UDP-glucose-5-
dehydrogenase (Ugdh) knock down mice have defects in astrocyte and endothelial cell 
migration, which is required for vessel formation (291). Ugdh is involved in production of 
UDP-GlcA, which is a precursor for the synthesis of GAG chains (292). Therefore, the 
absence of Ugdh results in loss of GAG synthesis, including HS.  In adults, Ugdh knock 
down mice had increased glial fibrillary acidic protein (GFAP) staining in astrocytes and 
Müller cells,  a marker of cell activation, and contributed to extensive retinal degeneration 
(291).  
In the retinal microvasculature, HS has been shown to be present, but staining was 
attributed to the basement membrane, and has not been described in the retinal eGlx 
(293).  HS may have a role in maintenance of tight junctions, which, as discussed in 




permeability. In tissue culture, high glucose induced shedding of HS on human retinal 
endothelial cells (hRECs) coincided with loss of tight junction proteins, occludin and ZO-1 
(294). It is possible that the eGlx and HS act as an initial and extra barrier in tight junctions, 
and damage to it results in a loss of regulation of tight junction proteins. This may result 
in increased permeability of lipids and proteins, resulting in some characteristic lesions 
seen in DR such as hard exudates (295). Interestingly, and related to this thesis, high 
glucose also increases HPSE expression in hRECs (294). Additionally, in vivo studies in a 
T1D mouse model showed that up-regulated HPSE expression by retinal endothelial cells 
was accompanied by loss of the same tight junction proteins in diabetic mice, suggesting 
a role for HS in maintenance of tight junctions and vascular permeability (294).  However, 
the authors of this article attributed this observation to loss of HS in the basement 
membrane, yet provided no evidence for this. It is therefore possible that in fact eGlx HS 
also has a role in maintaining the iBRB, as it is in direct contact with flowing blood, and 
has been shown in other microvasculature vessel beds to act as a protective shield for 
endothelial cells (55). Though there is minimal research on the role of eGlx in the retina, 
there is some evidence in diabetic humans and in experimental rodent studies showing 
that loss of eGlx results in increased permeability in the retina (57,59,60), though HS was 
not examined in these studies. These studies will be discussed in more depth in the next 
chapter as they relate to changes in diabetes. In this chapter I will focus on investigating 
the importance of HS in the eGlx of retinal microvasculature. As CHAPTER 3 and 4 have 
shown, HS plays an important role in maintenance of glomerular permeability, and the 
work in this chapter will provide evidence for a more global role for eGlx HS in different 
vessel beds such as the retina. 
5.1.2 Chapter Aims and Experimental Approaches  
The aim of this chapter is to establish a role for HS in the retinal eGlx. This is accomplished 
in two parts. 
1. Show that HS is present in the retinal eGlx using immunofluorescence. 
2. Show that removal of HS from retinal eGlx increases vascular permeability. This 
was accomplished in two ways. The first was by enzymatic removal of HS in the 
retina of healthy mice with heparinase III. This allowed me to investigate whether 
loss of HS had any effect on eGlx structure and function. The second was using 
the transgenic mouse model used in CHAPTER 3 (Ext1CKO), which allowed me to 




 Methods  
These methods are not inclusive. The methods described in this section are those that 
pertain specifically to this chapter or have been adapted for experiments in this chapter. 
All other methods are described in the CHAPTER 2 Methods and Materials.   
5.2.1 Heparan Sulphate Staining on Retina Whole Mounts and Imaging  
Mouse eyes were enucleated from fresh C57BL/6 mouse carcasses (provided by Dr. Sherry 
Flemming, Kansas State University) and put into 2% PFA/2% glutaraldehyde for 24 hours. 
After fixation, retinas were isolated under a dissection microscope as described in 
CHAPTER 2.  
Retinas were mounted onto glass slides followed by 10min incubation in 0.1% Triton-X. 
Retinas were blocked in 5% BSA for 1 hour. Anti-HS phage display antibodies RB4Ea12V, 
HS3A8V, HS4C3V, LKIV69V, EV3C3V, MPB49V (gift from Jerry Turnbull, The University of 
Liverpool) were diluted 1:5 in block solution and incubated at 4°C overnight. Secondary 
mouse anti-VSVG (sc-365019, Santa Cruz Biotechnology, Dallas, TX) was added for two 
hours at 1:50. Retinas were washed in PBS three times for 5min. Tertiary anti-mouse Alexa 
Fluor 488 (A-11001, ThermoFisher Scientific) was added for 1 hour at 1:200. Retinas were 
washed as before and counterstained with DAPI (D1306, ThermoFisher Scientific) for 5min 
and coverslip mounted with Pro long gold (P10144, Thermo-Fisher). Carl Zeiss 700 
confocal microscope was used for retina imaging provided by Kansas State University 
Confocal Core to determine antibodies that bind to eGlx HS . EGlx was determined based 
on location of staining, where luminal staining on surface of endothelial cells was deemed 
eGlx HS (FIGURE 5-1).  
Figure 5-1 Schematic of HS Staining in Retinal Vasculature 





5.2.2 Sodium Fluorescein Angiographies (FAs)  
5.2.2.1 Heparinase III Treated Mice 
Baseline FAs were performed on C57BL/6 mice as described in CHAPTER 2 at day 0. Two 
days later, mice were given heparinase III treatment as described in CHAPTER 2. Thirty 
minutes later, FAs were performed, and data analysed for solute flux as described in 











5.2.2.2 Endothelial Ext1CKO Mouse Model 
Ext1CKO and LMC mice were given 2mg/ml of doxycycline supplemented with 5% sucrose 
as described in CHAPTER 3 for 2 weeks to induce Ext1 knock out. After 2 weeks, FAs were 
performed on mice and analysis for solute flux done as described in CHAPTER 2. FIGURE 5-3 
shows a schematic of the experimental timeline.  
   
Figure 5-2 Treatment with Heparinase III for Solute Flux Measurements  
C57BL/6 mice were given baseline angiography on day zero. Two days later mice 
were treated with 8.2u/kg of Heparinase III. Thirty minutes later post treatment 
angiography performed. 
Figure 5-3 Induction of Knock Out in Ext1CK0 Mice for Solute Flux Measurements 
Control and Ext1CKO mice were given 2mg/ml of Doxycycline drinking water for 2 weeks 





 Results  
5.3.1 Presence of Heparan Sulphate in Retinal eGlx  
5.3.1.1 Retinal Vessels Are Coated in eGlx 
Although it is well accepted that the eGlx can be found in all of the body’s vasculature, a 
literature search of eGlx images in the retinal vessels yielded minimal results.  Broekhuizen 
et al. demonstrated eGlx in rat retinas with EM, but eGlx was very sparse and patchy in 
nature when compared to EM images of other capillary beds, such as heart and kidney, 
which is typically more continuous in nature (36,296). To determine the coverage of eGlx 
in mouse retina, eyes from AB cardiac perfused mice were imaged by EM. FIGURE 5-4A 
shows a low powered image of a mouse microvessel in the retina, showing the different 
components of the vessel, including surrounding pericyte, basal lamina, and basement 
membrane of the endothelial cell with an intercellular cleft and tight junction. The closed 
capillary endothelial structure can be observed, in contrast to capillaries located in the 
glomerullus, which are fenestrated. A higher magnification image shows clear eGlx 
covering the luminal side of the endothelial cell (FIGURE 5-4B). This eGlx appears  more 
continuous than what was described in Broekhuizen et al. and its presence suggests eGlx 











Figure 5-5 Retinal Vessels Have eGlx  
Representative EM images of retinal vascular from mice cardiac perfused with Alcian blue and 
glutaraldehyde. A. Low magnification image, retinal structures labelled.  B. High magnification 
image showing eGlx staining on luminal side of retinal endothelial cell (REnC) (arrow heads).  




5.3.1.2 Heparan Sulphate is Present in Retinal eGlx 
Although it has been well documented that HS is widely distributed in tissues, including 
the retina, it has not been well characterized in the retina vasculature. To determine if HS 
is present in the retina eGlx, I performed immunofluorescence on mouse retina whole 
mounts using six different phage display antibodies in order to find one which recognized 
eGlx HS epitopes, presenting as HS staining on the luminal side of endothelial cells in the 
retinal vasculature. As shown in  FIGURE 5-6 , there were variations in eGlx in HS staining 
patterns between the antibodies, and little to no staining with the LKIV69V and EV3C3V 
antibodies. HS3A8V and MPB49V appeared to stain primarily extravascular or basement 





























































































































































A magnified image  of RB4Ea12V staining is shown in FIGURE 5-7. HS staining in the eGlx is 
evident by the signal found on top of the endothelial cell nucleus on the luminal side of 
the vessel as described in methods. This confirmed that HS is present in the eGlx of the 
retina. This antibody also appeared to recognized basement membrane HS. Though there 
was some non-specific staining in the no primary control, there was no staining 









Figure 5-7 HS is Present in Retinal eGlx 
Mouse retina tissue stained with anti-HS RB4Ea12V phage display antibody (green) and DAPI nuclear 
stain (blue). Left: Image of vessel from retina flat mount. Inset shows magnified image of HS staining 





5.3.2 Heparinase III Treatment Studies 
5.3.2.1 Heparinase III Treatment Results in Loss of Retinal eGlx 
Although the role of HS has been investigated in other aspects of retinal physiology as 
described above, the role of HS in the eGlx had not yet been determined. To examine the 
role HS plays in the eGlx, retinal microvasculature EM images were taken from Alcian blue 
and glutaraldehyde perfused mice which had previously been treated i.v. with inactive or 
active heparinase III as in previous experiments. As shown in FIGURE 5-8 A, active enzyme 
treated mice had reduced eGlx which was patchy in nature. Quantitative EM confirmed 
that eGlx coverage was significantly reduced in active enzyme treated mice (FIGURE 5-8 
B). Although there was not a significant reduction in eGlx depth, there was a strong trend 
(FIGURE 5-8 B), and together with the coverage data, indicates the HS is important for eGlx 
structure.  
 
Figure 5-8 Heparinase III Treatment Results in Loss of Retinal eGlx 
A. Representative high magnification EM images of retinal vessel from mice treated with inactive or 
active heparinase III. Basement membrane (BM) and endothelial cell (E) shown. Arrow heads points 
to eGlx. B. EM images were analysed for changes in eGlx depth (left) and eGlx coverage (right). N=3 





5.3.2.2 Heparinase III Treatment Does Not Affect the Basement Membrane in the Inner 
Blood Retina Barrier  
As with basement membranes located in other microvasculature such as the glomerulus, 
the retinal basement membrane is abundant in HSPGs and loss of it may impact blood 
vessel integrity (297). To determine whether treatment with heparinase III treatment had 
any effects on the basement membrane structure, basement membrane thickness was 
measured from EM images. While there did seem to be a trend toward a decrease in 
thickness in active enzyme-treated mice, the results were not significant compared to 
inactive enzyme-treated mice (FIGURE 5-9), suggesting that heparinase III treatment does 









Figure 5-9 Heparinase III Treatment Does Not Affect the Basement Membrane in Blood Retina 
Barrier  
Basement membrane (BM) thickness of retina microvessels was measured in inactive and active 




5.3.2.3 Heparinase III Treatment Increases Retinal Solute Flux  
To determine whether removal of eGlx HS with heparinase III resulted in increased solute 
flux, solute flux measurements were taken in inactive and active enzyme treated mice 
using sodium fluorescein angiography imaging described in CHAPTER 2. To confirm that 
baselines were similar for both groups, solute flux measurements were taken two days 
prior to enzyme treatment. As shown in  FIGURE 5-10 A, solute measurements were similar 
for both groups of mice. However, treatment with active enzyme resulted in a significant 
increase in solute flux compared to inactive mice FIGURE 5-10 B, indicating that loss of HS 









Figure 5-10 Heparinase III Treatment Increases Retinal Solute Flux  
Solute flux measurements were taken for mice treated with active or inactive Heparinase III. A. 
Baseline solute flux measurements taken two days prior to treatment. B. Post treatment solute flux 






5.3.3 Endothelial Ext1CKO Mouse Model 
5.3.3.1 Ext1CKO Mice Have Increased Retina Solute Flux  
Enzymatic removal of HS by heparinase III negatively impacted retinal eGlx and increased 
solute flux in active enzyme treated mice. As a second method of validating the role of HS 
in the eGlx of the retina, I used Ext1CKO to determine whether endothelial specific 
reduction of HS synthesis resulted in loss of eGlx barrier function. To do this, I performed 
sodium fluorescein angiographies as previous, on LMC or Ext1CKO mice after inducing Ext1 
knockout. Solute flux measurements showed that Ext1CKO had a significant increase in 
solute flux compared to control mice (FIGURE 5-11), indicating that reduced endothelial 









Figure 5-11 Ext1CKO Mice Have Increased Retina Solute Flux 
Solute flux measurements were taken for LMC and Ext1CKO mice. N=5-8 mice, unpaired Student’s t-





 Discussion  
5.4.1 Heparan Sulphate is Present in Retinal eGlx 
To date, there has been minimal research focused on the eGlx in the retina. HS has been 
shown to be abundant all throughout the retina, including in the microvasculature 
basement membrane (293). While it is presumed that HS is a component of all eGlx 
throughout the body, the presence of HS specifically in the retinal eGlx had not been 
shown. Moreover, published EM images of retina eGlx did not appear to resemble the 
eGlx in other vessel beds such as in the kidney and heart tissue. However, we know eGlx 
is present as studies in T2D patients have shown that retina eGlx can be measured with 
darkfield side stream imaging, a technique that allows for eGlx measurements in vivo (58).  
Using retina tissue from healthy Alcian blue and glutaraldehyde perfused mice, I was able 
to visualise the eGlx in the retina. As in other tissues, and in contrast to published EM 
images, eGlx in the retina was present in a relatively uniform manner. To confirm that HS 
was present in the retinal eGlx, I performed immunofluorescence on retina flat mounts. 
HS varies greatly in structural diversity due to variation in length, sulfation and acetylation 
patterns, and domain structure, which also varies in tissue type and species (173). I 
therefore used a panel of antibodies previously reported to recognize distinct, but not yet 
specifically defined epitopes of HS in rat, mouse, and human tissue (172,173,298), to 
determine whether any of them recognized HS present in the retinal eGlx in mice. One 
antibody of the six tested, RB4Ea12V, recognized HS in the eGlx, evident by staining on 
the luminal side of the endothelial cell. This is confirmation that HS is present in the retinal 
eGlx, and to my knowledge is the first time that this has been conclusively shown. The 
presence of eGlx and HS in the retina microvasculature suggests it may play a functional 
role in permeability, as it has been shown to do in the glomerulus in CHAPTER 3. However, 
further studies were required to determine whether the role of HS and eGlx in 
permeability can be applied more broadly to other vessel beds such as the retina.   
5.4.2 Loss of Heparan Sulphate Reduced Retinal eGlx and Increases Solute Flux in 
the Eye 
5.4.2.1 Removal of Heparan Sulphate by Heparinase III 
To date, the only published work looking at the importance of eGlx components in the 
retina is one article which focuses on the role of HA, as previously discussed in CHAPTER 1 
(59). In this study, mice were treated with hyaluronidase and eGlx depth was decreased 




did note that hyaluronidase can also shed chondroitin sulphate, another GAG found in the 
eGlx, so the affects observed may not be specific to HA shedding.  This study suggests a 
role for eGlx in vascular permeability, however the method used to measure eGlx was 
indirect. In this study, TRITC -dextran (155kDa) and sodium fluorescein were injected into 
mice, and the diameter of the retinal vessel was measured on ImageJ with each tracer 
using fluorescent intensity profile peaks at each side of the vessel. The idea behind this 
method is that sodium fluorescein is a small solute that can easily diffuse through the 
glycocalyx (i.e. diameter observed represents the entire width of the vessel), while 
dextran is a large molecule which would be excluded by the eGlx (i.e. diameter observed 
represents the area where eGlx is not present). Therefore, taking the difference between 
the two measurements and dividing it by two, to account for each side of the vessel, 
represents eGlx depth. While this technique resembles the peak-to-peak method for eGlx 
measurements used by our group using live and fixed tissue with lectin staining (108,175), 
the resolution on the videos used to measure vessel diameter with fluorescent tracers is 
likely not good enough to accurately detect changes in the eGlx, and also does not allow 
for direct visualisation. Additionally, the study was focused on HA, so the role of HS was 
not determined. To investigate if HS contributes to eGlx structure and function in the 
retina, I treated mice with heparinase III. EM images showed that mice treated with active 
enzyme had a significant reduction in eGlx coverage and a strong trend toward a decrease 
in eGlx depth, suggesting HS is structurally important in retinal eGlx. Additionally, mice 
treated with active enzyme had a significant increase in solute flux compared to mice 
treated with inactive enzyme, suggesting a functional role for not only the eGlx, but also 
HS eGlx, in the retina.  However, it should be noted that the sample size was small for this 
study (n=3 mice per group) and it would be useful to increase sample size to further 
corroborate these results. Despite the small sample size for functional studies, these 
results show for the first time that eGlx HS is structurally and functionally important in the 
retina, suggesting its loss in disease may be detrimental to microvascular permeability.  
5.4.2.2 Reduction of HS Synthesis in Ext1 Mouse Model  
Treatment with heparinase III is a systemic treatment and therefore potential effects on 
other areas besides the eGlx HS cannot be completely dismissed. I therefore used Ext1CKO 
mice to determine what affect, if any, an endothelial specific reduction of HS synthesis 
would have on solute flux in the retina. Solute flux measurements in Ext1CKO mice were 
significantly increased compared to LMC mice, this strengthens the increased solute flux 




for iBRB integrity. However, as in CHAPTER 4, it would be useful to confirm reduced HS by 
immunofluorescence in the retinas of these mice, and future studies should focus on 
finding a suitable antibody to detect these differences.  
5.4.2.3 Future Work 
Interestingly, comparing baseline measurements of C57BL/6 mice in heparinase III studies 
to those of LMC in Ext1 knockout studies, shows an average solute flux measurement of 
8 cm/s and 4 cm/s, respectively. However, mice in Ext1 studies had been treated with 
doxycycline for 2 weeks. As the impact of doxycycline on retinal solute flux is not known, 
it may potentially account for solute flux differences observed between control mice from  
each study. To address this question, it would be useful to conduct solute flux experiments 
on age and sex matched LMCs from the Ext1 breeding line, comparing mice given 
doxycycline in their drinking water, to mice given normal drinking water. This would allow 
me to determine if the observed differences in the two studies are simply a result of 
doxycycline treatment.  Alternatively, as these mice do not have the exact same genetic 
background, it is possible that different genetics result in variations in solute flux. 
However, as both heparinase III and Ext1CKO mice had the appropriate controls, the 
increased solute flux observed in each study individually is still evidence of HS 
contribution to the iBRB integrity.  
Unfortunately, due to time constraints during my PhD, analysis on eGlx depth and 
coverage in Ext1CKO mice in the retina was not completed. However, work with this model 
is ongoing in our group and will be available for further studies. Additionally, it would be 
useful to confirm Ext1 knockdown in retina tissue. However, we have previously shown 
Ext1 knockdown in GEnC (CHAPTER 3) and this should reflect all endothelial beds equally. 
It would also be helpful to specifically confirm reduced HS synthesis by 
immunofluorescence in the retinas of Ext1CKO as mentioned above. However, despite the 
further needed work to confirm changes to the retina eGlx in these mice, this study shows 
that mice with reduced HS biosynthesis enzyme Ext1 and there reduced HS, results in loss 
of iBRB function and is in agreement with heparinase III treatment studies in which HS 
shedding and loss of eGlx coincided with increased solute flux.  
5.4.3 Conclusions and Significance 
The work presented in this chapter establishes a role for HS in the eGlx of the retina. To 
my knowledge, I have shown for the first time that HS is present in the eGlx of the retina, 




of HS was further confirmed by an Ext1 knockout model, showing that Ext1CKO mice had 
an increase in solute flux, suggesting that retinal eGlx HS is important for iBRB integrity. 
These studies will serve as the groundwork for investigating the role of HS in vascular 
disease in the retina, such as diabetic retinopathy  (CHAPTER 6), where there is evidence 











 Loss and Restoration of Retinal Endothelial 
Glycocalyx Heparan Sulphate in a Type 2 Diabetic Mouse 
Model  
 Introduction  
6.1.1 Mouse Models of Diabetic Retinopathy  
Currently there is no individual in vivo model that develops all of the vascular and neural 
complications that occur at all stages of  diabetic retinopathy (DR), but a number of 
models have been developed that replicate many of the aspects of the disease at different 
time points of DR observed in humans. As with DN, DR models are either inducible or 
genetic.  
The most common inducible model for DR is STZ, and is often used on a C57BL/6 
background or the F1 hybrid, a cross between FVB/N and C57BL/6J mice (299). STZ mouse 
models develop early signs of DR, such as  loss of astrocyte number and activation of 
retinal glia by 4-5 weeks after the onset of hyperglycaemia (300,301). In humans, changes 
in retinal glia have been shown to precede vascular damage (302). By six weeks, loss of 
retinal ganglion cells (RGC) can be observed, followed by retinal layer thinning of the inner 
nuclear and outer nuclear layer at 10 weeks (303). Loss of RGC have been shown in T2D 
patients with no DR, and is progressive in moderate and severe DR (304), making it an 
early sign of DR. Similarly, thinning of the inner and out nuclear layers have been observed 
in diabetics without clinical evidence of DR using optical coherence tomography (OCT) 
imaging, and is caused by ischaemia and retina tissue injury (305). OCT imaging uses 
interferometry to create a cross sectional image of the retina in vivo, and is of standard 
use in diabetic patients to monitor retinal health and diagnosis of DR (306). Basement 
membrane thickening, which is often observed in DR, was not found to occur on a 
C57BL/6J background up to 15 months after diabetes was induced (307). However, 
increased leak in the retina can be detected with fluorescent tracers like FITC-dextran in 
this model on a C57BL/6 background, although a marked increased does not occur until 6 
months after the induction of diabetes (308). Though this model may be a good one for 
studying DR in isolation, mice on a C57BL/6 background are a poor model of DN as 
discussed in CHAPTER 4, and therefore not a good choice for studying both microvascular 




The Ins2Akita mouse line, previously mentioned in CHAPTER 4, is a genetic model for 
studying DR. These mice develop some signs of vascular changes associated with DR, an 
important factor for the studies in this thesis. On a C57BL/6J background, mice developed 
signs of glial activation by 8 weeks after the commencement of hyperglycaemia, and 
retinal thinning after 22 weeks (309). After 12 weeks of hyperglycaemia, diabetic mice 
injected with BSA-FITC had increased retinal vascular leak (309).  Mice also had a loss of 
the tight junction protein occludin in their retinal vessels, which likely contributes to 
increased permeability (309). This model is now regarded as a useful tool for studying 
early signs of DR (310), but unfortunately is incompatible with studying early signs of DN 
in the same mouse, as mice on this background develop only mild albuminuria and do not 
show robust changes indicative of DN (217).  
The genetic T2D model db/db on a C57BLKS/J background  have also been used to study 
the development of DR. Db/db mice have loss of RGC at 8 weeks of age (311). Mice also 
have inner and out nuclear layer and total retinal thinning at 8 weeks of age (311), a 
feature of neurodegeneration in DR also found in humans (312). Pericyte loss, which is a 
hallmark of DR in humans (313), occurs by 18 weeks of age in db/db mice, along with the 
presence of active glia (300). Pericytes have been shown to play important roles in the 
retina including vascular remodelling and stabilization and maintenance of the iBRB (314). 
Additionally, an increase in FITC-dextran leak was reported at 20 weeks of age as well as 
an increase in albumin accumulation in the retina parenchyma, suggesting a breakdown 
in the iBRB (315). At 22 weeks, retinal vascular basement membrane thickening can be 
observed (316). These data suggest that  db/db mice may serve as a good model to study 
early vascular changes in DR, and have the added benefit of being a suitable models for 
DN with increased albuminuria from 8-25 weeks of age (227,228). Although db/db mice 
may not be the best model for studying each diabetic complication individually, their 
susceptibility to DR and DN to levels that are suitable for this study led me to choose db/db 
mice as a T2D model to investigate my hypotheses. As mentioned in CHAPTER 4, I am 
interested in early changes in the microvasculature. As a result, I used two time points of 
9 weeks and 11 weeks of age to investigate loss and restoration of eGlx, as the literature 
suggest there are retinal change associated with DR by 8 weeks of age. Importantly, these 
timepoints were also chosen to allow for a parallel investigation of changes in DN and DR.  
6.1.2 Heparanase in Diabetic Retinopathy  
As discussed in CHAPTER 1, diabetic rodent models have provided evidence for a loss of 




decrease in glycocalyx dimensions in T2D patients (57). However, what the cause of eGlx 
damage in diabetic retinas has not been examined. HPSE is found to be upregulated in the 
plasma of T1D and T2D patients as previously discussed (245,317,318). Though not much 
research has been done on the role of HPSE in DR, the presence of active HPSE in the 
plasma suggest that HPSE ultimately becomes systemic, with the possibility of affecting 
multiple vascular beds, including the retina. Epithelial, endothelial cells, leukocytes, 
granulocytes, and mast cells, have all been shown to be sources of HPSE (263,319). Human 
vitreous samples from DR patients have elevated HPSE levels (125). In addition, epiretinal 
membranes from DR patients also show increased HPSE, with evidence of vascular 
endothelial cells and leukocytes as the source of HPSE (125). In agreement with this, 
immunohistochemistry staining of retinas from T1D rats also have increased HPSE 
expression, with increased vascular endothelium staining (FIGURE 6-1) (125).  
 
 
Briefly mentioned in CHAPTER 5, a study on T1D mice showed upregulated HPSE 
expression in STZ treated C57BL/6 mouse retinas, which the authors claim coincided with 
loss of HS and TJ proteins (294). Although in vitro studies in human retinal endothelial 
cells did provide evidence for high glucose-inducing HPSE expression and loss HS, the 
author’s in vivo studies provided no evidence for loss of HS (294). They did however show 
reduced tight junction proteins and an increase in HPSE expression in vivo (294). Although 
the authors conclude that there is a loss of basement membrane HS, their in vitro data 
investigating loss of HS was obtained by western blot, so it cannot be assumed these 
Figure 6-1 HPSE Expression in Diabetic Retinopathy  
A. IHC on STZ-induced diabetic rats (DR) shows HPSE is increased when compared to non-diabetic 
rats (NR). Red arrows point to HPSE signal in endothelium of retinal vessel of DR, whereas NR has 
minimal staining (black arrows). Staining was also increased in ganglion cell layer (GCL), inner 
nuclear layer (INL), and outer nuclear layer (ONL). Image adapted from (Ma, et al. 2010)(125). 




results pertain to basement membrane HS as suggested in the article.  Since loss of HS 
was also not verified in vivo, more work needs to be done to confirm the loss of eGlx HS 
in the retina during diabetes. Despite this, these data support the idea that HPSE plays a 
role in diabetic retinopathy and preventing loss of HS may help prevent damage to the 
iBRB and associated increased microvascular permeability.   
6.1.3 Chapter Aims and Experimental Approaches  
The aim of this chapter is to show there is loss of retinal eGlx HS in diabetes, which results 
in increased vascular permeability. And that this is HPSE-dependent. To do so, I took the 
following two approaches.  
1. Show that retinal eGlx is damaged in a T2D model and results in loss of eGlx 
function and increase retinal permeability. This was done at two different 
timepoints, 9 weeks of age and 11 weeks of age.  
2. Show that damage to the eGlx can be prevented by treatment with a novel HPSE 
inhibitor, and results in reduced retinal permeability in diabetes. This was done 





















 Methods   
These methods are not inclusive. The methods described in this section are those that 
pertain specifically to this chapter or have been adapted for experiments in this chapter. 
All other methods are described in the CHAPTER 2 METHODS AND MATERIALS.   
6.2.1 Study Design for Nine-Week-Old Time Point  
At 7 weeks of age, lean control and db/db control mice were administered vehicle 
treatment (PBS), daily for two weeks s.c. Similarly, OVZ/HS-1638 group received daily 
injections for two weeks of OVZ/HS-1638 dissolved in PBS at 20mg/kg, subcutaneously. 
OCT imaging and sodium fluorescein angiographies were performed at 9 weeks as 
described in CHAPTER 2 except for sodium fluorescein injection, which was given 
intramuscularly (i.m) in this cohort.  At end point, mice were anesthetised and perfused 
as described in CHAPTER 2 for tissue collection and EM imaging. A schematic of the 








Figure 6-2 Study Design for Nine-Week-Old Time Point  
At 7 weeks, five lean and five db/db mice were treated with vehicle subcutaneously (s.c.). Five db/db 
mice were treated with 20mg/kg OVZ/HS-1638 HPSE inhibitor in vehicle, also by s.c. At 9 weeks OCT and 
sodium fluorescein angiographies (FA) were performed. Mice were cardiac perfused and tissue collected 





6.2.2 Study Design for Eleven-Week-Old Time Point 
At 9 weeks of age, lean control and db/db control mice were administered vehicle 
treatment (PBS), daily for two weeks by i.p. Similarly, OVZ/HS-1638 group received daily 
injections for two weeks of OVZ/HS-1638 dissolved in PBS at 20mg/kg, i.p. OCT imaging 
and sodium fluorescein angiographies were performed at 9 weeks as described in CHAPTER 
2 with the exception of anaesthesia for this procedure. For Micron IV imaging, mice were 
anaesthetised by intraperitoneal injection of 90μL/10g body weight of a solution 
containing 6 mg/mL ketamine (Ketavet; Zoetis Ireland Ltd., Dublin, Ireland) and 2 mg/mL 
Xylazine (Rompun; Bayer plc, Newbury, UK) mixed with sterile water. This differs from the 
method used in the 9-week old cohort, as specialised mask required for anaesthesia was 
not available. At endpoint, mice were anesthetised and perfused as described in CHAPTER 
2 for tissue collection and EM imaging. A schematic of the experimental design in shown 









Figure 6-3 Study Design for Eleven-Week-Old Time Point 
At 9 weeks of age, before treatment, OCT and sodium fluorescein angiographies (FA) were performed 
At 9 weeks five lean and five db/db mice were treated with vehicle i.p. Five db/db mice were treated 
with 20mg/kg OVZ/HS-1638 HPSE inhibitor in vehicle, also by i.p. At 11 weeks, mice were cardiac 




6.2.3 Optical Coherence Tomography (OCT) Images and Analysis 
6.2.3.1 OCT Images 
Mice were prepared for imaging as described in CHAPTER 2. OCT images were obtained on 
the Micron IV imaging system (Phoenix Research Labs). Scan area was chosen by selecting 
circular tool, using the optic nerve as a reference point, where the optic nerve was at the 
centre of the circle. It should be noted that the area selected for scanning must be 
consistent throughout animals in order to directly compare retinal thickness. This is due 
to the natural thinning of the retina, moving from the optic nerve to the outer edge of the 
retina.  
6.2.3.2 OCT Image Analysis: Retinal Thickness 
OCT images were taken using the Micron IV imaging system described above. To measure 
total retina thickness, a line from the top of the retina to the bottom of the retina (from 
ganglion cell layer to retinal pigment epithelium) (FIGURE 6-4) was drawn on FIJI and 
length measured. Choroid was excluded from retina thickness measurements as shown in 
(FIGURE 6-4). A minimum of 10 measurements were taken per mouse per timepoint 
measured. Average of measurements were then calculated for total retina thickness. 
 
 
Red line indicates where measurements are taken for total retinal thickness, from ganglion cell 
layer (GCL) to retinal pigment epithelium (RPE). Arrowhead points to choroid which is excluded 
from retina measurement. Vertical scale bar = 100µm. 






6.2.4 Albumin Staining, Imaging, and Analysis on Mouse Retinas 
6.2.4.1 Albumin Staining in Paraffin Embedded Retina  
Eyes from 9-week-old lean and db/db mice were enucleated and put into 4% PFA. Paraffin 
embedded eyes were sectioned longitudinally in 5μM sections at the University of Bristol 
Histology facility.  For staining, sections were deparaffinised in Xylenes for 10min, twice. 
Sections were then rehydrated by running through a decreasing percentage series of 
ethanol for 5min each (100%, 95% 70%, 50, deionised water). Sections were then 
incubated in PBS for 5min. Tissue was permeabilised and blocked with 0.3% Triton-X, 3% 
BSA in PBS solution for 30min. Goat anti-mouse albumin (A90-134A-17, Bethyl 
Laboratories) was then incubated at 1:200 in blocking  buffer overnight at 4°C in a 
humidity chamber. The following day, sections were washed three times for 5min in 0.3% 
Triton-X in PBS. Donkey anti-goat Alexa Fluor 594 (A-11058, ThermoFisher Scientific) was 
then incubated at 1:200 in blocking buffer for 1 hour at room temperature. Sections were 
washed as described above, followed by a 5min incubation in DAPI as previously described. 
Sections were washed twice in PBS for 5min and coverslip mounted as previous.  
6.2.4.2 Imaging and Analysis  
Sections were imaged on Nikon TI inverted confocal microscope (Nikon Instruments Inc). 
Exposure settings were kept constant for all sections. A minimum of four fields of view 
were taken per animal on 20x objective.   
To analyse extravascular albumin staining, brightfield images were used to trace around 
the retina in order to exclude choroidal and vitreous staining using FIJI (FIGURE 6-5 A). On 
the red channel, area and Intergraded density (IntDen) measurements were taken for 
total retina albumin measurement (FIGURE 6-5 B). Four background mean fluorescent 
measurements were taken as well to calculate CTCF.  As these eyes were not perfused, 
vascular staining, which appears as bright circular staining (cross section of vessel) or long 
tube like staining (longitudinal section of vessel) in the retina was traced around and area 
and IntDen measurements were taken (FIGURE 6-5 B,C). Total retina albumin CTCF was 
calculated using the same CTCF equation as previous and shown below.  





The same calculation was done for vascular albumin staining by adding together the sum 
of the vascular area and sum of the vascular albumin IntDen measurements using these 
totals to calculate CTCF. Subtracting vascular albumin CTCF from total retina albumin CTCF 
yields extravascular albumin staining CTCF, or: 
𝐸𝑥𝑡𝑟𝑎𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐴𝑙𝑏𝑢𝑚𝑖𝑛 𝐶𝑇𝐶𝐹 = 𝑇𝑜𝑡𝑎𝑙 𝑅𝑒𝑡𝑖𝑛𝑎 𝐴𝑙𝑏𝑢𝑚𝑖𝑛 𝐶𝑇𝐶𝐹 − 𝑇𝑜𝑡𝑎𝑙 𝐼𝑛𝑡𝑟𝑎𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐴𝑙𝑏𝑢𝑚𝑖𝑛 𝐶𝑇𝐶𝐹 
Equation 6-2 
 
CTCF for each fields of view were averaged for each mouse and the means of each group 









Figure 6-5 Analysis of Albumin Leak in Mouse Retina 
Mouse retinal sections are stained with anti-albumin and amount of extravascular albumin is 
quantified. A. The region of interest is outlined shown in yellow using bright field images ensuring that 
choroid is excluded. B. Channel is switched to albumin staining (red) and CTCF is measured for the entire 
retina. Vascular albumin staining appears as bright red punctate signal, indicated by arrow heads C. 
Total vascular albumin staining is traced around and CTCF is measured. Inset shows zoomed in area to 










6.3.1 Diabetic Mice at Nine Weeks of Age 
6.3.1.1 Nine-Week-Old Db/db Mice Have Retina Thinning which is Not Affected by 
OVZ/HS-1638 Treatment 
To assess if db/db mice had developed signs of neurodegeneration, which can be 
observed in early stages of DR, OCT images were used to measure changes in retinal 
thickness. FIGURE 6-6 A shows representative OCT images for lean, db/db, and db/db mice 
treated with OVZ/HS-1638. Although small changes are not visible by eye, measurements 
of thickness show that all db/db mice have a significant reduction in retinal thickness, 
which is not affected by OVZ/HS-1638 treatment FIGURE 6-6 B.  
 
 
Figure 6-6 Nine-Week-Old Db/db Mice Have Retinal Thinning which is Not Affected by OVZ/HS-1638 
Treatment  
A. Representative OCT images for non-diabetic (lean), diabetic (db/db), and db/db mice treated with 
OVZ/HS-1638 HPSE inhibitor (db/db+HI) Vertical scale bar = 100µm. B. Total retinal thickness was 
measured on OCT images. Minimum of 10 measurements per mouse. N=5 mice, one-way ANOVA, Tukey’s 





6.3.1.2 Nine-Week-Old Db/db Mice Have No Changes in Microvascular Basement 
Membrane Thickness  
Basement membrane thickening is a common feature of DR, and is associated with loss 
of integrity of the iBRB (320). To determine whether db/db mice had changes in 
microvascular basement membrane and whether OVZ/HS-1638 treatment had any effect 
on it, EM images were used to measure changes in basement membrane thickness 
between groups. At 9 weeks old, there were no significant changes in basement 
membrane thickness between groups, though there was a slight trend toward an increase 









Figure 6-7 Nine-Week-Old Db/db Mice Have No Changes in Basement Membrane 
Thickness 
EM images of non-diabetic (lean), diabetic (db/db), and db/db mice treated with OVZ/HS-1638 
HPSE inhibitor (db/db+HI) were analysed for changes in basement membrane (BM) thickness. 
Minimum of three capillaries were measured per mouse. N=5 mice, one-way ANOVA, Tukey’s 





6.3.1.3 Treatment with OVZ/HS-1638 Increases Retinal eGlx in Nine-Week-Old Db/db 
Mice 
There is some evidence in the literature suggesting that eGlx is reduced in the retina 
during diabetes. To determine if these mice had any changes in their eGlx, EM images of 
retinal microvessels from mice perfused with Alcian blue and glutaraldehyde were taken 
and analysed. Representative images of eGlx in these mice show that both lean and db/db 
mice treated with OVZ/HS-1638 had thick eGlx. Db/db mice treated with vehicle however 
appeared to have thinner and patchier eGlx compared to the other two groups, indicating 
damage to the eGlx  (FIGURE 6-8 A). Surprisingly, quantification of EM images showed 
there were no significant changes in eGlx depth between groups, however there was a 
strong trend toward a decrease in db/db mice and an increase in db/db mice treated with 
OVZ/HS-1638 (FIGURE 6-8 B). Similarly, there was a strong trend toward a decrease in eGlx 
coverage in db/db mice. However, there was a significant increase in eGlx coverage which 
OVZ/HS-1638 was given (FIGURE 6-8 B), indicating a restoration of eGlx.  
 
Figure 6-8 Treatment with HPSE Inhibitor Increases Retinal eGlx in Nine-Week-Old Db/db Mice 
 
A. Representative EM images of retina from non-diabetic (lean), diabetic (db/db), and db/db 
mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI). Basement membrane (BM) and 
endothelial cell (E) shown. Arrowheads point to eGlx. B. EM images were analysed for eGlx depth 





6.3.1.4 Db/db Mice Have No Changes in Solute Flux at Nine Weeks of Age 
Previous functional studies in CHAPTER 5 showed that eGlx plays a role in maintaining the 
iBRB, as healthy mice with loss of eGlx HS had increased solute flux. Although eGlx loss 
was not significant in db/db mice, there was a decrease. I therefore performed sodium 
fluorescein angiographies to determine if there were any changes in solute flux. At nine 











Figure 6-9 Db/db Mice Have No Changes in Solute Flux at Nine Weeks of Age 
Solute flux measurements for non-diabetic (lean), diabetic (db/db), and db/db mice treated with 
OVZ/HS-1638 HPSE inhibitor (db/db+HI) were taken at 9 weeks of age. N=3-5 mice per group. One-way 





6.3.1.5 Db/db Mice Have Increased Albumin Leak at Nine Weeks of Age which is 
Prevented by OVZ/HS-1638 Treatment  
As a second method of determining if db/db mice had a breakdown in the iBRB, despite 
no observed changes in solute flux, I stained for albumin in the retinas from nine-week-
old mice. Albumin staining on db/db retinas revealed staining in the retinal parenchyma 
space, indicating albumin leak, which was absent in lean mice and visibly reduced in mice 
treated with OVZ/HS-1638 (FIGURE 6-10 A). Quantification of images measuring 
extravascular albumin CTCF values showed that db/db mice had a significant increase in 
extravascular albumin compared to lean mice (FIGURE 6-10 B). Furthermore, this was 
significantly reduced when mice were treated with OVZ/HS-1638, indicating a protective 










Figure 6-10 Db/db Mice Have Increased Albumin Leak at Nine Weeks of Age, which  is Prevented by 
OVZ/HS-1638 Treatment  
 A. Representative immunofluorescence images of anti-albumin stained retina from non-diabetic (lean), 
diabetic (db/db), and db/db mice treated with OVZ/HS-1638  HPSE inhibitor (db/db+HI). Top panel: 
albumin and bottom panel: brightfield merge. Layers of retina indicated, ganglion cell (GCL), inner 
plexiform (IPL), inner nuclear (INL), and outer nuclear (ONL) B. Extravascular albumin CTCF was 
measured (white arrow heads) arbitrary units (a.u.), minimum of three field of view analysed. N= 5 




6.3.2 Diabetic Mice at Eleven Weeks of Age 
6.3.2.1 Db/db Retina Thickness Could Not be Assessed in Eleven-Week-Old Cohort 
Unfortunately, due to technical difficulties involving the use of the Micron IV Imaging 
system used for OCT imaging, I was not able to obtain OCT images for mice at 11 weeks 
of age. An incomplete set of images was obtained at 9 weeks of age. The images that were 
obtained show that db/db mice have a decrease in retinal thickness at 9 weeks (FIGURE 








Figure 6-11 Db/db Retinal Thickness Could Not be Assessed in Eleven Week Old Cohort 
Retinal thickness measurements from OCT images were taken for non-diabetic (lean), diabetic (db/db), 
and db/db mice treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI). Minimum of 10 measurements 





6.3.2.2 Db/db Mice Do Not Have Changes in Basement Membrane Thickness at Eleven 
Weeks of Age 
As in the 9-week-old cohort, I wanted to determine if mice at 11 weeks of age had any 
changes in basement membrane thickness, a characteristic change in DR. Basement 
membrane measurements using EM images showed no significant differences between 








Figure 6-12 Db/db Mice Do Not Have Changes in Basement Membrane Thickness at Eleven Weeks of Age 
EM images of non-diabetic (lean), diabetic (db/db), and db/db mice treated with OVZ/HS-1638 HPSE 
inhibitor (db/db+HI) were analysed for changes in basement membrane (BM) thickness. Minimum of 
three capillaries were measured per mouse. N=3 mice, one-way ANOVA, Tukey’s multiple comparison 





6.3.2.3 Changes in eGlx Could Not Be Reliably Assessed in Eleven-Week-Old Cohort 
As previous, loss and restoration of eGlx in db/db and db/db mice treated with OVZ/HS-
1638 was assessed using quantitative EM on images from mice perfused with Alcian blue 
and glutaraldehyde.   FIGURE 6-13 A   shows representative EM images from each group, 
where eGlx can be observed, albeit patchy and thinner than previously observed in all 
groups. Quantification of images showed no apparent changes in eGlx (FIGURE 6-13 B). 
Unfortunately, perfusion in this cohort did not seem to properly reach the eye and one 
animal in the OVZ/HS-1638 group did not perfuse at all, therefore statistical significance 





Figure 6-13 Changes in eGlx Could Not Be Reliably Assessed in Eleven Week Old Cohort  
A. Representative EM images of retina from non-diabetic (lean), diabetic (db/db), and db/db mice 
treated with OVZ/HS-1638 HPSE inhibitor (db/db+HI). Basement membrane (BM) and endothelial 
cell (E) shown. Arrowheads point to eGlx. B. EM images were analysed for eGlx depth (left) and 




Poor perfusion is further evident in low power images of the retinal microvessels, showing 
that vessel structure is collapsed (FIGURE 6-14), indicating that the vessels did not 














Figure 6-14 Collapsed Vessel Structure Due to Poor Perfusion  
Example of low magnification EM images of perfused mouse retinal vessels used for eGlx analysis. 




6.3.2.4 Changes in Solute Flux Could Not Be Reliably Assessed in Eleven-Week-Old Cohort  
To examine if db/db mice had reduced function of iBRB, sodium fluorescein angiographies 
were performed to determine if 11-week db/db mice had changes in solute flux. 
Unfortunately, as with the OCT images, technical difficulties prevented me from obtaining 
videos for analysis at 11 weeks of age. An incomplete set was obtained at 9 weeks of age, 
prior to the start of treatment. Solute flux measurements show a potential decrease in 
db/db mice, contrary to what would be expected if a break down in the iBRB had occurred 
(FIGURE 6-15). However, the small sample size does not allow for a statistical test to be 











Figure 6-15 Changes in Solute Flux Could Not Be Reliability Assessed in Eleven Week Old Cohort 
Solute flux measurements were obtained for non-diabetic (lean) and diabetic (db/db) prior to the start of 




6.3.3 Assessment of Model Suitability for Angiography Studies  
6.3.3.1 Aged Db/db Mice Do Not Show Changes in Solute Flux 
Although the 11-week-old cohort did not have a complete set of sodium fluorescein 
angiography videos for solute flux analysis, the 9-week-old cohort showed no changes in 
solute flux in db/db mice, which was contradicted by the retinal albumin staining in these 
mice. Albumin staining showed a clear increase in albumin leak and reduction by OVZ/HS-
1638 treatment. Furthermore, solute flux results in heparinase III and Ext1CKO studies in 
CHAPTER 5 suggest that this method of measuring solute flux is sensitive enough to 
measure changes in solute flux. I therefore conducted a pilot experiment to determine if 
this technique is suitable for db/db mice and whether it was possible to detect changes in 
solute flux in more progressed DR. To do this, I performed solute flux measurements on 
db/db or lean mice every two weeks, from 6 to 14 weeks of age. Unfortunately, one db/db 
mouse died at 7 weeks of age due to natural causes, and therefore the sample size for 
db/db mice was n=2 for the duration of the experiment.  As shown in FIGURE 6-16, there 
are no clear differences in solute flux between lean and db/db mice.  FIGURE 6-16 B also 
demonstrates that there is no progression of solute flux increase as would be expected if 




Figure 6-16 Aged Db/db Mice Do Not Show Changes in Solute Flux 
Solute flux measurements were taken every two weeks for non-diabetic (lean) and diabetic 
(db/db) mice from 6-14 weeks of age. A. Solute flux measurements for lean mice, n=3 mice. B. 





6.3.3.2 Sodium Fluorescein Absorption Rate is Delayed in Db/db Mice  
During acquisition of sodium fluorescein angiographies, it became apparent that there 
were differences in appearance of fluorescent signal between lean and db/db mice. As 
shown in FIGURE 6-17, at 9 minutes and 24 seconds, the angiography image for the lean 
mouse was significantly brighter compared to that of a db/db mouse. Saturation of 
sodium fluorescein is apparent in the main vessels, especially near the optic nerve where 
the central retinal artery and vein are located and feed into the retinal microvasculature 
(FIGURE 6-17 A) (321). The angiography in the db/db mouse however does not show 
similar intensity (FIGURE 6-17 B).  
Measurements of fluorescent intensity in large vessels in lean and db/db mouse are 
shown in FIGURE 6-18 A,B. Measurements for the lean mouse show that intensity starts 
to plateau near 50 seconds, with an intensity measurement nearing 140a.u. Fluorescent 
intensity in the db/db mouse however is steadily increasing through the entire duration 
of the video, and has an intensity value around 30a.u., at 40 seconds of recording. 
Similarly, in the exchange vessels, at 50 seconds, an intensity value of 20a.u. had been 
reached in the lean mouse, whereas at 50 seconds in the db/db mouse, the intensity value 
was approximately 3a.u. This indicates that there is a substantial difference in absorption 
rate of the sodium fluorescein between lean and db/db mice, which results in difficulty 
comparing lean and db/db mice solute flux measurements.  
Figure 6-17 Comparison of Sodium Fluorescein Intensity in Lean and Db/db Mice  
A. Sodium fluorescein angiography for a lean mouse at time 9:24 minutes. Saturation is evident by 
yellow signal (arrowhead). B. Sodium fluorescein angiography for db/db mouse at time 9:24minutes. 







Figure 6-18 Fluorescent Intensity Curves for Main Vessels and Exchange Vessels in Lean and Db/db 
Fluorescent intensity profiles for main vessel (top graphs in A. and B.) and exchange vessels 
(bottom graphs in A. and B.) for lean mouse and db/db mouse. Red lines indicate measurements 
at 50 seconds A. Lean mouse main vessels plateaus near 50s, at which point intensity values are 
near 140a.u. Exchange vessel at 50s are near 20a.u. for intensity readings. B. Db/db mouse main 
vessels had a steady increase throughout recording, with an intensity value of 30a.u. at 50s. 
Exchange vessel at 50s had an intensity value near 3a.u. Note difference in curve shape between 




 Discussion  
6.4.1 Treatment with OVZ/HS-1638 Has Restorative Effects on Retinal eGlx 
Structure and Function in Nine-Week-Old Diabetic Mice 
The aim for this chapter was to show that eGlx is damaged during diabetes in a T2D model 
using db/db mice, and that treatment with a novel HPSE inhibitor can prevent eGlx 
damage and associated microvascular changes in permeability that occur in early DR. In 
agreement with the literature, which shows retinal thinning in db/db mice by 8 weeks of 
age, 9-week-old db/db mice had a significant reduction in retinal thickness compared to 
lean controls but was not affected by OVZ/HS-1638 treatment. In humans, signs of 
neurodegeneration can be observed by OCT in diabetic patients even before early clinical 
signs associated with DR can be observed, such as microaneurysms and small 
haemorrhages (322). Apoptosis of retinal cells, including photoreceptors, ganglion cells, 
and astrocytes, result in a reduction of retinal thickness and has been observed in diabetic 
human samples  and experimental models of DR (323). The reasons for increased 
apoptosis is not well defined, but early changes are unlikely to be due to ischaemic 
necrosis, as apoptosis can be detected in STZ rats only one month after the onset of 
diabetes, before any vascular occlusions are apparent (323). It is however possible that 
increased vascular leak could contribute to increased apoptosis. In experimental diabetes 
in rats, increased vascular permeability can be observed after one month of diabetes 
measured by FITC-BSA (324), a similar time frame as when apoptosis is observed. Another 
factor that may contribute is microglial activation which occurs at early stages of the 
disease and results in a proinflammatory (M1) and anti-inflammatory (M2) phase (325). 
To explain, in early DR, the M1 and M2 phases occur at the same time, but progression of 
DR shifts toward a decrease in the M2 phase, resulting in classical proinflammatory signals 
like NFκB (325), involved in expression of proinflammatory cytokines, chemokines, and 
adhesion molecules (326), resulting in increased apoptosis. However, it is unclear if 
treatment with a HPSE inhibitor would be expected to prevent retinal thinning, as HPSE 
has been shown to have both pro- and anti-apoptotic effects (327,328) and would need 
to be investigated in more detail to determine the effects of HPSE inhibition on 
neurodegeneration. However, retinal thinning in db/db mice confirm that mice have 
developed early signs of DR.  
Basement membrane thickening is considered a histological hallmark of DR, resulting 
from accumulation of basement membrane components like fibronectin, type IV collagen, 




basement membrane can be detected before other lesions associated with DR, and may 
even contribute to vascular lesions, pericyte loss, and acellular capillaries (329). To assess 
changes in microvascular ultrastructure in these mice, basement membrane thickness 
was measured in EM images from mice retinas at 9 weeks. Results showed there was no 
significant increase in basement membrane thickness in 9-week-old mice db/db or  
OVZ/HS-1638 treated db/db compared to lean mice. Though there was a slight trend 
toward an increase in diabetic mice, db/db mice do not typically develop significant 
basement membrane thickening until 22 weeks (316), therefore 9 weeks is likely too early 
of a time point to observe these changes.  Changes to the eGlx were also measured with 
EM, and db/db mice showed a strong trend toward a decrease in eGlx depth and coverage 
compared to lean mice, though not significant. On the other hand, db/db mice treated 
with OVZ/HS-1638 had a strong trend toward an increase in eGlx depth and had a 
significant increase in eGlx coverage compared to db/db mice treated with vehicle. This 
study may lack power, and it is possible a larger sample size would show significant 
differences. Additionally, as this is an early time point, small but significant changes in 
eGlx may be not be as apparent with a small sample size. Although no conclusive remarks 
can be made due to the lack of significant decrease of eGlx in db/db mice, this data suggest 
that there is some loss of eGlx at 9 weeks of age in db/db mice, and that treatment with 
OVZ/HS-1638 has restorative effects on eGlx, especially eGlx coverage.  
As increased vascular permeability is a serious issue that occurs in DR and is an early 
indication of DR progression, I investigated if db/db mice had any changes in solute flux 
and whether treatment with OVZ/HS-1638 had any effects. CHAPTER 5 results showed that 
loss of eGlx HS was associated with increased solute flux in the eyes, and therefore 
expected to see changes in solute flux in db/db mice. Surprisingly, there were no changes 
in solute flux between any of the groups. Furthermore, there was a substantial amount of 
variation in solute flux in lean and db/db mice treated with OVZ/HS-1638, which made it 
difficult to determine if there was any trend. One explanation for these results is that it is 
too early to detect changes in solute flux, as other studies saw that increased permeability 
using FITC-dextran was not detected in db/db mice until 20 weeks (315). However, as data 
presented in this chapter demonstrates, and as will be discussed in a later section, there 
may also be issues of incompatibility of db/db mice with this method of measuring solute 
flux.  
As mice had no changes in solute flux, I used an alternative method to determine if mice 




anti-albumin antibody to examine if there was an increase in extravascular leak. In 
contradiction with solute flux results, db/db mice had a significant increase in 
extravascular albumin compared to lean mice. Importantly, albumin leak was also 
prevented by treatment with OVZ/HS-1638 in db/db mice. One explanation for the 
discrepancy observed between solute flux and albumin leak, is that solute flux is 
measuring the changes that occur at a specific timepoint, i.e. at the time of solute flux 
measurement. Albumin staining however is detecting albumin accumulation. It is 
therefore likely that, although increased solute flux was not detected, 9-week-old mice 
do have areas of increased vascular leak, as shown by immunofluorescence, and is 
prevented by treatment with OVZ/HS-1638. Together with the eGlx data, this suggest that 
protection of HS degradation, likely in the eGlx evident by EM data, has restorative effects 
on the iBRB and maintenance of permeability. This is the first time that restorative effects 
have been shown in the eGlx by a HPSE inhibitor treatment in diabetes, and suggests that 
HS has a role in the iBRB, which can be protected in diabetes by preventing its degradation. 
However, because HS staining was not performed on these sections, it cannot be 
conclusively stated that OVZ/HS-1638 acts directly on the eGlx HS. In future studies, HS 
staining should be done on retinal tissue to determine if HS is reduced in the eGlx of db/db 
mice and determine if HS levels in the eGlx are restored by treatment with OVZ/HS-1638. 
Of note, data in CHAPTER 5, in which healthy mice were treated with heparinase III and 
had loss of eGlx, suggest that circulating HS shedding enzymes such as HPSE in diabetes, 
may also result in eGlx HS loss in the retina. Indeed, there did seem to be a decrease in 
eGlx in db/db mice, albeit not significant and possibly due to small sample size. It is 
possible that a later time point would also allow for a greater and more significant extent 
of eGlx damage, in which restorative effects can also be demonstrated.  
6.4.2 Effects of OVZ/HS-1638 Treatment Were Not Reliably Assessed in Eleven-
Week-Old Db/Db Mice   
Unfortunately, there were technical issues that resulted in the 11-week-old cohort to yield 
inconclusive data. To begin, issues with the use of the Micron IV for acquiring OCT images 
for measurements of retinal thickness occurred due to lack of the required equipment. At 
the time of these angiographies, the specialised mask required for anaesthesia during 
angiography imaging was not available and therefore the injectable anaesthetics 
ketamine and Xylazine were used as described in the  methods of this chapter, and have 
been successfully used by members of the University of Bristol Ophthalmology group. For 




possibly due to the large amounts of adipose tissue which can absorb the anaesthetic 
(330), delaying the effect of the drug and therefore increasing the likely hood of overdose 
if too much is administered. As a result, the majority of the mice could not be anesthetised 
long enough to acquire images.  The incomplete set of OCT images acquired at 9 weeks of 
age showed that as in the 9 week old cohort previously described above, db/db mice did 
have a decrease in retinal thickness compared to lean mice, however statistical 
significance could not be determined due to sample size.  
Measurements of basement membrane thickness by EM at 11 weeks showed no 
significant changes between groups. But as mentioned previously, basement membrane 
thickening may not occur until later stages of DR in these mice, as it has been observed at 
22 weeks of age in the literature. However, accurate measurements of basement 
membrane thickness may have been affected by poor perfusion, as was evident by eGlx 
staining. As noted in CHAPTER 2, mice were cardiac perfused with ringer solution to clear 
the system of red blood cells, followed by perfusion with Alcian blue and glutaraldehyde, 
which simultaneously fixes the tissue for EM while also staining the eGlx. Careful 
measures are taken to ensure perfusion conditions are optimal, including filtering the 
Alcian blue solution to avoid precipitate which may hinder perfusion. However, there are 
occasionally instances in which perfusions are not optimal, and either do not fully perfuse 
some organs or fail to reach certain parts of the body. In this cohort, it was apparent that 
the perfusions did not properly perfuse the eyes, as eGlx staining was visibly patchier and 
thinner than previously observed, even in lean controls. Vessel structure was also 
collapsed, suggesting improper fixation of microvessels. Attempts to measure eGlx 
changes in these mice were still made, but retinal eGlx measurements showed no 
apparent differences in eGlx. Additionally, because the eyes of one animal failed to 
perfuse completely, statistical significance could not be determined for this cohort due to 
insufficient numbers. Therefore, no conclusions on changes in eGlx can be reliably drawn 
from this study.  
As the Micron IV imaging system was also used for sodium fluorescein angiographies, and 
previously mentioned issues were encountered, a complete set for solute flux 
measurements were not obtained for this study. As a result, solute flux measured at 9 
weeks of age in this cohort could not be tested for statistical significance. However, the 
solute flux measurements which were taken show no trend of increased solute flux in 9-




Although this cohort did not yield any eye data which directly contributes to the 
hypothesis of this thesis, changes in retinal thickness agreed with the previous 9-week-
old cohort. Additionally, it was learned that the use of ketamine/Xylazine for this strain of 
mice is not suitable and should be avoided in any future studies. Furthermore, the solute 
flux measurements taken in this study gave evidence that solute flux measurements using 
this technique in db/db mice may not be suitable as they show contradicting results with 
albumin staining in the retina. This lead me to further investigate the use of this technique 
in this model discussed below.  
6.4.3 Db/db Mice May Not Be Compatible with Solute Flux Assay  
As the results in 9-week-old mice showed that mice had increased albumin leak, with no 
observable increase in solute flux, I investigated if the db/db mice were a good model for 
measuring changes in solute flux. By aging db/db mice from 6-14 weeks of age and 
performing solute flux measurements every two weeks, I was able to determine if there 
were any differences between lean and db/db mice as DR progressed. It was surprising to 
see that there was no observable increase in solute flux in db/db mice. In fact, solute flux 
measurements appeared to be less on average at 14 weeks in db/db mice than at 6 weeks. 
One noticeable feature when performing sodium fluorescein angiography in lean and 
db/db mice, was that the sodium fluorescein signal seemed to take longer to saturate in 
the main vessel compared to lean. Indeed, looking at a video snap-shot for a lean mouse 
after approximately 10 minutes showed that main vessels were near saturated, especially 
closer to the optic nerve. However, main vessels in db/db mice were not saturated by 10 
minutes, suggesting a difference in sodium fluorescein uptake, which may skew solute 
flux measurements. These differences were further confirmed by comparing fluorescent 
intensity profiles for the main vessels. Fluorescent intensity profile for the lean mouse 
begin to  plateau or reach a steady state, as would be expected from previous results in 
CHAPTER 5 and discussed in CHAPTER 2, but the intensity values themselves were much 
higher than db/db mice. This seemed to also affect the fluorescent intensity values for the 
exchange vessels, though notably there did not seem to be a change in the shape of the 
curve for exchange vessels. This suggest an issue with sodium fluorescein uptake, as main 
vessels are the first to perfuse with sodium fluorescein. This difference in uptake may be 
due to the significant differences in fat content between lean and db/db mice, as sodium 
fluorescein was injected i.p. in these mice. In humans, the use of sodium fluorescein 
angiography imaging is used to determine alterations in retinal vasculature, where a 




vascular lesions have occurred (331). Therefore, the rate at which sodium fluorescein is 
absorbed into the system does not affect the results. In fact, the use of oral administration 
has been shown to be a safe and effective way to administer sodium fluorescein for 
angiographies, where signal often does not appear until thirty minutes after ingestion 
(331).  However, because solute flux is a rate measurement, dramatic differences in 
uptake could have an effect. This might also explain why the use of sodium fluorescein 
angiographies in the heparinase III studies and the Ext1CKO  model did not have similar 
issues, as mice in these groups were similar in weight.  A way around this issue would be 
to inject sodium fluorescein via t.v. injection for diabetic studies, however, the set up for 
imaging is not conducible to this method. As described in CHAPTER 2, mice are on a floating 
stage that allows for fine adjustments in mouse position to bring the retina into focus, 
making t.v. injections practically difficult and would require substantial adjustments to 
the set up. Tail vein injections would also be a more lengthy process, increasing the 
likelihood of the development of acute anaesthetic induced cataracts, a known side effect 
of prolonged anaesthesia in mice (332), which would affect imaging of the retina.  
Additionally, studies performed by our collaborator, Professor David Bates, who originally 
developed this assay in a STZ rat model, has evidence that a direct intravenous injection 
does not allow for accurate measurement of solute flux, as vessels saturate too quickly 
(personal communication). Therefore, the use of db/db mice for measurements of solute 
flux using sodium fluorescein angiography imaging may not be compatible or requires 
further optimisation before it can be used in this model. 
6.4.4 Conclusions and Significance  
The work presented in this chapter suggest that a novel HPSE inhibitor OVZ/HS-1638 
prevents increased retinal albumin leak in a T2D mouse model of DR at 9 weeks of age. 
Although protection of eGlx HS was not specifically shown in this study, treatment with 
HPSE inhibitor significantly increased eGlx coverage, indicating a restorative effect on the 
eGlx during diabetes. Treatment with OVZ/HS-1638 also significantly reduced the amount 
of extravascular albumin in db/db mice when compared to db/db mice treated with 
vehicle, indicating that break down of the iBRB can be prevented by preventing HS 
degradation with HPSE inhibitor treatment. This is the first time that protective effects on 
the eGlx and iBRB by inhibiting HPSE has been shown, demonstrating the potential 
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 Heparan Sulphate is Functionally Important in the Microvascular 
Endothelial Glycocalyx in the Kidney and Eye  
7.1.1 Summary of Results for Aim 1 
The first aim for this thesis was to demonstrate the importance of HS in the eGlx in the 
kidney and retinal microvasculature. Microvessels are an essential component in the 
circulatory system, as they are involved in blood-tissue exchange which is necessary for 
the delivery of oxygen and nutrients to the tissues in which they are located (1). The 
appropriate delivery of nutrients is made possible by regulation of microvascular 
permeability in different vessel beds. Two types of vessels exist in the vascular system, 
fenestrated and continuous, and as discussed throughout this thesis, the glomerulus in 
the kidney and retina in the eye serve as two examples of such vessel beds. While the 
glomerulus and the retina have two very distinct structures to match the need of its 
respective tissue type, there are similarities as well. Both the glomerular and retinal 
vessels have endothelial cells which are in direct contact with flowing blood and are the 
first cell in the permeability barriers that form the glomerular filtration barrier (GFB) and 
the inner blood retina barrier (iBRB).  The presence of the eGlx is common to both of these 
vessel beds, as well as all other vessel beds in the body. As previously discussed, the eGlx 
is known to have a role in the maintenance of microvascular permeability in the kidney, 
and some evidence exists for its role in the retina. However, the role that the various eGlx 
components have in structure and function has not been fully established and is 
important to understand, as damage to the eGlx is associated with increased  vascular 
permeability in diseases such as diabetes. 
To this end, I have examined the role of HS in the eGlx in the glomerulus and retina in 
maintaining the integrity of the GFB and the iBRB. Using two different approaches, I have 
shown that HS is important for maintaining barrier properties in both the glomerulus and 
retina. I first showed conclusively that HS is indeed present in the eGlx of both the 
glomerulus and the retina, using immunofluorescence. Although HS is regarded as the 
most abundant GAG in the eGlx, making up to 90% of the total GAGs in the glycocalyx (12), 
surprisingly, to my knowledge there is no visual evidence demonstrating its presence in 
the eGlx in tissue samples in the literature. And so, this is the first time that HS in the eGlx 




The first approach used to demonstrate a role for HS in the eGlx was with the use of 
heparinase III to enzymatically remove HS in the glomerulus and retina in healthy mice. 
Treatment with an HS shedding enzyme resulted in structural damage to the eGlx, 
measured by EM in both vessel beds. In vitro studies by our group as well as others on 
GEnCs have indeed shown that treatment with heparinase III results in loss of cell surface 
HS and increased albumin passage across the cell monolayer (10). While parallel studies 
for REnC have not been done, REnC in which HPSE is upregulated, do show increase HS 
cleavage, pointing to potential similarities between the GEnC and REnC eGlx (294).  
Functional studies presented in this thesis on heparinase III treated mice provided 
evidence for a role of HS in the eGlx, as mice treated with active enzyme had increased 
glomerular albumin permeability (Ps’alb) and increased solute flux in the retina, 
compared to inactive enzyme-treated mice. This is evidence that eGlx HS is functionally 
important for maintaining GFB and iBRB integrity. Loss of eGlx in these mice did not 
coincide with any other structural changes in the GFB or iBRB, suggesting that eGlx HS 
specifically is an important factor in maintaining barrier properties.  
As a second approach to investigate the importance of eGlx HS, the Ext1CKO model in which 
the Ext1 enzyme required for HS chain elongation is conditionally knocked out in 
endothelial cells, was used. Because this is a whole-body knockout, these mice could be 
used to study both vessel beds. Analysis of EM images showed that Ext1CKO mice had  
significant loss of eGlx, in line with heparinase III studies above. Unfortunately, due to 
time constraints, I was not able to analyse eGlx in the retinas of these mice, though eGlx 
functional studies were performed, discussed below. Previous work by our group showed 
that Ext1CKO mice have a significant increase in Ps’alb when compared to litter mate 
controls (LMC). Although these mice did not have a significant increase in albuminuria 
under normal conditions, treatment with L-Lysine, a tubular reabsorption inhibitor, 
revealed a significant increase in albuminuria in Ext1CKO mice, suggesting a masking effect 
of tubular reabsorption on increased albumin permeability. I also performed vascular 
integrity studies in the retina and found that as in the glomerulus, Ext1CKO mice had a 
significant increase in solute flux compared to LMCs. Of note, the assay used to measure 
solute flux is a novel method of measuring changes in the iBRB in the retina and was 
developed through the collaboration with Professor David Bates and Dr. Kenton Arkill. 
Additionally, the software developed by MSc student Kevin Ho in collaboration with our 
group is a new analysis tool with the potential to be used in clinical settings to detect early 




is an important component in the GFB and iBRB, and removal of it in the eGlx results in 
loss of barrier integrity and increased permeability. This suggest a possible mechanism in 
diseases such as diabetic nephropathy (DN) and diabetic retinopathy (DR), in which loss 
of barrier integrity results in increased permeability associated organ damage.   
7.1.1.1 Limitations of This Study and Follow-Up Studies  
A major limitation of this study was the availability of suitable antibodies to detect 
changes in HS in both the heparinase III treated mice and Ext1CKO mice, as discussed in 
CHAPTER 3 and CHAPTER 5. Although heparinase III has been used in a multitude of studies 
as a method to shed HS in vivo and in vitro (10,170,333), it would be useful to confirm loss 
of HS in the eGlx specifically after treatment with heparinase III. However, I did show that 
treatment with heparinase III resulted in a decrease in eGlx, and heparinase III’s specificity 
for heparan sulphate is well documented (196,334), indicating that the results observed 
after heparinase III treatment can be attributed to loss of eGlx HS. In Ext1CKO, reduction in 
Ext1 mRNA was confirmed by qPCR in GEnCs, however the HS antibody used could not 
detect changes in the glomeruli of these mice. As mentioned in CHAPTER 3, this may be 
due to pre-existing HS chains that are present, as Ext1 is involved in HS chain elongation. 
In vitro studies have shown that Ext1 knockout cells can still produce HS, though the chain 
length is significantly shorter compared to control cells (335). Therefore, the antibody 
used in this study may detect these shorter chains. 
 In the future, it will be necessary to find a suitable HS antibody that can be used to detect 
changes in eGlx HS, and can confirm loss of HS in heparinase III treated animals as well as 
Ext1CKO mice. For heparinase III treatment studies, one possible candidate is the 3G10 
antibody, which recognizes the neo-epitopes 3G10 on HS. This epitope is generated when 
HS is cleaved by heparinase III (336), therefore I would expect to see an increase in signal 
with the use of this antibody in heparinase III treated animals. For Ext1CKO mice, as well as 
heparinase III treated mice, use of commercially available antibodies such as 10E4 or 
JM403 may be suitable, as treatment with heparinase III has been shown to almost 
completely abolish signal using these antibody (210), and would therefore expect to see 
some decrease in Ext1CKO mice as well, which should have shorter HS chains, therefore less 
available epitopes. Alternatively, isolation of endothelial cells and measurement of HS 
chain length using anion-exchange HPLC (high-performance liquid chromatography), as 
was done in the study mentioned above (335), can be used to confirm reduction in HS in 




It should also be noted that interpretation of the results obtained with these two different 
models should be carefully considered, as well as how they relate to diabetic studies in 
this thesis. While heparinase III treatment tells us something about the effect on HS 
shedding in the eGlx, as would be expected in the case of upregulated HPSE in diabetes, 
Ext1CKO mouse studies gives information about the effect of reduced HS synthesis in the 
eGlx. In vitro studies on aortic endothelial cells treated with high glucose show a 
significant reduction in GAG isolated from cells, and a significant increase in GAGs in the 
media of the cells (337), suggesting increased GAG shedding. Importantly for 
interpretation of these results, the researchers also performed correlation studies on 
total HS disaccharides and total GAGs found in cultured endothelial cells, and found that 
there was a positive correlation between the two (337). The authors suggest that this is 
evidence that investigation of total GAGs reflect the total HS present in the endothelial 
cells (337), making these results reflective of changes in HS. There is, however, evidence 
in glomerular epithelial cells and mesangial cells from T1D rats, that diabetes results in 
reduced synthesis of HS in these cells (338). It is therefore possible that a combination of 
both occur in diabetes, and therefore heparinase III and Ext1CKO studies may reflect two 
different aspects of HS loss in diabetes.  
7.1.2 Possible Mechanisms for the Contribution of eGlx Heparan Sulphate to 
Vascular Permeability Barriers 
The work presented in this thesis provides evidence that HS is an important component 
of the eGlx, which contributes to the functional role of the eGlx in the GFB and the iBRB. 
However, how HS contributes to the barrier properties of eGlx has yet be determined and 
will require further investigations. The following is a discussion of possible mechanisms 
for how HS contributes to the eGlx barrier properties in the GFB and iBRB based on the 
data presented in this thesis and available published literature.  
7.1.2.1 Heparan Sulphate’s Contribution to the eGlx of the Glomerular Filtration Barrier  
In the GFB, the eGlx has an established role in permeability, as numerous studies by our 
group and others have shown that loss of eGlx coincides with increased albumin 
permeability in GEnC cell monolayers, and increased albuminuria and glomerular albumin 
permeability in  animal models  (33,108,116,155,170). FIGURE 7-1 shows a schematic of 
ways in which eGlx HS may contribute to barrier function. One way in which HS likely 
contributes to the eGlx barrier function, is through its anionic charge. HS as well as other 
GAGs have a net negative charge due to their carboxylic acid and sulphated groups which 




charged layer as mentioned in CHAPTER 1.  In fact, HS has been shown to have the highest 
negative charge density of any other known biomolecules (340). Indeed, it has been 
shown that treatment of rats with heparinase III reduces anionic sites in the GBM, 
evidence that there is a contribution to the anionic charge by HS in the GFB (184). A study 
using all-atom molecular dynamic (MD) simulations focused on HSPGs, also provides 
evidence that HS contributes to the anionic charge of the eGlx (16). In a healthy state in 
which HS remains abundant, the eGlx is able to repel molecules such as plasma proteins 
based on charge density alone, acting as a physical barrier to plasma proteins (341) 
(FIGURE 7-1 A). However, loss of HS and consequently damage to the eGlx may allow for 
larger molecules such as plasma proteins and albumin, to passively diffuse through the 
GFB through the endothelial cell fenestrations (FIGURE 7-1 B) which are 60-70nm in 
diameter, and physically large enough to allow the passage of large molecules such as 
albumin (30).  
Figure 7-1 Possible Mechanisms  for HS Contribution to eGlx Barrier Function in the GFB 
A. In healthy conditions, eGlx HS acts as a physical barrier and contributes to net negative charge 
inhibiting free passage of large molecules through fenestrations. HS may also provide a barrier in 
junctional complexes like tight junctions (TJ). B. In a disease state, loss of eGlx HS results in increased 
passage of large molecules through the fenestrations. Loss of eGlx HS may also impact charge and TJ 





The role of eGlx HS in junctional complexes such as tight junctions or adherens junctions 
of GEnCs is unclear. In vitro studies have shown that removal of HS by heparinase III or 
HPSE, had no significant impact on transendothelial electrical resistance (TEER), but did 
result in increased albumin passage as previously mentioned (10). TEER measurements 
are used to determine the integrity of tight junctions in a cell monolayer, where it is 
inversely related to the amount of passage of water and small solutes (10). Therefore, an 
increase in TEER, would be equivalent to a decrease in the passage of water and small 
solutes.   Additionally, removal of HS had no effect on vascular endothelial cadherin (VE-
cadherin), a vital protein in the endothelial cell-to-cell barriers which are sealed by cell-
cell adhesions molecules(342). However,  another study on GEnC showed that treatment 
with advanced glycated end -products (AGEs), which interestingly  are also increased in 
diabetes, resulted in loss of tight junction proteins occludin and claudin-5 by 
immunofluorescence, which was accompanied by a decrease in TEER and an increase in 
4kDa FITC-dextran passage(343).  Treatment with AGEs also induced upregulation of 
MMP-2 and MMP-9 in these studies (343). Our group has shown that MMP-9 has been 
shown to mediate eGlx loss by shedding of the HSPG, sydencan 4 (344). It is therefore 
possible that HS, by way of HSPGs, does have a role in the maintaining tight junction 
integrity in GEnC, and that loss of HS increases paracellular passage of plasma proteins as 
shown in FIGURE 7-1 B. However, more studies would need to be conducted to make any 
conclusions as these studies did not directly address this question. It should also be noted 
that GEnCs do not form clear fenestrations in tissue culture, likely making the role of tight 
junctions in in these studies much more important in maintaining barrier function than in 
vivo. It is likely that tight junctions play a more crucial role in microvessels which are 
continuous and lack fenestrations, such as the retina, discussed below.  
7.1.2.2  Heparan Sulphates’ Contribution to the eGlx of the Inner Blood Retina Barrier  
A lot less is known about the eGlx in the iBRB. While previously mentioned studies have 
shown the presence of eGlx in animal models and eGlx can be measured in human retinal 
vessels, few studies have shown a functional role. Functional studies that have been done 
focused on HA, as discussed in CHAPTER 5, and showed that treatment of mice with  
hyaluronidase resulted in reduced eGlx and increased permeability (113). However, HS 
has not been investigated in the retina eGlx until now. Furthermore, there is currently no 
published work which has directly addressed how the eGlx and HS contribute to the 
maintenance of the iBRB. The data presented in this thesis provides strong evidence that 




accomplished is not clear as these microvessels have a much more tightly regulated 
permeability barrier which is immune privileged and the endothelial cells  lack 
fenestrations (345). As discussed in CHAPTER 1, vascular permeability in the retina is 
regulated by paracellular transport and transcytosis. But how does the HS eGlx contribute 
to these, as the eGlx is on the surface of vascular endothelial cells? 
 As in the GFB, HS may act as a physical barrier in tight junctions as demonstrated in FIGURE 
7-2 A, and loss of eGlx HS can result in an opening in which plasma proteins can escape 
through already damaged tight junctions (FIGURE 7-2 B). Loss of tight junction proteins 
such as occludins have in fact been observed in experimental models of diabetes such as 
T1D rats in the retina (346). However, there is some evidence that HS itself may have a 
bigger role in the maintenance of junctional complexes. Studies previously described in 
human retinal endothelial cells (hREC) showed that shedding of HS, likely resulting from 
the observed upregulated HPSE in high glucose treated cells, coincided with a loss of 
occludin (294). This suggests that loss of HS may lead to changes which result in loss of 
tight junction proteins. However, one major pitfall to this study was that protein levels 
were investigated only by Western blot, therefore localisation of the proteins could not 
be concluded.  On a similar note, cell surface HSPGs are known to act as reservoirs of 
growth factors such as VEGF (347). In the retina, shedding of HS may result in the release 
of VEGF, which is well known to increase vascular permeability, and is associated with loss 
of eGlx (33,123). Interestingly, treatment of bovine retinal endothelial cells (BRECs) with 
VEGF results in enhanced phosphorylation of occludin and ZO-1 (346). Phosphorylation of 
these junctional proteins is thought to modulate their cellular localisation, where 
phosphorylation results in cytoplasmic localisation (348), i.e. loss in membrane tight 
junction localisation. Increased phosphorylation of junctional proteins is also associated 
with increase permeability both in vitro in BRECs as well as in vivo in rat models in which 
VEGF is injected into the vitreous of the eye (348,349). Therefore, it is possible that eGlx 
HS not only acts as a physical barrier as mentioned above, but also acts to maintain tight 
junction integrity through its growth factor binding/sequestering capabilities, such as 
binding of VEGF. When HS is shed, release of growth factors may induce a breakdown in 
tight junction protein complexes, allowing an increase in paracellular transport of plasma 
proteins as shown in FIGURE 7-2 B. Further adding to this, treatment of rat fat pad 
endothelial cells (RFPECs) with heparinase III results in decreased expression of Connexin 
43 (Cx43), a gap junction protein (333). And loss of Cx43 is associated with increased 




and is also reduced in the retinas of DR patients (350,351). This provides further evidence 
that changes in HS can indirectly impact junctional complexes. 
 
Figure 7-2 Possible Mechanisms  for HS Contribution to eGlx Barrier Function in the iBRB 
A. In healthy conditions, eGlx HS acts as a physical barrier, inhibiting of passage of molecules 
through tight junctions (TJ) and may shield receptors that are involved in transcellular transport. 
B. In a disease state, loss of eGlx HS results in loss of barrier at TJ. Additionally, HS shedding may 
induce loss of TJ integrity by deregulation of TJ proteins, resulting in increased paracellular 
transport. Loss of eGlx HS may also increase transcellular transport directly by exposure of 
receptors or indirectly by downstream signalling resulting in increased vesicle formation.  Image 




Alternatively, HS eGlx may also have a role in regulation of transcellular transport. In 
addition to the effects of VEGF on permeability mentioned above, VEGF has been shown 
to induce permeability through an increase in transcytosis in vivo in monkeys which 
received intravitreal injections of VEGF (123). However, it should be noted that this study 
had a small sample size of four animals, three treated with VEGF and one control, so more 
work is needed to make any definitive conclusions. These studies do however line up with 
in vitro work on BRECs, which showed that cells treated with VEGF have a significant 
increase in vesicle related genes such as caveolin-1 and flotillin-1 and -2 (352). 
Interestingly, caveolae which are named after the structural molecular component of 
plasmalemma vesicles, cavoline-1 mentioned above, have been shown to contain 
receptors for albumin (48). It is therefore possible that shedding of HS results in 
downstream signals that result in increases vesicular transport of plasma proteins such as 
albumin, as demonstrated in FIGURE 7-2 B.  In fact, T1D rat models have increased retinal 
vascular endothelial cell endocytosis, and is perhaps contributed to by loss of eGlx HS via 
the VEGF effects on vesicle formation mentioned previously.  It is also possible that loss 
of HS exposes receptors that are normally masked by the eGlx. For example, loss of the 
HSPG syndecan-1 results in increase adhesion of leukocytes in retinal blood vessels after 
TNF-α stimulation (353), suggesting that loss of HS results in exposure of adhesion 
molecules as shown in FIGURE 7-2 B, that could mediate an increase in receptor mediated 
vesicular transport. As this was not the focus of this thesis, further experiments will need 
to be done to determine exactly how HS contributes to iBRB integrity, though the work in 
this thesis establishes a foundation for further investigation into eGlx HS and vascular 
permeability in the retina.    
 Preventing Heparan Sulphate Degradation Prevents Damage to 
the Endothelial Glycocalyx In Diabetic Microvascular Diseases 
7.2.1 Summary of Results for Aim 2 and Aim 3 
Completion of the first aim gave strong evidence that HS has a structural and functional 
role in the eGlx in the GFB and the iBRB, as loss of HS lead to increased glomerular 
permeability and solute flux in the eye. As vascular diseases such as DN and DR are 
associated with a break down in the GFB and iBRB resulting in increased vascular 
permeability, the second aim of this thesis was to determine if the eGlx is damaged in 
these vessel beds in db/db mice, a type 2 diabetic mouse model. Once loss of eGlx was 




OVZ/HS-1638 could prevent loss of HS and associated eGlx damage, preventing increased 
vascular permeability observed in DN and DR. The overarching goal, was to demonstrate 
that early treatment in the same diabetic animal, could prevent the increased vascular 
permeability associated with DN and DR.  
I began this investigation at an early time point in which db/db mice were treated with 
OVZ/HS-1638 from 7-9 weeks of age, with an endpoint of 9 weeks.  In the kidney, db/db 
mice showed an increase in albuminuria and glomerular albumin permeability at end 
point, however this was not associated with significant loss of eGlx in the GFB. Though 
unexpected, as discussed in CHAPTER 4, it is possible that there were moderate changes in 
eGlx, but moderate changes likely require a bigger sample size to see significant 
differences. Furthermore, mice did not have any significant changes in GFB ultrastructure, 
suggesting this time point may have been too early to investigate robust eGlx changes in 
DN. Though no significant protective effects were observed in the eGlx with OVZ/HS-1638 
treatment or with albuminuria, db/db mice treated with OVZ/HS-1638 did not have a 
significant increase in glomerular albumin permeability contrary to vehicle treated db/db 
mice, suggesting a mild protective effect  on GFB function at this time.  
In the same mice, a significant reduction in retinal thickness was observed in db/db mice, 
as is commonly observed in early stages of DR. Db/db mice did not have a significant loss 
of eGlx, though there was a strong trend toward a decrease. Unfortunately, no changes 
were observed in solute flux in these mice, but as discussed in CHAPTER 6, this model may 
not be suitable for the assay used to measure solute flux without further optimisation. 
However, db/db mice had a significant increase in extravascular albumin in their retinas 
at 9 weeks, measured by immunofluorescence. Presence of extravascular albumin 
staining likely results from an accumulation of albumin leak over a period, as opposed to 
solute flux which measures changes at the time of measurement. In DR patients, 
accumulation of lipid and proteinaceous material such as albumin, results in the formation 
of hard exudates, indicating a breakdown in the iBRB (354).  Treatment with OVZ/HS-1638 
resulted in a significant increase in eGlx coverage in the retina, compared to db/db mice 
treated with vehicle, indicating a restorative effect on eGlx HS. Additionally, extravascular 
albumin was significantly reduced, further confirming that HS is important for barrier 
function and preventing its degradation in the retina during diabetes prevents breakdown 




Because db/db mice at 9 weeks of age did not show measurable changes in eGlx, I used a 
later time point in which mice were treated from 9-11 weeks of age. Db/db mice had 
changes in GFB ultrastructure, consistent with the development of DN. Db/db mice had 
an increase in albuminuria, which was associated with loss of eGlx, and increase in 
glomerular albumin permeability.  Db/db mice treated with OVZ/HS-1638 however did 
not have a significant increase in albuminuria, contrary db/db mice treated with vehicle. 
This was associated with restoration of eGlx, and a significant decrease in glomerular 
albumin permeability. These data indicate that HS shedding and loss of eGlx results in 
increased permeability in the kidney, and therapeutically targeting it by preventing its 
degradation in diabetes has restorative effects on the GFB.  This was further confirmed by 
PAS staining, in which mice treated with OVZ/HS-1638 had a significant reduction in 
glomerular fibrosis compared to vehicle treated db/db mice. This indicates that treatment 
with OVZ/HS-1638 in diabetes not only has protective effects on eGlx, but also may 
prevent progression of DN, as glomerular fibrosis is a characteristic pathological change 
in DN (355).  
Unfortunately, the data obtained for the retina portion of this cohort did not yield any 
conclusive results. The first issue arose with imaging of the mouse retina in vivo, due to 
use of unsuitable anaesthetics for this mouse model. This resulted in an incomplete set of 
data of retina images. However, the images that were obtained at 9 weeks in these mice 
did show a similar trend to the 9-week-old cohort, where db/db mice had retinal thinning. 
This same issue resulted in an incomplete set of solute flux measurements for this cohort, 
though as mentioned above, the data presented in CHAPTER 6 suggest that this method of 
solute flux measurement is not suitable for this mouse model, and will require significant 
optimisation should this model be chosen for future studies.  Another issue that arose 
was poor fixation of the retinal tissue in these mice, which was evident by collapsed 
vessels by EM. This resulted in eGlx staining which was suboptimal in all groups. Despite 
this, eGlx was measured and no apparent changes were observed between groups, 
though statistics could not be performed due to insufficient sample size resulting from 
one mouse which did not perfuse. As a result, no conclusions on eGlx changes and 
protective effects of OVZ/HS-1638 treatment could be made at this time point.  
7.2.2 Limitations of This Study and Follow-Up Studies  
As with the aim 1, one limitation in the investigation of aims 2 and 3 is the inability to 
confirm a loss of HS in the eGlx specifically. As discussed in CHAPTER 1, HS is linear 




variations in number of acetyl groups and sulfation (14). These variations are functionally 
important and differ in different tissues types and species. As a result, there is a wide 
range of epitopes which can be recognized.  For example, two commonly used antibody  
JM403 and 10E4, discussed previously, require an N-unsubstituted glucosamine residue 
and an N-sulphated glucosamine residue for antibody binding, respectively (356), 
however both epitopes may not be present in all tissues or cell types. Similarly, the phage 
display antibodies such as HS3A8V and EV3C3V used in this thesis, were raised against 
bovine kidney HS and human lung HS, respectively (357). Published studies with these 
antibodies showed that both had the same binding pattern in rat lung tissue from 
embryonic days (E) 15.5 of gestation (357). However, the same two antibodies had 
different binding patterns in E17.5 rat lung tissue (357). This demonstrates how variable 
HS chains can be even in the same species, making it difficult to find a suitable antibody 
to detect changes.  
While loss of HS in DN has been shown in glomeruli from humans and experimental rodent 
models (109,282,358), reduced HS is often attributed to loss of GBM HS, and eGlx HS has 
not been specifically addressed.  Of note, a study performed on Wister-Munich rats 
showed that glomeruli from T1D rats had reduced HS staining using the antibody JM403, 
after 5 months of diabetes (109). On the other hand, another study also performed on 
Wister-Munich rats after 5 months of diabetes, showed no changes in glomerular HS, but 
the researches used  the antibodies   3G10, 10E4, and monoclonal antibody (mAb) 865 
(359). This nicely demonstrates the difficulty and great importance in finding a suitable 
antibody to detect changes in eGlx HS, as discussed above.  Reduced HS synthesis has 
been shown in the retinas of diabetic Wistar-Munich rats by assessing the incorporation 
of radiolabelled 35S-sulphate into HS (297), and may be a suitable way  to measure changes 
in HS. However, this was performed on whole retinas, therefore changes to the eGlx 
cannot be concluded. Future studies should therefore involve finding a suitable antibody 
or method to detect changes in the eGlx of the glomerulus and retina, as mentioned in 
aim 1.  
Another limitation in this study involves the mouse model chosen to investigate DN and 
DR in the same animal. Historically, DR and DN  have been shown to be strongly linked, 
with the likelihood of developing one increasing the chance of developing the other 
(360,361). However, these associations have primarily been investigated in humans, and 
to my knowledge, there have not been any published studies investigating the 




diabetic mouse models, as was done in this thesis.   As discussed in CHAPTER 4 and CHAPTER 
6, the use of db/db mice was chosen based on a literature search which upon reviewing, 
gave evidence that db/db mice were a suitable model to study early changes in DN and 
DR, at the same timepoints of 9 and 11 weeks as end points. Db/db mice are 
hyperglycaemic and become albuminuric by 8  weeks of age and have increased vascular 
permeability in the retina measured by FITC-dextran by 20 weeks (215,315). In children 
with T1D, changes in sublingual eGlx has been observed before any clinical signs of 
vascular complications become apparent in the eye or kidney (362).  As I was investigating 
early changes in the eGlx during DN and DR, the hope was that by 9-11 weeks, mice would 
have developed changes in eGlx and associated increase in vascular permeability. In 
retrospect, this model may not have been the best choice, as db/db mice at 9 weeks of 
age did not show significant changes in eGlx in glomeruli or the retina, and so protective 
effects on eGlx structure by the OVZ/HS-1638 could not be concluded. However, some 
restorative affects were seen in eGlx coverage in the retinas of 9-week-old mice by 
OVZ/HS-1638. It is possible that these studies lacked power to detect small but significant 
changes in the eGlx. However, a breakdown in the GFB and iBRB was evident at this 
timepoint, by glomerular albumin permeability assays and albuminuria, and extravascular 
albumin staining in the retina, respectively. These results indicated that mice at 9 weeks 
of age did have some changes associated with DN and DR, and I therefore reasoned that 
a later timepoint may yield more robust changes in the eGlx.  
As a result, I performed the same studies with an 11-week-old end point and did in fact 
find that there were significant changes in eGlx and permeability in the glomeruli from 
db/db mice, which were prevented by OVZ/HS-1638 treatment. But studies in the eye 
were not conclusive, primarily due to technical difficulties mentioned previously. 
Furthermore, investigation of the solute flux assay used to show functional changes in the 
eGlx, revealed that this assay may not be suitable for db/db mice. As evidence provided 
in CHAPTER 6 shows, this is likely due to the large differences in body mass which resulted 
in differences of sodium fluorescein absorption between non-diabetic and diabetic mice, 
which appeared to skew solute flux measurements, as described in CHAPTER 6.  
As a result, I was unable to directly and conclusively address the loss and restoration of 
eGlx HS in the GFB and iBRB in the same animal, which was the overarching goal for this 
thesis. It is possible that the 11-week time point would have been suitable to study 
changes in eGlx in both vessel beds had there been no issues encountered in the retina 




be primarily a body mass issue. As will be discussed in the FUTURE STUDIES section of this 
chapter, a model in which non-diabetic and diabetic rodents have less of a difference in 
body fat, would potentially help avoid the issue encountered with db/db mice.  
 Clinical Implications of This Work 
 The work presented in this thesis is a step toward finding a treatment which helps prevent 
microvascular complications in diabetes. Currently, the most important goal in T1D and 
T2D patients is the maintenance of blood glucose levels within a normal range and control 
of blood pressure(127). As discussed in CHAPTER 1, to achieve this, in addition to lifestyle 
interventions, the use of exogenous insulin, or use of other glucose lowering agents such 
as SGLT2 inhibitors and metformin are now common practice in in T1D and T2D patients, 
respectively. Use of ACE inhibitors and RAAS blockers also aid in lowering blood pressure 
(135).  Despite this, DR continues to be the most frequent cause of blindness in 20-74 year 
olds, and DN is the most common cause of end stage renal disease in the Western world 
(363,364). As diabetes diagnoses has been on an upward trend for decades, and currently 
there is no cure for T1D or T2D, the development of therapeutics that can prevent and/or 
alleviate microvascular complications such as DR and DN remains crucial.  
One of the features that links microvascular complication in diabetes is the associated 
increase in permeability, resulting in damage to the respective organ. In DN, loss of the 
eGlx in diabetes has been established, and is now known to contribute to increased 
vascular permeability. Though some studies have looked at the eGlx in the retina, the 
association of eGlx loss in DR is not as strong, as few studies have investigated its role in 
the retina microvasculature. The data in this thesis not only provides evidence that eGlx 
is functionally important in the eye, but also that HS is an important component of the 
eGlx, which contributes to microvascular barrier function in both the eye and kidney. 
Importantly, together these data indicate similarities between the eye and kidney 
microvasculature, despite their anatomical differences, suggesting that a single treatment 
may be effective in preventing damage to the eGlx in both vessel beds. It is possible that 
this treatment can be applied more widely to all vessel beds in diabetes, such as the brain, 
in which diabetics are at increased risk for developing vascular dementia and Alzheimer’s 
disease contributed to by alterations in the blood brain barrier (365).    
Currently, there are no treatments that specifically target the glomerulus in DN, and 
although treatments such as anti-VEGF signalling therapies that target the retina are 




have therapeutic effects on the kidney. In fact, there is evidence that treatment with anti-
VEGF therapies in retinopathy patients may even lead to proteinuria and glomerular 
endothelial cell injury (366,367). The data in this thesis suggests that development of a 
treatments which can therapeutically target eGlx HS systemically, may prevent or 
diminish the development of microvascular complication in diabetes.  
In addition, the diabetic studies conducted in this thesis are further evidence that damage 
to the eGlx is an important factor in the development of DN and DR. Loss of eGlx in the 
GFB was associated with increased HPSE and increased glomerular permeability, and 
inhibiting HPSE with OVZ/HS-1638 restored GFB properties in diabetes.  Although loss of 
eGlx in the eye was not significant in diabetes in the small cohort of mice, eGlx coverage 
results suggest that eGlx HS can be therapeutically targeted, as treatment with OVZ/HS-
1638 significantly increased eGlx coverage in the retina. Furthermore, restoration of the 
iBRB by OVZ/HS-1638 treatment was evident by reduced extravascular albumin staining 
in the retina. Together, these data suggest that indeed, treatment with a OVZ/HS-1638 
can therapeutically target eGlx HS systemically in DN and DR, as mentioned above. 
Although other HPSE inhibitors have been used in a handful of diabetic studies showing 
therapeutic affects in the kidney and eye (114,318,368,369), to my knowledge this is the 
first study to show that the use of HPSE inhibitors can be used to prevent eGlx damage in 
diabetes and associated microvascular permeability changes. Of note, this work has the 
possibility to be translated into clinical use, as HPSE inhibitor clinical trials are already 
underway for use in various cancers (256,265).  
In addition to showing potential for the use of HPSE inhibitors as therapeutic treatments 
for DN and DR, this thesis provides evidence for efficacy of a novel class of HPSE inhibitors 
in DN and DR. As discussed in CHAPTER 4, currently available HPSE inhibitors are linear 
polysaccharides, which are costly to produce and have undefined structures, increasing 
batch-to-batch variation. Additionally, many of the HPSE inhibitors used still possess 
significant anticoagulant activity.  The HPSE inhibitor used in this study is a dendrimer, a 
new class of structurally unique HPSE inhibitors. Work by our collaborator Dr. Olga 
Zubkova has shown that this inhibitor has nanomolar potency and has significantly lower 
anticoagulant activity compared to commercially available HPSE inhibitors PG545 and 
M410 (271).  Additionally, OVZ/HS-1638 had no cytotoxic effects on cell lines tested at 
100µg/mL, or 15-32µM, which is 100-1500 times higher than the IC50 required for HPSE 




collaborator is currently evaluating pharmacokinetics, bioavailability, and safety of this 
HPSE inhibitor class in hopes that it can progress to clinical testing (271).  
 Future Work 
As this thesis provided evidence for a functional role of HS in the eGlx, future studies 
should be conducted to determine a mechanism for how it contributes to vascular 
permeability. As discussed earlier in this chapter, potential mechanisms for its 
contribution may include both physical barrier properties as well as regulation of 
junctions and transcellular pathways. This has not been actively investigated, and those 
studies which have been done on HS in the GFB and iBRB primarily focus on its role in the 
basement membranes of the respective vessel beds. Studies aimed at investigating the 
loss of eGlx HS and resulting affects should therefore be conducted. To my knowledge, 
the effect of loss of HS charge specifically in the eGlx in the GFB for example, has not been 
tested. Experiments in which eGlx HS is enzymatically shed and confirmed by 
immunofluorescence, could be used to determine what the effects on eGlx charge are, 
and its associated loss of function, which was demonstrated in CHAPTER 3 and CHAPTER 6. 
However, the technical difficulty of this should be noted, as traditional investigations into 
loss of anionic sites after HS removal have focused on the GBM, labelled with cationic 
molecules such as cuprolinic blue or polyethyleneimine (184,370). But the GBM is a stable 
structure which does not require special fixation techniques for visualization, whereas the 
eGlx requires stabilisation with a cationic molecule such as Alcian blue, which would 
interfere with anionic labelling. 
 It would also be interesting to determine if treatment with heparinase III in a healthy 
state results in changes in junctional complex proteins such as ZO-1 and occludins in the 
iBRB, which are associated with increased HPSE as discussed early in this chapter. This can 
potentially be accomplished with the use of immunogold labelling, allowing for direct 
visualisation of eGlx and tight junctions at an ultrastructural level while also assessing 
potential changes in junctional proteins. Immunogold labelling has been successfully used 
to stain for tight junction proteins in vitro as well as tissue sections (371,372). These 
studies would provide further insight into how HS contributes to the eGlx, allowing for a 
better understanding of how HS can be therapeutically targeted in disease.   
As discussed in earlier sections, the mouse model chosen for this experiment did not allow 
for a full investigation into the development and prevention of DN and DR in the same 




particularly in the eye, where, based on the literature discussed in CHAPTERS 4 and 
CHAPTER 6, it appears that development of microvascular changes associated with DR may 
be slower than DN, although evidence of retina vascular leak was observed at 9 weeks in 
db/db mice.  Therefore, future studies could be performed in the same db/db mouse 
model near 20 weeks, in which increased vascular permeability in the retina has been 
shown through the use of FITC-dextran (315). However, because db/db mice develop 
albuminuria by 8 weeks and this study focuses on early microvascular changes in DN and 
DR, it is possible that a 20-week timepoint would be too late for DN studies.  
Alternatively, rat diabetic models may be a better model to investigate changes in eGlx 
and HS in the eye and kidney in parallel. T1D Wistar rats have been shown to have 
increased BSA-fluorescein extravasation in the retina and kidney after 6 weeks of diabetes 
induction (373). Additionally, increased urine albumin excretion and glomerular sclerosis 
can be observed in these rats by  5 weeks after induction of diabetes (374,375). In the 
retina, this model was shown to have reduced visual function of 31%, measured by 
electroretinography (ERG), after 4 weeks of diabetes (376). Reduced eGlx was also 
visualised in diabetic Wistar rats just 1 week after diabetes, measured by EM in tissue 
from cationic colloidal perfused rats (57). In future studies, it would also be useful to 
perform ERG to measure retinal function. Classical ERG objectively evaluates retinal 
function by using diffuse flashes of light and measuring the electrical response of the 
retina. In diabetic patients, reduced retina function is measured with ERG, and has been 
shown to correlate with retinopathy severity as well as a predictor of developing 
retinopathy (377,378). Additionally, because the proposed model is a T1D model, 
differences in body mass should not be an issue in solute flux measurements and would 
allow for functional measurements of solute flux. In fact, our collaborator, Professor David 
Bates, has successfully shown increased solute flux in T1D rats compared to non-diabetic 
rats (unpublished data). Therefore, this model may be a good model in future studies to 
study the effects of diabetes on eGlx and restoration by HPSE inhibition in DN and DR in 
parallel.  
In addition to the use of a different model, the optimal route of injection for OVZ/HS-1638 
will need to be investigated in future studies. The studies conducted in this thesis used i.p. 
and s.c. While i.p. did have restorative effects in the kidney, the issues that arose in the 
11-week-old cohort did not allow for efficacy to be examined in the retina. Use of s.c. as 
a route of administration in the 9-week-old cohort did appear to yield some protective 




because eGlx was not significantly reduced in the kidney or the retina at this timepoint, 
protection of the eGlx by i.p. administration could not be concluded. In humans, the use 
of HPSE inhibitors in clinical trials such as PG545 and PI-88 have been administered i.v. 
and s.c. (262,266,268,379,380). For PI-88, which has been the most extensively tested 
HPSE inhibitor, s.c. appeared to be the best route of administration (379). Of course, oral 
administration would be the most clinically advantageous due to ease of administration, 
which dendrimers are well suited for due to their tuneable functionality (381,382).  Indeed, 
dendrimers have been successfully used as delivery system to orally administer drugs like 
propranolol, triclosan, and ketoconazole (382). It is possible that OVZ/HS-1638 can be 
used orally or modified to be more suitable for oral administration. However, it is evident 
from published studies that route of administration and efficacy will differ with different 
HPSE inhibitors and will need to be determined for new dendrimer HPSE inhibitors such 
as OVZ/HS-1638.  
 Conclusions and Final Remarks  
This thesis has provided evidence which indicates HS is structurally and functionally 
important in the eGlx in two structurally unique vessel beds, the glomerulus and in the 
retina microvessels. Using two approaches in mice, enzymatic removal and a transgenic 
mouse model, I was able to show that loss or reduction of eGlx HS resulted in structural 
damage and loss of barrier function in the GFB and iBRB. These parameters were 
measured by EM in both tissue types, and by permeability and solute flux assays in the 
glomerulus and retina, respectively. Although follow up immunofluorescence studies 
need to be done to directly confirm loss of HS in the eGlx, results showing damage to the 
eGlx using two HS targeting approaches is a good indication that the results observed are 
likely due to HS changes.   
 Using a T2D mouse model, I was further able to demonstrate diabetes resulted in 
significant increase in permeability and extravascular albumin accumulation, in the kidney 
and the eye, respectively. This increase was associated with a significant loss of eGlx in 
the kidney, and a trend in eGlx loss in the eye, albeit at two different time points for each 
vessel bed. Furthermore, the data indicated that treatment with a novel HPSE inhibitor 
OVZ/HS-1638 resulted in restoration of eGlx structure and GFB barrier properties in the 
kidney. In the eye, a significant increase in eGlx coverage was observed with OVZ/HS-1638 
treatment, which coincided with a significant reduction in extravascular albumin 




microvascular complications of diabetes such as DN and DR, with the possibility of 
treatment translating to other diseases which involve similar microvascular changes 
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